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Interleukin 1 alpha and beta are well-characterised cytokines that are
thought to function in localised inflammation and immunoregulation. In vitro
and in vivo studies on the biological activities of IL-1 also indicate a role
in the tissue destruction of many inflammatory disease processes.
The detection of IL-1 in biological fluids is complicated by the
presence of inhibitory and cytotoxic factors that interfere in bioassays. We
have used immunoassays to measure IL-1 alpha and beta levels in human plasma.
Detection of plasma IL-1 beta required a chloroform extraction step to remove
factors that mask immunoreactive epitopes.
We have used these procedures to compare the levels of circulating IL-1
activity in normal individuals and patients with rheumatoid arthritis (RA).
RA patients had raised plasma IL-1 beta concentrations that correlated with
measures of disease activity. Individuals tested longitudinally also showed
correlations between disease activity and plasma IL-1 beta. Interleukin 1
alpha levels however were not raised in RA when compared to age-matched
healthy controls, but serial measurements in individual patients did
correlate with some conventional measures of disease activity.
Biochemical studies showed that both IL-1 forms were bound to high
molecular weight carriers in chloroform extracted plasma. The binding did not
appear to interfere with bioactivity, but the complexes were identified by
immuno- and bioassay only following chloroform extraction, suggesting the
presence of other masking factors in plasma.
Using iodinated IL-1 a specific 43 kDa IL-1 beta binding protein was
identified in plasma and synovial fluid. This protein was partially purified
and characterised.
The primary translation product of IL-1 beta is a 31 kDa propeptide that
requires processing to a 17 kDa peptide to become biologically active. In
other studies IL-1 beta propeptide processing by monocytic cell membrane
preparations was demonstrated. This proteolytic event could be inhibited by
some protease inhibitors and a synthetic peptide designed from the amino acid
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Efficient activation of the immune system in response to an infective
agent is essential for host defence. This activation process involves an
adaptive response in which specific antigenic epitopes trigger the clonal
expansion of T and B lymphocytes, and local mobilisation of phagocytic cells
capable of removing foreign material in an innate response.
Adaptive immunity is initiated by uptake and presentation of antigen by
accessory cells to T lymphocytes, and by the binding of antigen to surface
immunoglobulin on B cells. T lymphocytes recognise processed antigen,
associated with the cell surface major histocompatibility complex (MHC), via
the T cell receptor (Springer, 1990). Two structural forms of MHC molecule
exist. Class I MHC binds peptides synthesised endogenously such as viral
components in infected cells, class II MHC processes exogenous antigen
following uptake by endocytosis. The interaction between antigen presenting
cells and T cells is strengthened by the involvement of surface adhesion
molecules. The MHC/antigen complex is in turn recognised by two types of T
cell: able to kill infected cells (cytotoxic T cells); or promote the
expansion and differentiation of other activated cell types (helper T cells),
in particular B cells. Class I MHC binds T cells via an association with the
CD8 molecule, whereas class II interacts with CD4. As a result of specific
activation and T cell help particular B cells undergo clonal expansion and
antibody synthesis.
Activation of the cells recognising an antigen results in the selective
expansion of a small number of lymphocyte clones. The production of an
effective response is dependent on various cellular interactions, involving
direct cell-cell contact and release of soluble factors such as cytokines.
Cytokines are a group of low molecular weight peptide regulatory molecules
(Green, 1989). Responsiveness of lymphocytes to cytokines results in
proliferation, maturation and activation of primed cells.
The innate response is also highly dependent on soluble factors.
Cytokines are involved in the recruitment of phagocytic cells, increasing
local blood supply and vascular permeability, activating infiltrating cells
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at the site of injury, and in remodelling damaged tissue once the infective
agent has been eliminated.
Cytokines are important mediators of local cell activation, such as in
regional lymph nodes during initiation of immune responses or at sites of
tissue damage. However they also have systemic roles and can act in a
hormone-like manner on entering the blood or lymphoid circulation. This is
seen particularly in the acute phase response where infection results in a
number of metabolic changes, including fever and acute phase protein
production in liver cells.
Cytokines have long been regarded as modulators of the immune response
but increasing evidence suggests that they may also play an important role in
normal homeostatic functions, connective tissue remodelling and
haematopoiesis. Their ability to influence cellular proliferation and
differentiation indicates a possible function in normal growth and
development.
1.1.b. Cytokines and interleukins
Cytokines are inducible peptides with wide ranging effects on many cell
types, acting through specific receptor molecules. They may affect
proliferation, differentiation and function depending on the cell type and
the particular in vivo environment. Examples of cytokine families include
interleukins, tumour necrosis factors, colony stimulating factors,
interferons and various other peptide growth factors.
The interleukins are a group of cytokines originally described as
mediating communication between leukocytes. Increased understanding of their
biological functions has led to interleukins being re-defined as: being
inducible in leucocytes and other cell types, involved in the inflammatory
response, and having a known amino acid sequence.
1.2. INTERLEUKIN-1 (IL-1)
Interleukin 1 is a well characterised cytokine thought to be a central
mediator in the mobilisation of the immune response and localised
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inflammatory reactions, it is also implicated as having a role in various
normal metabolic processes. Though initially described as a product of
activated macrophages, there are many cellular sources that respond to
different stimuli (Table 1.2.1.). Interleukin 1 exerts wide variety of
effects, through activation of specific receptor molecules, and has
autocrine, paracrine and endocrine functions.
Recently many advances have been made in understanding the molecular and
cell biology of IL-1 and the role of inhibitory factors in regulating its
effect.
1.2.a. History
Interleukin 1 was initially described as a protein able to produce a
febrile response when injected into animals (Atkins, 1955) and was named
endogenous pyrogen. Following this, various macrophage products were
identified and named according to their biological activity. In 1972 murine
lymphocyte activating factor (LAF) was shown to act as a co-mitogen for
thymocytes (Gery and Waksman, 1972). A B cell activating factor (BAF) was
identified in 1979 (Wood and Cameron, 1978) and leukocytic endogenous
mediator (LEM, Kampschmidt et al, 1973) was well characterised as an inducer
of acute phase changes. Other activities described include osteoclast
activating factor (Dewhirst et al, 1985), mononuclear cell factor (MCF; Krane
et al, 1982) that stimulated prostaglandin and collagen synthesis by
fibroblasts, and pig catabolin (Saklatvala and Dingle, 1980) capable of
inducing cartilage breakdown in vitro.
The term interleukin 1 was introduced in 1979, since then the cloning
of IL-1 has established the common identity of these factors and has verified
the activities of this cytokine.
1.2.b. Cellular sources and inducers of IL-1 production
Many cell types have been shown to produce IL-1, however the traditional
laboratory source is from peripheral blood monocytes. A wide range of
specialised cell types such as T and B lymphocytes, smooth muscle,
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endothelial and various brain cell types have been shown to synthesise IL-1.
Cellular sources of IL-1 are summarised in Table 1.2.1.
Resting monocytes produce no IL-1, however, stimulation by a number of
agents will rapidly induce IL-1 mRNA and protein synthesis. Bacterial
derivatives, such as cell wall components, are direct activators of IL-1
production, as are viral and yeast particles. Non - infective agents for
example urate, silica and asbestos can induce IL-1. Products of the immune
system itself such as antigen-antibody complexes other cytokines and
complement components also act as stimuli. In in vitro laboratory systems
stimuli such as lipopolysaccharide (LPS), phorbol myristic acetate (PMA),
calcium ionophores and ultra violet (UV) irradiation are commonly used with
different cell types (di Giovine and Duff, 1990).
Interleukin 1 can also be induced by itself and by other cytokines such
as tumour necrosis factor (TNF) alpha, interferons (IFNs) alpha and beta and
colony stimulating factors (CSFs). Lymphocytes activated by exposure to
antigen can promote IL-1 synthesis by production of other cytokines or by
direct cell-cell contact primarily between activated T cells and macrophages.
1.2.c. Biological effects of interleukin 1
The effects of IL-1 in vitro and in vivo were confirmed when the
recombinant proteins became available. The observed properties are consistent
with IL-1 having a role in both local defence, at a site of infection or
injury, and in generalised activation of an immune and systemic non-immune
response. The biological effects of IL-1 are summarised in Table 1.2.2., the
molecule is shown to have an extensive range of actions involving the
maturation, growth and differentiation of many cell types.
Interleukin 1 also acts at a local level in the lymph node to activate
cells involved in the immune response, such as T cells via the induction of
IL-2, its receptor and IL-4. In the human system antigen, is thought to
activate both T cells and accessory cells resulting in IL-1 production and
therefore clonal expansion of the activated lymphocytes (Mizel, 1987).
Interleukin 1 is also thought to act as a helper factor during B cell
5
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activation (Durum et al, 1985).
At a systemic level IL-1 is involved in the acute phase response. For
many years the ability of IL-1 to induce fever has been known, and also to
stimulate hepatocyte production of acute phase reactants including
metalloproteins, and alter serum zinc and iron levels. Experimental animal
models in which IL-1 has been administered intravenously result in effects
comparable to those seen in the human acute phase response (reviewed by
Dinarello, 1989).
1.3. THE INTERLEUKIN 1 MOLECULE
Interleukin 1 is produced as two distinct gene products, alpha and beta,
that have similar activity profiles and receptor binding characteristics,
these can be differentiated biochemically on the basis of isoelectric
focusing point (pi). The genes encode propeptides that are subsequently
cleaved to give the mature protein. Only processed IL-1 beta is biologically
active while both the IL-1 alpha propeptide and cleaved C-terminus (17 kDa)
have receptor affinity and biological activity.
1.3.a. The interleukin 1 gene
In 1984 the nucleotide sequence for murine IL-1 alpha cDNA was reported
by Lomedico et al, shortly followed by that for human monocytic IL-1 beta
(Auron et al, 1984). March et al (1985) then isolated and expressed two
human IL-1 cDNAs. The IL-1 alpha cDNA encoded a 271 amino acid (30.6 kDa)
propeptide which was proteolytically cleaved to give a 159 amino acid (17.5
kDa) mature acidic (pi 5) molecule. The IL-1 beta cDNA codes for a 269 amino
acid (30.75 kDa) precursor that is processed to the 153 amino acid (17.4 kDa)
neutral and biologically active form. The human IL-1 cDNAs have been
expressed in Escherichia coli (E coli), simian COS cells and Xenopus laevis
oocytes (Gubler et al, 1986; Rosenwasser et al, 1986; Auron et al, 1984).
Comparison between the human cDNAs shows 45% homology at the nucleotide level
suggesting that the two forms arose by a gene duplication event (March et al,
1985).
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Interleukin 1 alpha and beta have now been characterised at the gene
level, and both are known to be located on chromosome 2 (Lafarge et al, 1989;
Webb et al, 1986). The IL-1 genes have a similar overall structure with seven
exons and six introns. The human IL-1 alpha gene, sequenced by Furutani et al
(1986), is 10.2 kb long and has similar structural organisation to the murine
IL-1 alpha gene (Telford et al, 1986). The human IL-1 beta gene, (Bensi et
al, 1987) spans a 7.5 kb region. Analysis of the two human genes shows that
both have comparable exon length and splice site locations. The N terminal
cleaved part of the propeptides are encoded by exons 2, 3 and 4, with the
mature protein within exons 5, 6 and 7. It has been postulated that the IL-1
beta gene arose from retrotransposition of the alpha gene by Clark et al,
(1986), who identify a slightly larger gene form of 9.7 kb.
1.3.b. Gene expression
In unstimulated cells IL-1 protein can not be found indicating that
neither gene is constitutively expressed. However activation by a suitable
stimulus results in the rapid appearance of mRNA for both IL-1 alpha and
beta. In activated mononuclear cells IL-1 beta mRNA is approximately ten
times more abundant than that for IL-1 alpha (March et al, 1985). However
when total production of the respective proteins is considered IL-1 alpha is
the predominant form (Lonnemann et al, 1990; di Giovine et al, submitted). It
has therefore been suggested that IL-1 alpha mRNA may undergo more efficient
translation (Dinarello, 1989).
Analysis of the IL-1 genomic sequence identifies potential regulatory
regions, the conservation of intron structure between the two forms suggests
that these may be involved in gene control (Bensi et al, 1987). Searches for
promoter motifs has shown CAAT and TATA box sequences in the IL-1 beta gene.
The IL-1 alpha gene, however, has a poor TATA box and no obvious CAAT (Clark
et al, 1986). Other regulatory motifs have been shown in the IL-1 genes
including glucocorticoid regulatory elements, regions containing OCT 1 sites,
and binding sites for SP-1 like factors.
Studies on regulation of gene expression showed transient expression of
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IL-1 beta in response to LPS, thought to be mediated by both transcriptional
and post-transcriptional mechanisms (Fenton et al, 1987). Alterations in the
stability of IL-1 mRNA is thought to be involved in the regulatory mechanisms
(Fenton et al, 1988). A transcriptional activator has been identified that is
able to bind to upstream sequences of the pro IL-1 beta gene (Clark et al,
1988). Arend et al (1989a) have suggested that a transcriptional repressor of
IL-1 beta expression is produced by in vitro aged monocytic cells, and that
production of this factor may be linked to their differentiation to
macrophages. A recent report (Schindler et al, 1990) demonstrates
transcription of the IL-1 beta gene without the induction of protein
synthesis in blood mononuclear cells. Work by Turner et al (1988) has shown
that activation of the myelomonocytic cell line, THP-1 results in a similar
increase in transcription rate for IL-1 alpha and beta genes. They
demonstrate that the higher steady state level of IL-1 beta mRNA in THP-1
cells and monocytes is as a result of post-transcriptional control mechanisms
extending the half life of the mRNA (Turner et al, 1989). A similar effect is
seen in response to interferon gamma treatment (Burchett et al 1988).
Prostaglandins are reported to reduce the expression of IL-1 by a post-
transcriptional mechanism (Knudsen et al, 1986).
In vivo the systemic IL-1 level is potentially regulated by a complex
feedback network involving neuroendocrine hormone effects. Interleukin 1 is
able to stimulate adrenocorticotrophic hormone production (ACTH), either by a
direct action on the anterior pituitary or by stimulating the release of
corticotrophin releasing factor from the hypothalamus (reviewed in Lumpkin,
1987). Expression of the gene encoding pro-opiomelanocortin, the precursor of
both ACTH and the neuropeptide alpha-melanocyte stimulating hormone (alpha
MSH) is enhanced by IL-1 (Brown et al, 1987). ACTH acts on the adrenal glands
to promote corticosteroid production which, in turn, can inhibit IL-1
synthesis (Besedovsky et al, 1986; Knudsen et al, 1987). Alpha MSH is able
to inhibit IL-1 effects both in vitro and in vivo (Cannon et al, 1986;
Robertson et al, 1988).
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1.3.c. Interleukin 1 protein structure
Comparison of the sequences of the IL-1 protein molecules shows 62%
homology between human and murine IL-1 alpha but only 26% between human alpha
and beta forms (March et al, 1985). Of the identical residues the majority
are towards the C terminal of the 17 kDa molecule, though some homology is
also seen in the first 80 amino acids of the precursor peptide.
The structure of the interleukin 1 proteins has been analysed by various
groups. The initial crystal structure determination of mature IL-1 beta was
reported by Priestle et al in 1988, the molecule is composed of 12 beta
strands interacting via a complex network of hydrogen bonds to form a barrel
like structure. The overall shape was described as a distorted tetrahedron,
each face being triangular with hydrophobic side chains filling the interior.
The same group in 1989 described a refinement of the model from studies at
higher resolution (Priestle et al, 1989), they confirmed the original
structure and also described a high degree of conservation of amino acids
located at the interior. There was little clustering of invariant surface
amino acids and so definition of the area involved in receptor recognition
was not possible. Finzel et al (1989) showed a similar structural model with
predominant beta strands and no alpha helix. To account for the high affinity
of IL-1 for its receptor it is proposed that a region of large surface area,
containing several peptide segments, is necessary for the interaction. The
IL-1 alpha crystal structure has also been reported (Graves et al, 1990) and
shows a capped barrel shaped molecule with similar topology to IL-1 beta. The
N-terminal regions however are positioned differently, possibly explaining
why the additional propeptide residues in the IL-1 beta precursor interfere
with receptor binding.
Interleukin 1 propeptide structure has only been examined for the beta
form, using circular dichroism spectra (Hazuda et al, 1989). The data suggest
that mature and precursor forms both have similar secondary structure, the
latter though having some alpha helical regions. The IL-1 beta propeptide may
have a more open tertiary structure which would account for its increased
protease susceptibility in comparison to the mature form.
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Considerable effort has gone into defining functional domains within the
IL-1 molecules. By introducing point mutations various reports have shown
that isolated amino acid changes may result in alterations in local protein
structure, but in most cases overall folding and biological activity remain
unchanged (Driscoll et al, 1990; Gronenborn et al, 1986). The histidine at
position 30 (MacDonald et al, 1986) of IL-1 beta was shown to be important in
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stabilising part of the protein structure. A mutation of Arg to a glycine
was demonstrated significantly to reduce IL-1 beta bioactivity while
resulting in a smaller disruption of receptor binding ability (Gehrke et al,
1990). Muteins with enhanced activity have been produced (Huang et al, 1987),
and it is suggested that this effect may be due to altered stability, or
differences in interactions with the receptor molecule. It has been proposed
that other mutations, that reduce IL-1 bioactivity, are likely to act by
disrupting the tertiary structure (Priestle et al, 1989).
Truncated IL-1 molecules have been tested for biological activity and in
the majority of cases have shown that loss of a few amino (N) or carboxyl (C)
terminal amino acids considerably reduces the function of both forms
(DeChiara et al, 1986; Mosley et al, 1987a; Zurawski et al, 1986). This may
be due to disruption of the barrel-like structure of the folded molecule
(Finzel et al, 1989), particularly in the case of the C terminal region where
antibody binding has been shown not to affect interaction with the receptor
(Lillquist et al, 1988). Other antibody studies (Massone et al, 1988) show
that binding to regions 133-148 and 251-269 inhibited IL-1 beta activity in
the thymocyte proliferation assay and prevented fibroblast secretion of PGE2.
A synthetic peptide corresponding to amino acids 163-171 of IL-1 beta
was shown to have immunostimulatory but not inflammatory activity (Antoni et
al, 1986), however the peptide was only active at very high concentrations. A
tripeptide analogue of IL-1 beta (amino acids 193-195) was found to
antagonise the effect of the parent molecule in a rat paw hyperalgesic model
(Ferreira et al, 1988), but did not show agonist or antagonist IL-1 effect in
in vitro assays. The best characterised synthetic peptide studied
(Palaszynski, 1987) was composed of residues 237-269 of IL-1 beta. The
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peptide antagonised IL-lin the thymocyte assay and bound to the receptor.
1.4. THE CELL BIOLOGY OF INTERLEUKIN 1
1.4.a. Cell localisation
Various groups have studied the subcellular localisation of IL-1 using a
number of techniques. By fractionating cells to produce crude organelle
preparations, Matsushima et al (1986c) showed that in monocytes 95% of the
IL-1 could be found in the cytosol. The remaining activity was shown in
membrane and particulate fractions following detergent extraction. A similar
study by Bakouche et al, (1987a) identified IL-1 with crude plasma membranes
and with lysosomal and cytosolic compartments. Part of this activity appeared
to be in the inactive precursor form. Interleukin 1 could not be localised to
the endoplasmic reticulum. Conlon et al (1987) showed cell surface labelling
for IL-1 alpha but not IL-1 beta by flow cytometry.
Immunofluorescent staining of the stimulated U937 line co-localised IL-1
beta with cell microtubules (Baldari and Telford, 1989). By immunoelectron
microscopy IL-1 beta was predominantly found in the cytoplasmic ground
substance, no staining was identified at the plasma membrane or within the
endoplasmic reticulum, Golgi apparatus or secretory vesicles (Singer et al,
1988).
Various groups have identified IL-1 bioactivity at the plasma membrane,
though neither IL-1 molecule has an obvious hydrophobic spanning region
(Kurt-Jones et al, 1985; Beuscher and Colten et al, 1988). The activity was
inhibitable only with antibodies against IL-1 alpha (Fuhlbrigge et al,
1988b). However, this may be due to leakage of IL-1 precursor molecules from
the cell following insufficient parafomaldehyde fixation (Minnich-Carruth et
al, 1989; Suttles et al, 1990a). Fuhlbrigge et al (1988a) demonstrated, by
cell labelling, a transient association of IL-1 alpha with cell membranes in
transfected fibroblasts. Another group, also using transfected fibroblasts,
found no membrane IL-1 using a fractionation protocol designed to wash off
loosely bound proteins (Young et al, 1988). Interleukin 1 alpha propeptide is
also suggested to associate with the plasma membrane via a lectin-like
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interaction with integral proteins (Brody and Durum, 1989).
1.4.b. Interleukin 1 processing
Interleukin 1 alpha and beta are both produced as large molecular weight
(31 kDa) precursors that are cleaved at a specific site to give mature C-
terminal molecules. Incorrect processing that either leaves or deletes extra
amino acids has been shown, in the case of IL-1 beta, to affect the
bioactivity of the resultant product (Black et al, 1988). The majority of
work concerning the mechanisms involved in IL-1 cleavage has concentrated on
the beta form. The IL-1 beta primary translation product has no receptor
binding or biological activity, the IL-1 alpha propeptide however elicits
similar responses to the mature molecule (March et al, 1985; Hazuda et al,
1989).
Both IL-1 gene products are 31 kDa precursor molecules. Interleukin 1
alpha is cleaved from a 271 amino acid (aa) propeptide to the 159 amino acid
1 1 O 1 1 ^
mature form at the bond between arginine and serine (Gubler et al,
1986). Pro IL-1 beta has 269 amino acids and is processed to the 153 aa
mature form at the aspartate 116-alaninesite (Cameron et al, 1985). The
propeptide molecules have a high level of homology in the N terminal region
up to amino acid 80, however this area has no obvious signal sequence or
membrane spanning domain though IL-1 is secreted in vitro. Near the
proteolytic site a short sequence of polybasic residues are found that have
been compared to known processing sites on other prohormones (March et al,
1985). The bond cleaved in the IL-1 beta precursor is an uncommon substrate
for many proteolytic enzymes, being preceded by valine, histidine and
aspartate (Black et al, 1988).
The interleukin 1 processing event is highly inefficient, intracellular
IL-1 bioactivity has long been known to exceed extracellular activity
following LPS stimulation (Gery and Lepe Zuniga, 1984). Studies concerning
the kinetics of IL-1 protein production and release have shown that IL-1
alpha is predominantly cell associated, 95% being retained within the cell
following 18 hours of culture. Interleukin 1 beta, however, accumulates
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within the cell during the first two hours of culture and is then released
resulting in high extracellular levels (di Giovine et al, submitted).
Considerable cellular accumulation of IL-1 beta immunoreactivity is seen even
if secretion occurs, much of this may be the inactive 31 kDa form. Auron et
al (1987) estimate a ratio of 5:1 for intracellular to extracellular IL-1,
and suggest that this is due to the absence of an efficient signal sequence
to facilitate transport. Studies measuring IL-1 production and secretion by
immunoblotting show that mature IL-1 beta (17 kDa) is only found in culture
supernatants. However at the same time much larger amounts of extracellular
and intracellular propeptide have been reported (Bomford et al, 1987). It is
difficult to determine whether the presence of extracellular propeptide is
the product of specific secretion or a result of cell death.
Certain stimuli are able not only to induce IL-1 production but also to
increase the amount of secreted bioactive protein. Agents showing this effect
such as silica (Lepe-Zuniga and Gery, 1984) and monosodium urate (di Giovine
et al, submitted) are often particulate in nature and may cause membrane
damage, resulting in leakage of IL-1 protein from cells. The production of
large amounts of IL-1, usually for purification purposes, has identified a
superinduction protocol using cycloheximide (Mizel, 1982). Pulse labelling of
superinduced cells showed that a large amount of the radiolabelled IL-1
could be detected extracellularly and the majority was in a low molecular
weight form (Giri et al, 1985). This phenomena has been suggested to result
from a synergistic effect of the inducing agents leading to high IL-1 levels,
and a cytotoxic effect resulting in release of greater levels of
extracellular mature protein.
The presence of processed 31 kDa IL-1 in culture supernatants has led to
the suggestion that an enzyme responsible for cleavage is located either at
the cell surface or is secreted by the cell (Black et al, 1988; Bomford et
al, 1987). Hazuda et al (1988) however could show no processing of added
precursor by mononuclear cells in culture. Reports of specific processing of
pro IL-1 beta by cell membrane preparations (Black et al, 1988) and cytosolic
fractions (Kostura et al, 1989; Black et al, 1989b) have appeared.
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The gene encoding the cleavage enzyme may show tissue specific
expression. Both IL-1 alpha and IL-1 beta genes have also been transfected
into fibroblasts and no observable processed or secreted product was found
(Fuhlbrigge et al, 1988a; Young et al, 1988). In keratinocytes pro IL-1 beta
is also synthesised but is not converted to the mature molecule (Kupper et
al, 1986). The enzymes demonstrated in cytosol and membrane preparations have
not been found in non-myeloid cell types (Kostura et al 1989; Black et al,
1988).
It has been postulated that in certain situations, non-specific
proteases may be involved in IL-1 processing, resulting in production of
intermediates with extra N terminal amino acids (Hazuda et al, 1990). Such
proteolytic activity is described in inflammatory joint exudates from
arthritic patients and in lavage fluids from individuals with sarcoidosis.
1.4.c. Secretion of interleukin 1
Little is known about the mechanisms involved in the secretion of IL-1
from cells, as neither IL-1 molecule has a recognisable hydrophobic signal
sequence (March et al, 1985). It is unclear whether proteolytic processing
occurs before or after secretion, and the relevance of membrane damage as a
means of release in the in vivo situation is unknown.
Some reports describe a dissociation between the production of
intracellular IL-1 and its secretion, the data is summarised by Cavaillon and
Haeffner-Cavaillon (in press). The majority of studies use stimuli such as
the lipid A component of LPS or activation by cellular adhesion molecules to
dissociate synthesis and secretion events (Cavaillon et al, 1989; Cavaillon
et al, 1990). Many of these reports use bioactivity as an assessment of cell
associated and secreted IL-1 levels, and so do not differentiate between IL-1
alpha and beta or identify the IL-1 beta propeptide. One report, however,
describes the enhancement of IL-1 beta secretion by recombinant complement
5a (C5a) in which the cell associated IL-1 beta levels are not altered
(Cavaillon et al, 1990). Bacle et al (1990) reported that monomeric
complement stimulates IL-1 production but not release, whereas the polymeric
17
form induces both. A similar effect has also been demonstrated for interferon
gamma augmentation of IL-1 beta secretion (Cavaillon and Haeffner-Cavallion,
in press). This effect is seen with different types of stimuli, liposome
encapsulated LPS also results in normal levels of intracellular IL-1 but no
secreted molecule (Bakouche et al, 1987b). Kern et al (1988) have shown that
dexamethasone is able dramatically to inhibit the secretion of IL-1 beta
while only moderately reducing its synthesis.
Burchett et al (1988) showed that stimulation of in vitro aged monocytes
resulted in lower levels of total IL-1 production, and in the proportion of
IL-1 beta protein that was secreted when measured by bioassay or
immunoblotting. Other studies showed that when activation of IL-1 production
occurred in unstimulated cells it was characterised by a transient increase in
intracellular activity with no apparent secretion (Mizel and Rosenstreich,
1979; Lepe-Zuniga and Gery, 1984).
Secretory proteins are commonly translocated across the membrane and
into the lumen of the endoplasmic reticulum (ER), during or shortly after
synthesis. Involved in this process are integral protein signal sequences
and receptor-like components in the cytosol and on the target membrane
(reviewed by Verner and Schatz, 1988).
A protein is directed to its target membrane by a signal sequence that
is usually located at the N terminus (Gierasch, 1989). This sequence is
likely to be recognised as a characteristic secondary or tertiary structure.
The signal region binds to the cytosolic face of the ER, and the growing
protein is translocated across the membrane as a loop that opens when the C
terminus reaches the luminal side. Secretory proteins such as ovalbumin (Meek
et al, 1982) are known in which an internal signal sequence is utilised.
A number of cytosolic components are necessary for the translocation
event. A signal recognition particle binds to the emerging signal sequence
during translation, this may result in arrest of further protein synthesis.
The complex then associates with a docking protein on the ER, where the
signal sequence can interact with a membrane signal sequence receptor (Walter
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et al, 1984). It is thought that other cytosolic chaperon molecules are
involved in translocation, these may be important in maintaining the loosely
folded conformation of the nascent protein allowing it to pass through the
membrane (Pelham, 1989; Flynn et al, 1989). The signal sequence is usually
removed by integral membrane proteases on the luminal side of the ER.
Within the ER a protein is able to fold into its mature tertiary
structure and oligosaccharides may be added. It is transported to the ef¬
face of the Golgi apparatus where oligosaccharides are modified. When
complete the protein leaves the trans -face of the Golgi via the budding off
of transport vesicles, these are directed either to secretory vesicles or to
the plasma membrane (Schwartz, 1990).
Interleukin 1 molecules have no characteristic signal sequence, though
Auron et al (1985) used hydropathy index data to suggest that a 17 residue N
terminal hydrophobic region may substitute for this function. In comparison
the TNF molecule has a long hydrophobic segment that is thought to promote
efficient secretion. It has been suggested that IL-1 is therefore released by
means of an alternative mechanism (Furutani et al, 1985).
Reticulocyte lysate preparations have been shown to be incapable of
inserting the IL-1 propeptide into dog pancreas microsomes (Lomedico et al,
1984; Suttles et al, 1990b). Various studies indicate that IL-1 forms are not
present in the ER, Golgi or secretory vesicles (Singer et al, 1988). Baldari
et al (1987) report that fusion of a characteristic leader sequence onto IL-1
beta results in high secreted levels of the correctly processed molecule.
However other workers were unable to effect secretion from E. coli when IL-1
beta was fused to an efficient signal region (Denefle et al, 1989).
A number of secretory pathways for IL-1 have been suggested. The debated
presence of membrane IL-1 has resulted in the theory that a membrane linked
intermediate may play a role in release of the alpha form (Bakouche et al,
1987a). In the case of IL-1 alpha the propeptide has been demonstrated to
associate with the membrane via a lectin-like interaction (Brody and Durum,
1989). This membrane form is suggested to be involved in the secretory
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pathway by which IL-1 alpha is released from the cell.
A report by Bursten et al (1988) showed that both IL-1 alpha and beta
precursors may be covalently linked to myristic acid during synthesis, this
modification was lost with removal of the pro-peptide portion. Myristylation
is thought to occur co-translationally (Sefton and Buss, 1987) and to direct
proteins to the plasma membrane (Pellman et al, 1985).
Another modification reported for IL-1 involves precursor
phosphorylation, which may also provide some localisation signal. Weiel et al
(1986) showed that LPS stimulation of macrophages resulted in increased
phosphorylation of a number of proteins, the highest level being seen in a 33
kDa species. Two reports of IL-1 precursor phosphorylation have since been
published, Beuscher et al (1988) identified residue Ser^® in IL-1 alpha as a
32 P labelled site and Kobayashi et al showed that the IL-1 alpha molecule was
phosphorylated at ten fold higher levels than IL-1 beta. Labelling was not
seen in mature IL-1. Beuscher et al report that phosphate labelled IL-1 alpha
localises to the lysosomes, in agreement with Bakouche et al (1987a) who
propose cleavage in and secretion from these organelles. The second report
suggests that pro IL-1 alpha is more susceptible to proteolytic cleavage
following phosphorylation which may serve as a signal for processing.
The observed association of pro IL-1 beta with tubulin has led to the
suggestion that direct transport to the cell surface may be mediated by the
microtubular network (Baldari and Telford, 1989). The role of tissue specific
mechanisms has also been questioned, prompted by the co-localisation of IL-1
in keratinocytes with the secretory lamellar bodies (Didierjean et al, 1989).
1.4.d. Novel secretory pathways
A group of secretory proteins has recently been identified which lack
the classical signal sequence and may follow a novel secretory pathway
(Muesch et al, 1990). Members of this group include IL-1, acidic and basic
fibroblast growth factors and platelet derived growth factor. These are
present at high intracellular levels, indicative of inefficient secretion,
and do not undergo modifications that usually occur in the ER or Golgi.
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Evidence for a novel pathway is provided by Rubartelli et al (1990). They
propose that IL-1 is selectively located in intracellular vesicles that may
be part of the endocytic pathway. These fuse with the plasma membrane in a
temperature and calcium dependent manner and the precursor molecule is
cleaved on release from the cell. An involvement of calcium in IL-1 secretion
has also been suggested by Suttles et al (1990b) who found that calcium
ionophores enhanced release and processing.
1.5. THE INTERLEUKIN 1 RECEPTOR (IL-1 R)
Though IL-1 alpha and beta have little sequence homology both have
comparable actions and appear to act through a common receptor. Initial work
to identify the receptor led to the cloning of an 80 kDa protein with high
affinity (dissociation constant 10 ~^®M) for both IL-ls. Since then further
studies have shown the existance of other IL-1 binding molecules. The best
characterised of these is a 60-70 kDa molecule that appears to act as a
distinct receptor on B cells and monocytes.
1.5.a. The 80 kDa interleukin 1 receptor
The 80 kDa IL-1 receptor has been identified on a number of cell types
(Dower and Urdal, 1987). Commonly, studies use human or murine T cell or
fibroblast lines, but the receptor molecule has also been identified in
tissues such as cultured synovium (Chin et al, 1988), human and murine
neutrophils (Paganelli-Parker et al, 1989) and rat brain sections (Farrar et
al, 1987).
The initial report identifying the 80 kDa IL-1 binding protein was
published by Dower et al in 1985. They showed that radiolabeled IL-1 could
be cross linked to a molecule on a murine T lymphoma line, and estimated that
there were 500 receptors/cell with an affinity constant of approximately
10"Further work showed that this receptor bound both IL-1 alpha and beta
(Dower et al, 1986). At the same time Bird and Saklatvala (1986) had
identified a common class of receptor for IL-1 alpha and beta on connective
tissue cells. The rate of association of ligand to receptor is very slow, and
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once bound IL-1 does not dissociate (Kilian et al, 1986). The protein has
been solubilised and its characteristics as an isolated molecule shown to be
similar to the native form (Paganelli et al, 1987).
Analysis of the receptor showed that the protein was glycosylated,
treatment with N-glycanase reduced its molecular weight to 62 kDa (Urdal et
al, 1988). However an antiserum capable of immunoprecipitating the IL-1/IL-1R
complex has identified a 52-56 kDa unprocessed form by in vitro translation
that binds ligand (Rangnekar and Plate, 1988). The receptor binds the IL-1
alpha but not the beta propeptide (Mosley et al, 1987b).
1.5.b. Cloning and characterisation of the IL-1R
The murine IL-1 receptor was cloned by direct expression from mRNA
isolated from the EL-4 line (Sims et al, 1988). The cDNA sequence identifies
a protein of molecular weight 64.6 kDa, a similar size to that estimated for
the deglycosylated receptor. The extracellular N-terminal segment is 319
amino acids long and has seven potential N-linked glycosylation sites. It
forms three domains that are comparable to those seen in members of the
immunoglobulin superfamily. The transmembrane region consists of a stretch of
21 uncharged amino acids, while the cytoplasmic domain has 217 residues and
includes a potential protein kinase C phosphorylation site. Purification of
the IL-1 receptor protein and amino acid sequencing of protease fragments
confirmed the identity of the cloned molecule (Stern et al, 1989).
Transfection of the murine IL-1R cDNA into Chinese hamster ovary cells
resulted in expression of the molecule at the cell membrane and enhanced
functional responses to IL-1 (Curtis et al, 1989). The human 80 kDa receptor
was cloned by Sims et al (1989) and shown to have similar structural
characteristics to the murine molecule. When transfected into COS cells two
classes of receptor with affinity constants comparable to those on the parent
cells were expressed.
Analysis of the structure of the IL-1 receptor indicates that though the
size of the 80 kDa molecule is not altered under reducing conditions breaking
of a disulphide bond may lead to loss of binding activity (Paganelli-Parker
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and Kilian, 1988). A study by Speziale et al (1989) shows that the presence
of high concentrations of lectins affects the ability of IL-1 to bind to its
receptor, suggesting that carbohydrate moieties may be important for ligand
interactions. Further reports indicate slight differences in size of the
IL-1R seen in some instances (Bird and Saklatvala, 1987) may be due to
alterations in carbohydrate levels on the protein. Mancilla et al (1989)
suggest that the lectin effect differs according to cell type. Solari (1990)
has shown two receptor forms on D10 cells of 80 and 60 kDa that have
comparable peptide cleavage maps but may have different glycosylation
patterns. These forms can also be distinguished by their preferential binding
characteristics for IL-1 alpha and beta. Savage et al (1989) also show, using
antibody recognition, that a 73 kDa receptor on their D10 line is related to
the 80 kDa molecule.
1.5.c. The 60 kDa interleukin 1 receptor
The 60 kDa receptor was first described by Matsushima et al (1986a) on
Epstein Barr virus transformed B cells, it was shown that more IL-1 alpha
than beta was required to inhibit labelled IL-1 beta binding. Further reports
have shown that cells with this receptor preferentially bind IL-1 beta
(Scapigliati et al, 1989), but at a lower affinity than that seen for the
80 kDa receptor (Horuk et al, 1987). This lower affinity is thought to be due
to a combination of a lower rate of association and a higher rate of
dissociation of ligand (Horuk and McCubrey, 1989). The two receptor forms
were compared using IL-1 analogues, and were shown to have different binding
profiles (Horuk et al, 1987). By binding IL-1 alpha to B cell lines Bensimon
et al (1989b) have shown the presence of a 68-72 kDa receptor band that can
be separated into a high and a low affinity component.
The B cell receptor is glycosylated and treatment with endoglycosidase F
reduces its molecular weight to approximately 48 kDa (Horuk and McCubrey,
1989). This form of IL-1 receptor is thought to be a distinct gene product as
antibodies specific for the T cell receptor do not recognise the smaller
molecule (Chizzonite et al, 1989). The mRNA for the 80 kDa receptor is also
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not found in B cells by Northern analysis or SI nuclease protection (Bomsztyk
et al, 1989).
A recent study by Benjamin and Dower (1990) suggests that on the
majority of EBV transformed B cell lines two classes of receptor exist, these
show differential affinities for IL-1 alpha but bind 1L-1 beta with the same
affinity. Two molecular weight factors can also be demonstrated at 80 and 70
kDa. The EBV positive Burkitt lymphoma, Raji line is proposed to represent a
second type of B cell that expresses only the 70 kDa factor and is unable to
bind IL-1 alpha (Benjamin et al, 1990). In the case of the insulin receptor
two molecules with different affinities have been described, that are
produced as a result of alternative splicing of the same mRNA (Mosthaf et al,
1990).
1.5.d. Interleukin 1 receptor expression
The IL-1 receptor molecule is present at variable levels depending on
cell type (Sipe, 1989). On T lymphocytes expression of IL-1R has been
demonstrated on CD4+ cells (Lowenthal and MacDonald, 1987), levels can be
increased by stimulation with concanavalin A, with similar kinetics to the
IL-2 receptor (Shirakawa et al, 1987; Dower and Urdal, 1987). The IL-1
receptor has also been shown on CD8+ cytotoxic T lymphocytes (Klarnet et al,
1989). Recent reports describe variable receptor expression on the D10 cell
line that can be modified by exogenous stimuli or ageing of the cells
(Solari, 1990; Savage et al, 1989). In the case of the B cell receptor,
glucocorticoids have been shown to increase the number of binding sites but
not to affect affinity (Akahoshi et al, 1988).
It has often been noted that the affinity constant of the described
receptor forms is several orders of magnitude above the concentration of IL-1
required to elicit a biological response (Savage et al, 1989). However some
groups have detected higher affinity receptors and suggest these are
responsible for mediating IL-1 function. Chin et al (1987) have shown that
receptors on human lung fibroblasts bind IL-1 with dissociation constants in
the picomolar range. Lowenthal and MacDonald (1986) demonstrated two classes
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of IL-1 binding on EL-4 cells one has higher affinity and comprises 1-2% of
the total receptor number. It has been suggested that the appearance of this
form may be due to conformational changes in the receptor (Dinarello et al,
1989). It is possible that such high affinity receptors cannot be confidently
identified by conventional Scatchard analysis.
1.5.e. Proteins associated with the IL-1 receptor
High molecular weight cross-linked bands at about 140 and 120 kDa have
been demonstrated by various groups (Martin et al, 1988; Bird et al, 1987;
Dower et al, 1985). The former may represent a complex between the 80 kDa
characterised receptor and a 40 kDa moiety described by Kroggel et al (1988),
while the latter may include a 26-30 kDa molecule (Bron and MacDonald, 1987;
Savage et al, 1989). The 30 kDa band has been partially characterised and
increased levels are seen after treatment of D10 cells with lectin, it may in
some way stabilise the receptor within the membrane. This data has been used
to describe a two chain IL-1 receptor in which the smaller molecule
transduces the cellular signal. A recent report by Lewis et al (1990) using
anti IL-1 receptor antibodies identifies components at 45, 50 and 68 kDa that
associate with the 80 kDa receptor. An EL-4 cell variant has been identified
that can bind IL-1 but is defective in its ability to internalise (Von Hoegen
et al, 1989). This data has been used to suggest the need for a second factor
to achieve ligand internalisation in these cells (Lewis et al, 1990).
1.5-f- Interleukin 1 signal transduction
There are several theories concerning the mechanism by which the IL-1
receptor binding event transduces a signal to the nucleus. It has been shown
that binding of IL-1 to the 80 kDa molecule results in rapid internalisation
of ligand (Bird and Saklatvala, 1987). It appears that some receptor-bound
IL-1 is degraded in the lysosomes (Matsushima et al, 1986d; Quarnstrom et al,
1988) while a fraction can be located in an intact form at the nucleus (Mizel
et al, 1987; Curtis et el, 1990). Interleukin 1 receptors are present in
intact isolated nuclei (Grenfell et al, 1989).
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To account for the more rapid effects of the cell in response to IL-1
various mechanisms have been suggested. Rosoff et al (1988) propose a novel
system in which diacylglycerol is produced in the absence of
phosphatidylinositol mobilisation. Other studies suggest adenylate cyclase
activation (Chedid et al, 1989) or receptor phosphorylation (Gallis et al,
1989) as potential second messenger systems. Phosphorylation of cellular
proteins in response to IL-1 has been observed (Kaur and Saklatvala, 1988). A
32triad of 27 kDa factors that label with P at serine or threonine residues
following IL-1 stimulation, has been demonstrated. Transmodulation of
epidermal growth factor receptors has also been shown in response to IL-1,
this is again thought to be dependent on phosphorylation of the receptor
itself, but not to act via protein kinase C activation (Bird and Saklatvala,
1989).
In the case of the 60 kDa receptor there is little apparent
internalisation (Horuk et al, 1987), but a transient translocation of protein
kinase C to the membrane has been noted (Bomsztyk et al, 1989).
1.6. MODULATORS OF INTERLEUKIN 1 ACTION
It has long been known that factors present in biological fluids are
able to affect the in vitro functions of IL-1. Initial reports noted that LAF
activity in serum could only be detected when samples were at high dilution
(Wood et al, 1983b) and that the levels of these factors could be influenced
by the immunological condition of the host (Dinarello et al, 1981). More
recently specific IL-1 inhibitors have been identified and characterised to
varying degrees. These inhibitors could act at several levels: they can bind
IL-1 itself and prevent receptor interaction, act as specific receptor
antagonists, or alter the response of the cell to ligand binding (Larrick,
1989).
1.6.a. Interleukin 1 inhibitors
One IL-1 inhibitor has been particularly well characterised and recently
cloned. The molecule was first identified by two groups, Arend et al (1985)
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demonstrated that monocytes stimulated by PMA or immune complexes produced a
22 kDa factor able to inhibit IL-1 action in the LAF assay and on articular
chondrocytes. A factor of comparable molecular weight was demonstrated in the
urine of febrile patients (Seckinger et al, 1987b) and was able to prevent
the production of PGE2 and collagenase in response to both IL-1 molecules.
The inhibitor was further shown to compete with iodinated IL-1 for cell
binding sites suggesting a direct interaction with the receptor molecule
(Seckinger et al, 1987a). Kinetics of production of the inhibitor suggest
that release may be induced during monocyte differentiation (Roux-Lombard et
al, 1989).
The inhibitor has been purified and shown to be present as three forms
with similar N-terminal amino acid sequence but differing in their degrees of
glycosylation (Hannum et al, 1990). The factor binds to the 80 kDa IL-1
receptor with a similar affinity to the ligand but does not compete for
binding on a B cell line. Eisenberg et al (1990) isolated the inhibitor cDNA
and showed that it encoded a protein with a classical signal sequence and was
processed to a 17.1 kDa mature protein. When expressed in E. coll the
inhibitor had similar mobility to the non-glycosylated, purified form and
blocked IL-1 activity in the fibroblast assay. Sequence comparison with both
IL-Is shows 26% homology with IL-1 beta and 19% with IL-1 alpha. A similarity
in hydrophobicity plots is seen with IL-1 beta at the C-terminal region. The
same inhibitor has also been cloned from the myelomonocytic line U937 and
expressed in E coli (Carter et al, 1990). This molecule has been shown to
inhibit the in vivo IL-1 effects on corticosteroid induction and neutropenia.
Another glycoprotein, uromodulin, isolated from the urine of pregnant
women has been shown to be inhibitory in the thymocyte proliferation assay
(Brown et al, 1986). The 85 kDa molecule (related to Tamm-Horsfall protein)
was found to act by binding to both IL-1 and lectin (Muchmore and Decker,
1987). Due to its selective localisation in the kidney uromodulin has been
suggested to play a role in the renal regulation of circulating IL-1 activity
(Hession et al, 1987).
Brown and Rosenstreich (1987) described a 30-35 kDa moiety also derived
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from human urine that was able to inhibit IL-1 action in the LAF assay, but
was inactive in other assays (Korn et al, 1987). The protein was found to
have sequence homology with DNAse 1 (Rosenstreich et al, 1988), and acted by
releasing unlabelled thymidine from dead cells effectively diluting the
tracer (Svenson and Bendtzen, 1989).
A synthetic peptide with homology to the envelope proteins of a number
of viruses has been shown to inhibit monocyte cytotoxicity, studies indicate
that the effects of IL-1 were blocked. The peptide inhibits IL-1 in the LAF
assay and on the D10 line (Kleinerman et al, 1987), and has been demonstrated
to prevent signal transduction by the IL-1 receptor (Gottlieb et al, 1989).
Other less well-characterised inhibitors have been described, most have
been identified by the thymocyte co-mitogenic assay, the effects seen may
therefore be a result of non-specific interactions with the lectin or other
cytokines known to be active in the system. Monocytes activated with
cytomegalovirus and B cell lines have been reported to produce a 95 kDa
inhibitor (Rodgers et al, 1985; Scala et al, 1984; Roberts et al, 1986). LAF
inhibitors have also been produced by epidermal cells and neutrophils in
culture (Schwarz et al, 1987; Tiku et al, 1986).
The effects of IL-1 are also subject to modulation by other cytokines,
the best characterised is TGF beta that blocks IL-1 action in vitro in the
thymocyte proliferation assay (Wahl et al, 1988).
1.6.b. Soluble receptor molecules
In a variety of cases the surface receptor for a particular ligand has
been identified in soluble form. Different cellular mechanisms result in
release of these molecules. In some cases separate genes encode the surface
and soluble receptors (Kress et al, 1983). Other instances describe
alternatively spliced mRNA, in the case of the N-CAM adhesion molecule an in-
frame stop codon is introduced that terminates the coding sequence before the
transmembrane segment (Gower et al, 1988). The major histocompatability Qa-2
antigen and CD16 have an anchoring phospholipid tail that is subsequently
cleaved (Stroynowski et al, 1987; Huizinga et al, 1988). The IL-2 receptor
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however is solubilised by proteolytic cleavage at the cell surface (Robb and
Kutny, 1987).
Soluble receptors have been suggested to serve a regulatory role, they
may bind to and inhibit the action of the ligand as is the case with the IL-2
receptor (Kondo et al, 1988; Symons et al, 1988), or serve as carrier
molecules.
Soluble receptors have now been described for a number of cytokines
including IL-6 and interferon gamma (Novick et al, 1989), IL-4 (Mosley et al,
1989), TNF (Schall et al, 1990) and IL-7 (Goodwin et al, 1990).
A soluble form of the 80 kDa IL-1 receptor has not yet been identified,
but by constructing a cDNA of residues 1-316 a truncated receptor has been
expressed. This receptor binds IL-1 alpha in a comparable manner to the
intact molecule (Dower et al, 1989), and has IL-1 inhibitory activity in an
in vitro B cell proliferation assay (Maliszewski et al, 1990) and an in vivo
allograft rejection system (Fanslow et al, 1990).
1.6.c. Circulating autoantibodies
The presence of autoantibodies to cytokines in normal individuals has
been discussed by Bendtzen et al (1990) in a recent review. They have been
implicated to occur commonly at low levels and may have a carrier function
protecting the molecule from degradation and elimination, or serve as
inhibitory factors to control cytokine effects. Pharmacological
administration of an anti-interferon/interferon complex resulted in reduced
systemic clearance while not affecting in vitro anti-viral activity
(Rosenblum et al, 1985). Autoantibodies to TNF and lymphotoxin have been
identified in the serum of healthy individuals and laboratory animals (Jeffes
et al, 1989) suggesting that they are a normal phenomenon. Higher levels of
anti-TNF antibodies have also been associated with infections and
inflammatory disease (Fomsgaard et al, 1989). Other cases of autoantibodies
to cytokines had previously only been seen in disease states (Panem et al,
1982; Bost et al, 1988) or when the immunogen had been administered in
therapeutic trials (Vallbracht et al, 1981).
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A high molecular weight IL-1 alpha binding factor present in human sera
was investigated and found to be due to circulating autoantibodies. Further
investigation has shown these to be present in the sera of 10% of normal
individuals (Svenson et al, 1989), they have higher affinity than some cell
surface IL-1 receptors and can compete in ligand binding assays.
1.6.d. Alpha 2 macroglobulin
Alpha 2 macroglobulin (alpha 2M) is a common molecule in serum known to
bind many circulating proteins and has various immunomodulatory effects. The
protein is composed of four subunits and undergoes a conformational change on
entrapment of ligand. This may serve to expose a hydrophobic region that can
interact with macrophages and hepatocytes and facilitate uptake from the
circulation (Feldman et al, 1985).
Cytokine interactions with alpha 2M have recently been reviewed (James,
1990). An early report showed that platelet-derived growth factor was able to
interact with plasma alpha 2M (Huang et al, 1985). In the case of basic
fibroblast growth factor alpha 2M appears to bind covalently and inactivate
the molecule, and may promote its removal from the circulation (Dennis et al,
1989). However transforming growth factor beta (TGF beta) binds in two ways
to alpha 2M: covalently and as a latent, acid removable form (Huang et al,
1988) that may retain biological activity (O' Conner-McCourt and Wakefield,
1987). Alpha 2M is thought to act as a carrier molecule for serum IL-6 and
complex formation does not inhibit IL-6 biological activity but makes the
cytokine more resistant to proteolytic degradation (Matsuda et al, 1989).
Two groups have investigated the binding of IL-1 to alpha 2M, Borth and
Luger (1989) demonstrated labelled IL-1 binding to a high molecular weight
moiety in human plasma that could be precipitated by antibodies to alpha 2M.
Teodorescu et al (1988) showed that IL-1 bound covalently and non-covalently
to alpha 2M and that the complex retained bioactivity.
1.7. THE PHYSIOLOGICAL AND PATHOLOGICAL ROLES OF IL-1
The importance of IL-1 in eliciting an effective immune response and in
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mediating a local inflammatory reaction have been previously discussed,
however IL-1 may also be involved in normal physiological processes as is
indicated by its presence in various ex vivo biological fluids. Endogenous
pyrogen activity has been shown to be raised in the plasma of normal subjects
following exercise (Cannon and Kluger, 1983), and in women after ovulation
(Cannon and Dinarello, 1985). Interleukin 1 bioactivity has also been
demonstrated in amniotic fluid, indicative of a role in reproduction (Romero
et al, 1989). A role for IL-1 in systems such as normal bone turnover and
sleep processes have also been suggested (Gowen et al, 1983; Dinarello,
1989).
The protective roles of IL-1 in response to acute infection have been
discussed. A chronic disease state or autoimmune reaction may result from
abnormal regulation of these host defence mechanisms. The inflammatory
processes associated with local IL-1 release are themselves damaging to host
tissue, if the subsequent repair process is inefficient or if cytokine
production is dysregulated severe tissue damage may occur, as seen in
conditions such as rheumatoid arthritis (Duff et al, 1988b).
The postulated role of IL-1 in a number of destructive disease
processes, such as diabetes, kidney inflammation and neurological disease has
been summarised by di Giovine and Duff (1990). Many of the in vitro
properties of IL-1 suggest that it may be produced at high concentrations in
the joint and contribute to the destructive process seen in rheumatoid
arthritis.
1.7.a. Interleukin 1 in rheumatoid arthritis
Rheumatoid arthritis (RA) is a disease with both local and systemic
manifestations. The disease is characterised by inflammation of the synovial
membrane that lines the joint space, This leads to proliferation of synovium
and cellular infiltration. The synovium then invades articular cartilage and
subchondral bone, resulting in the joint destruction that is characteristic
of RA (Henderson et al, 1987). The disease also has many systemic
manifestations: an acute phase response is often seen in acute flares and
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muscle wasting, weight loss and depression of cell-mediated immunity are
typical (Duff, 1989). An overall activation of the immune system in RA is
indicated by the presence of autoantibodies in the serum and joint exudate
and raised levels of various soluble surface protein and receptor molecules
released following cellular activation, such as the soluble IL-2R and CD8
(Wood et al, 1988; Symons et al, 1990).
Many of the actions of IL-1 indicate that it may play a role in the
disease process of rheumatoid arthritis. Porcine catabolin was initially
identified by its ability to induce cartilage resorption (Saklatvala, 1981),
and it was later demonstrated that this was due to IL-l's stimulatory effect
on chondrocytes resulting in the secretion of collagenase and proteoglycanase
(Gowen et al, 1984). Synovial cells also produce prostaglandins and reactive
oxygen species in response to IL-1, resulting in further inflammation and
tissue damage (Dinarello, 1986). Additionally IL-1 has bone resorbing
activity in vitro (Gowen et al, 1983). Intra-articular injection of IL-1
results in leukocyte infiltration into the joint space and the breakdown of
articular cartilage (Pettipher et al, 1986). Many of the systemic
disturbances seen in RA such as fever, the acute phase response and immune
activation could also be attributed to IL-1.
Further evidence for a role of IL-1 in RA is its presence in
inflammatory joint effusions. The measurement of IL-1 in biological fluids is
difficult as bioassays may be non-specific and sensitive to any inhibitors
present. A number of reports, however, have identified and partially
characterised IL-1 bioactivity in synovial exudates (Wood et al, 1983a; Nouri
et al, 1984; Fontana et al, 1982). Interleukin 1 has also been shown to be
released by disaggregated synovial tissue into culture medium (Wood et al,
1985). Since specific immunoassays have become available high levels of both
forms of IL-1 have been detected in RA synovial fluid (Symons et al, 1989; di
Giovine et al, 1990), and in a double knee study IL-1 beta levels have been
shown to be higher in the fluid from an inflamed joint when compared to a
less inflammed or uninvolved contralateral joint (Rooney et al, in press).
Interleukin 1 mRNA levels in synovial tissue have been studied. In
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cultured disaggregated tissue IL-1 alpha mRNA levels were higher than beta,
but expression was more transient (Buchan et al, 1988). Using in situ
hybridisation on synovial sections IL-1 beta mRNA appears most abundantly and
is commonly expressed by cells staining with macrophage markers (Duff et al,
1988a; Firestein et al, 1990).
1.7.b. Measurement of circulating IL-1 levels
For some time it has been evident that serum or plasma contains many
inhibitory factors that prevent detection of IL-1 by bioassay. Detection of
circulating IL-1 therefore necessitated prior fractionation. This often
resulted in the demonstration of activity at higher and lower molecular
weights than predicted for IL-1 (Dinarello et al, 1984). The availability of
immunoassays has allowed more reliable detection of blood IL-1 levels, though
some of the protein may be in the biologically inactive precursor form.
Factors also appear to be present in plasma that can mask IL-1
immunoreactivity in some assays (Capper et al, 1990; Cannon et al, 1988).
Many studies of IL-1 production in normal and disease situations have
therefore used isolated peripheral blood mononuclear cells, to determine
levels of synthesis and ex vivo activation state. These investigations have
identified two distinct populations, that are described as high and low
producers respectively (Molvig et al, 1988). The intersubject variability of
IL-1 production in response to LPS has been described as extending over two
orders of magnitude (Endres et al, 1989), and can be attributed in part to to
the MHC class II haplotype expressed by the individual (Santamaria et al,
1989).
Studies concerning the rate of clearance of IL-1 using animal models
showed that IL-1 was primarily cleared by the kidney (Kampschmidt and Jones,
1985). More recent work with radiolabeled IL-1 beta showed biphasic
clearance from the blood with half lives of 3 minutes and 4 hours
respectively (Klapproth et al, 1989). Circulating IL-1 was seen to be
associated with the plasma fraction (Newton et al, 1988) and the route of
clearance was again found to be the kidney, significant amounts of IL-1 were
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also found to localise in the liver and intestine.
1.8. STUDY AIMS
Interleukin 1 is a factor with an important role in the mobilisation of
an efficient immune response through both a systemic and a localised
inflammatory action. It may however have destructive potential if the
controls regulating its production or action are ineffective.
The aim of this study was to identify circulating IL-1 present in both
normal and disease states. In particular, levels in rheumatoid arthritis were
examined, in an attempt to assess further the role of IL-1 in the
pathogenetic process. We also hoped to define any factors that associated
with the molecule in plasma and assess their ability to modify or inhibit IL-
1 bioactivity.
As an approach to modulating the potentially-damaging effects of IL-1 in
vivo we also tried to identify and characterise cellular enzymes responsible
for processing the beta form. The aim was to block enzyme action using
synthetic peptides designed around the cleavage site of the IL-1 beta
propeptide, and thus prevent either release from the cell or the surface/






Continuous cell lines and primary cultures were maintained in RPMI 1640
(Northumbria Biologicals Ltd (NBL), Northumberland), which was supplied as a
lOx concentrated solution. The stock was diluted with sterile distilled water
(Travenol; Baxter, Norfolk) and sodium bicarbonate added as a buffering agent
(2.2g/l; NBL), the pH was then adjusted to 7.4 with sodium hydroxide (IN;
NBL). Before use, medium was supplemented with 5 or 10% heat inactivated
(56° C for 30 minutes) foetal calf serum (FCS, NBL), glutamine (2mM; NBL) and
penicillin/streptomycin (lOOU/ml; NBL).
2Cell lines were routinely cultured in 75cm flasks (Costar, NBL) and
passaged as required. Growth was maintained at 37° C in a humidified
atmosphere with 5% CC^- Culture supernatants were regularly tested for the
presence of mycoplasma (Section 9.1.a.).
2.1.b. Interleukin 1 bioassay
A subclone of the mouse thymoma EL-4 cell line originally described by
Gearing et al, (1987) was used for IL-1 assay. The line EL-4.NOB-1 when
stimulated by IL-1 responds by producing IL-2, which can be measured by its
ability to maintain the viability of the IL-2 dependent cytotoxic T cell line
CTLL-2. The NOB-1 line was routinely grown in RPMI with 5% FCS and passaged
regularly to keep cultures at a low density. If allowed to reach high density
cells start to secrete IL-2 spontaneously. Growth in low serum medium (1%
FCS) for one week was used to restore inducible production. CTLL-2 cells were
grown in media containing 5% FCS and supplemented with 5% crude T-cell growth
factor (TCGF) prepared from rat spleen cell culture (Section 9.1.b.).
Cultures were re-fed with TCGF every 2-3 days.
For assay, EL-4 cells were washed and resuspended in fresh medium at a
density of 2xl0^/ml and lOOul seeded in 96 well plates (NBL). Human
recombinant IL-1 alpha or IL-1 beta (National Institute for Biological
Standards and Control (NIBSC), Hertfordshire) was used as a standard curve at
concentrations between lng/ml and lOOfg/ml. Samples were tested in triplicate
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at 10%, 1% and 0.1%. One hundred microlitres of standard, sample, or media as
a negative control, was added to appropriate wells and the plate incubated
for 24 hours.
Culture supernatants were then harvested, 50ul was transferred from each
well into a duplicate 96 well plate. CTLL-2 cells were resuspended at
lxlO^/ml in fresh media and 50ul was added to each well. Rat TCGF at 5% was
used as a positive control, and media alone as negative control.
After 20 hours of culture, viability of the CTLL-2 cells was measured using a
colourimetric assay first described by Mosmann (1983). 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazoluim bromide (MTT; Sigma, Dorset),
is a yellow substrate that is converted to a blue formazan product by
mitochondrial enzymes. Ten microlitres of MTT (5mg/ml in phosphate buffered
saline (PBS, Section 9.3.a.)), was added to each well for 4 hours, the
formazan was then solubilised by addition of lOOul 0.04N hydrochloric acid
(HC1; BDH) in isopropanol (Sigma). This was measured as optical density (OD)
by scanning plates at 570-630nm using a Dynatech MR-700 microplate reader.
2.I.e. Anti IL-1 antiserum
Specificity of the IL-1 bioassay was assessed using sheep antisera
(NIBSC) raised against recombinant human IL-1 alpha or IL-1 beta. Antisera
were screened by incubation for 2 hours at room temperature with standard
IL-1 preparations prior to EL-4 assay. A titre of 1 in 1000 was found
specifically to inhibit lOOpg/ml of IL-1 activity. In further experiments
antibody at this titre was used to neutralise IL-1 in biological samples.
2.1.d. IL-1 inhibitor assay
To test for specific inhibitors of IL-1 activity, the sample was pre-
incubated with either IL-1 alpha or IL-1 beta (at lOpg/ml) for 2 hours at
room temperature. EL-4.NOB-1 cells were then added and the assay continued as
described. Viability of EL-4 and CTLL-2 cells after culture was tested by
adding 0.5% trypan blue (Sigma) in PBS.
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2.I.e. Cellular production oflL-lbeta
Various human monocytic cell lines were tested for their ability to
produce IL-1 beta propeptide and to process it to the mature 17kd form. HL-60
and U937 lines were cultured in RPMI-1640 with 5% FCS and passaged every 2-3
days, THP-1 cells required 10% FCS and media supplemented with 2x10 M
2-mercaptoethanol (BDH, Glasgow).
The stimuli used for activation were LPS, from (E. coli) serotype
0127:B8 (lOOng/ml and lOug/ml; Sigma), zymosan from Saccharomyces cerevisiae
(lmg/ml; Sigma), and PMA (0.lug/ml and lug/ml; Sigma). Cultures were
separated into supernatant and cellular fractions, cells were lysed using 1%
sodium dodecyl sulphate (SDS, BDH) with protease inhibitors (Aprotinin, from
bovine lung, 0.67U/ml; Sigma, and Pepstatin A, lOug/ml; Sigma) and processed
for Western blotting (Section 2.9.a.).
2.1.f. Protease inhibitor effects
THP-1 cells were found to produce 31kd IL-1 beta and to process it to
the mature 17kd form, this line was used to examine the effects of protease
inhibitors. Various protease inhibitory factors were tested; aprotinin was
added at 0.67U/ml, Pepstatin A at lOug/ml, phenylmethylsulphonylfluoride at
ImM (PMSF, Sigma) and leupeptin at lOug/ml (from Streptomyces species,
Boehringer Mannheim, Lewes). 3,4-Dichloroisocoumarin (3,4-DC, Boehringer
Mannheim) and 1,10-phenanthroline (1,10-PA, Sigma) were found to be toxic at
high levels and so final concentrations of 100 and lOng/ml were used.
Inhibitors were added to cells at the start of culture in serum free medium
with 0.lug/ml PMA to stimulate IL-1 production. After 24 hours stimulation,
supernatants were removed, the cells were lysed as described, and 31 kDa and
17 kDa levels of IL-1 beta were measured by Western blotting under reducing
conditions (Section 2.9.a.). To assess mRNA levels cell preparations were
made as described for slot blot analysis (Section 2.8.b.).
38
2.2. INTERLEUKIN 1 BETA PROCESSING
2.2.a. Processing of cell lysate IL-1 beta
Inhibition of processing was tested in a cell lysate system. Pro IL-1
beta was produced by stimulating 1x10^ THP-1 cells/ml with 0.lug/ml PMA for
24 hours. Culture supernatant was then removed and the cells sonicated for
four 30 second bursts at a frequency of 8 microns, on ice in fresh, serum
7
free media at 1x10 cells/ml. The nuclei were removed by centrifugation for
10 minutes at 400xg, membranes were separated by a second spin at 48000xg for
30 minutes. The supernatant was removed and stored at -2(f C, the pellet was
1
resuspended at 1x10 cell equivalents/ml and frozen. Cell lysate and membrane
preparations were used for processing activity, preparations were only thawed
once before use.
For inhibition experiments crude 31 kDa propeptide was added to an equal
volume of unstimulated cell lysate, membranes or fresh cells at lxlO^/ml. The
processing reaction was incubated at 37° C for 1, 2, 6, 12 and 24 hours and
then frozen, production of mature 17 kDa IL-1 beta was assessed by Western
blotting under reducing conditions (Section 2.9.a.).
2.2.b. Processing of recombinant pro IL-1 beta
A recombinant form of human IL-1 beta propeptide was also used in
processing experiments. The 31 kDa precursor was produced in £. Coli and was
obtained as a partially purified solution at 55ug/ml in lOOmM Tris-HCL with
ImM sodium azide, from Glaxo Group Research, Greenford. Preparations of cell
7
lysate, membranes and supernatants were produced at concentrations of 1x10
cell equivalents/ml, as described (Section 2.2.a.). Cells were also
fractionated after stimulation with lOOng/ml LPS or PMA for 2 hours. Some
membrane preparations were heated to 50° C for 10 minutes to determine the
temperature sensitivity of the processing activity.
Processing experiments were carried out by incubating 5ul of recombinant
propeptide with lOul of the different cell fractions, or tissue culture
medium as a negative control, for 2 hours at 37° C. The reaction was stopped
by freezing to -20p C. Cell lysates, membranes and supernatants were all
39
tested for intrinsic IL-1 immunoreactivity after a comparable incubation
time.
2.2.c. Time course of IL-1 beta propeptide processing
Recombinant IL-1 beta propeptide was incubated with medium alone, THP-1
cell lysates or membrane preparations. Aliquots of the reaction were removed
immediately, and after 15 min, 30 min, 45 min and then 1, 1.5, 2, 2.5, 3, 4
and 5 hours. The aliquots were frozen immediately and analysed by Western
blotting under reducing conditions (Section 2.9.a.).
2.2.d. Inhibition of processing
Protease inhibition of processing was examined, the protease inhibitors
previously described (Section 2.1.f.) were used at lx and lOx the described
concentrations, apart from 3,4-DC and 1,10-PA that were used at 1 and
lOug/ml. The elastase inhibitor elastatinal (Sigma) was also tested at a
concentration of 1 and lOmM.
2.2.e. Synthetic peptides
Synthetic peptides were made by D. MacLean from the University of
Edinburgh Department of Chemistry using an Applied Biosystems 430 A Peptide
Synthesiser. They were purified by an initial gel filtration step, followed
by an ion exchange column and finally reverse phase HPLC. The product gave a
single peak by analytical HPLC and a single band by isoelectric focusing.
Peptides were designed from the sequence around the cleavage site of pro IL-1
beta. Peptide A consisted of amino acids 102-138 of the precursor molecule,
peptide B residues 111-122, and peptide C was composed of a sequence on the N
terminal side of the processing site at residues 101-112. Peptides were
freshly made up to a 10 molar solution in dimethyl sulphoxide (DMSO, Sigma)
5 7and diluted to 10 -10" M with serum free medium.
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2.3. PREPARATION OF EX-VIVO SAMPLES
2.3.a. Blood samples
Blood samples for measurement of IL-1 immunoreactivity were taken
immediately into 5ml potassium ethylenediamine tetra-acetic acid (K^EDTA,
- 35x10 mol/1) tubes (Labco, Labsales) with 0.67U/ml aprotinin. Larger volume
samples were taken into 50ml polypropylene tubes (NBL) also containing
EDTA (Sigma) and aprotinin. When possible cells were spun down immediately at
200xg for 10 minutes, alternatively they were stored at 4° C until
centrifugation. Platelets were then removed by a further spin for 10 minutes
at lOOOxg, 500ul aliquots of plasma were stored at -2CP C.
To ensure that possible LPS contamination and storage of samples at 4° C
was not affecting IL-1 measurement, aliquots of a single blood sample were
incubated in collection tubes for various lengths of time between 0 and 4
hours. Similar tubes were spiked with lOOng/ml LPS and stored at 4° C for the
same times before plasma preparation.
Large scale plasma samples for chromatographic separation were further
treated by dialysis overnight against 10 volumes of the column starting
buffer used. Dialysis tubing used had a molecular weight cut-off of 12-14 kDa
(Gibco-BRL).
2.3.b. Synovial fluid
Synovial fluid was collected and immediately centrifuged to remove
cellular material, samples were then pooled and stored at -7(P C in 500ml
volumes. On thawing 3ml of 0.5M Na2EDTA (Sigma) was added to prevent
clotting, hyaluronidase (Sigma) was added to a concentration of lOOU/ml and
incubated for 45 minutes at 37° C. Fluid was then dialysed against 5 litres of
starting buffer for 24 hours, and centrifuged at 400xg to remove any
precipitate.
2.3.C. Sample concentration
Small scale concentration, of up to 20ml, was done using Centrifugal
Ultrafree filters (Millipore, Bedford) with 30 kDa molecular weight cut-off.
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Centrifugal units were washed through with 20ml of distilled water before
use. Twenty millilitre aliquots of sample were added to the filter cup unit
which was then put onto the receiver unit and centrifuged at 2500xg for 30
minutes. The filter cup was removed and concentrate recovered by a further
spin of the inverted unit into a second tube.
Large scale concentration, of samples of over 1 litre used a Minitan
Tangential-Flow system (Millipore). Sample was circulated across four
polysulphone filter plates of 30 kDa cut-off. Plates were preconditioned by
passing PBS through the system before use. Sample was fed into the unit,
filtered at a back pressure of 10 psi and recirculated until the retentate
volume was 50-100ml.
2.3.d. Plasma extraction
Extraction of plasma, first described by Cannon et al (1988), was found
to increase the level of detectable IL-1 beta by immunoassay. Aliquots of
plasma were therefore thawed and extracted twice; two volumes of chloroform
(BDH) were added to one of plasma and shaken for 5 minutes. The two phases
were separated by centrifugation at lOOOOxg for 10 minutes and the upper,
aqueous phase removed. The extracted plasma was respun to remove any
remaining precipitate and stored at -2(F C before IL-1 assay.
2.3.e. Assessment of disease activity
Samples were taken from normal healthy controls and patients with
definite or classical rheumatoid arthritis (Ropes et al, 1958) who were
attending a rheumatology out patient department, or had been admitted to a
rheumatology ward. The patient group was assessed for a number of measures of
disease activity including Ritchie joint index (Ritchie et al, 1968),
duration of early morning stiffness, and visual analogue pain score.
Corresponding patient blood samples were taken to test standard
laboratory measures of disease activity such as haemoglobin concentration
(Hb), white cell count (WCC), platelet count (Pit), erythrocyte sedimentation
rate (ESR), and rheumatoid factor titre (RhF).
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2.3.f. Patient drug treatments
All patients were receiving non-steroidal anti-inflammatory drugs, and
some also received second line therapy. Hospitalised patients studied
longitudinally all had either oral or intra-articular steroids, three
received oral or injectable gold, and one longitudinal and two out-patients
were given anti-malarials.
2.3.g. Statistical analysis
Comparison of mean values were analysed using Students f-test, and
correlations assessed with the Spearman rank correlation coefficient.
2.4. INTERLEUKIN 1 IMMUNOASSAYS
2.4.a. IL-1 beta Enzyme-Linked Immunosorbent Assay (ELISA)
Two IL-1 beta ELISA's were used; one commercially available from Cistron
Biotechnology (Laboratory Impex, Middlesex) and the other using reagents
kindley supplied by Roussel UCLAF (Romainville).
2.4.a.i. Cistron IL-1 beta ELISA
The assay is a four stage test in which a monoclonal antibody specific
for IL-1 beta is supplied coated onto a 96 well microtitration plate. To this
was added lOOul of either standards or samples in duplicate; the IL-1 beta
preparation supplied was reconstituted with deionised water to 50ng/ml and
diluted in the buffer provided to give a range of concentrations between
lOOOpg/ml and 20pg/ml. Samples were diluted in buffer if necessary. The plate
was then covered and incubated for 2 hours at 37° C. Wells were then washed
three times, using the solution provided which was diluted with 400ml of
water. Excess buffer was removed and secondary antibody, polyclonal rabbit
anti-human IL-1 beta reconstituted in deionised water, was added for a
further 2 hours. Following a second wash, horseradish - peroxidase (HRP)
labelled anti-rabbit immunoglobulin G (IgG), in assay buffer, was added and
the plate incubated at room temperature for 30 minutes. The substrate was
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prepared immediately before the final wash step, by dissolving the
o-phenylenediamine (OPD) tablets provided in water, prior to use 3% hydrogen
peroxide was added. One hundred microlitres of substrate was pipetted into
each well and the reaction left at room temperature up to 15 minutes to
develop. Sulphuric acid (50 ul, 4N; BDH) was added to stop the reaction and
the colour intensity in the plate measured at 490nm using a microtiter plate
reader.
2.4.a.ii. Roussel IL-1 beta ELISA
The Roussel IL-1 beta ELISA was used as described by Fontaine et al
(1989). It was performed on Maxisorb microtiter plates (Nunc, Gibco-BRL).
Plates were coated with lOOul of a lOug/ml solution of a monoclonal anti-IL-1
beta in coating buffer (0.1M sodium carbonate, pH 9.6), at room temperature
for 16-24 hours. Antibody solution was then removed and plates blocked with
200ul of 3% bovine serum albumin (BSA, Sigma A4503) in PBS for 30 minutes.
The plate was washed three times in PBS with 0.1% polyoxyethylenesorbitan
monolaurate (Tween 20, Sigma). Interleukin 1 beta standard was reconstituted
to lOOug/ml with distilled water, and was further diluted in PBS with 0.1%
bovine serum albumin (BSA) and 0.1% Tween 20 to give a concentration range
between 2ng/ml and 20pg/ml. Samples and standards were added in duplicate at
50ul/well. At the same time 50ul monoclonal anti-IL-1 beta HRP conjugate
(2ug/ml) was also added, and incubated at 4° C overnight. Substrate was made
up just before use, one OPD substrate tablet (lOmg; Sigma) was dissolved in
substrate buffer (0.065M disodium hydrogen phosphate (Aldrich, Dorset),
0.017M citric acid monohydrate (Fisons, Loughborough), pH 6.3). The plate was
washed, 3% hydrogen peroxide (Sigma) was added to the substrate and lOOul
pipetted into each well. The reaction was incubated at room temperature in
the dark for 15 minutes and stopped with 50ul of 4N sulphuric acid. Optical
density was read at 490nm.
2.4.b. IL-1 alpha radioimmunoassay (RIA)
A commercially available specific IL-1 alpha RIA was obtained from
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Amersham International pic. Before starting the assay all reagents were
brought to room temperature, dilution buffer was heated to 40° C until the gel
melted and was then made up to 50ml volume with deionised water. The assay
was done in 5ml polypropylene tubes (Sarstedt, Leicester). Human recombinant
IL-1 alpha was provided as a standard and was reconstituted with buffer, to a
concentration of 320fmol/ml. This stock was further diluted to give a
concentration range between 160fmol/ml and 5fmol/ml, lOOul of standard or
sample was added to the tubes in duplicate. Rabbit anti-human IL-1 alpha
antisera was reconstituted to 11ml with buffer, and lOOul was added to each
tube, these were mixed, covered and incubated for 4 hours at room
temperature. Iodinated IL-1 alpha was used as tracer, it was reconstituted
with assay buffer and lOOul added to each tube. The assay was incubated at
4° C for 16-20 hours. Donkey anti-rabbit antisera was provided coated onto a
magnetisable polymer, Amerlex M. Two hundred and fifty microlitres/tube was
added, vortexed and incubated for 10 minutes at room temperature. The
Amerlex-antibody complex was separated by centrifugation at 1500xg for 10
minutes at 4° C. The supernatant was decanted and tubes inverted on absorbent
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paper to drain excess fluid. The amount of I IL-1 alpha present was
determined by counting in a gamma counter for 60 seconds.
2.4.c. Assay validation
To ensure that immunoassays were suitable for measuring plasma IL-1,
recovery of added protein and dilution characteristics were assessed; plasma
had IL-1 standard added to give a final concentration of 200pg/ml both before
and after extraction, percentage recovery was determined. Plasma with added
IL-1 and untreated plasma were serially diluted before assay to confirm
parallel dilution characteristics. Plasma from both normal and patient groups
were tested in this manner.
Inter-assay variability was determined, and in some cases standard
curves were prepared in a plasma sample known to have low endogenous IL-1,
to control for potential plasma effects in the assay.
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2.5. ANALYSIS OF PLASMA IL-1 BINDING PROTEINS
2.5.a. Gel filtration
Radiolabeled IL-1 was added to plasma to allow identification of any
IL-1 binding proteins. For analysis of binding factors under physiological
conditions 3ml volumes of unextracted or extracted (Section 2.3.d.) plasma
had 3ng of *^I IL-1 alpha or beta (specific activities 70-120uCi/ug and 126-
253uCi/ug respectively; DuPont, Hertfordshire) added, these were incubated
overnight at 4° C. Specificity of binding was determined by including a
hundred fold excess of non-labelled IL-1 (Biogen SA) or TNF alpha (a gift
from Dr Guenther Adolph, Ernst Boehringer Institut fur Arzneimittel, Austria)
in the reaction. The molecular weight of any IL-l/protein complexes formed
was examined by passing the incubation reaction down a gel filtration column
in PBS buffer, and measuring radiolabel in the resulting fractions (Section
2.6.).
2.5.b. Covalent cross-linking
The presence of binding proteins was also analysed using covalent cross-
linking techniques. Fifty microlitre aliquots of plasma samples or partially
purified binding protein were incubated overnight at 4° C with 0.5ng of
radiolabelled IL-1, with relevant cold competition controls. Reactions were
treated with freshly prepared cross-linker for 30 minutes at 4° C. Various
homobifunctional cross - linking reagents were used, all were prepared at
lOmg/ml concentrations in DMSO and 5ul/reaction was added; disuccinimidyl
suberate (DSS) and ethylene glycolbis(succinimidyl succinate) (EGS) were
obtained from Pierce and Warriner (Cheshire). The cross-linking reaction was
stopped by adding an equal volume of loading dye (Section 9.5), and samples
were analysed by sodium dodecyl-sulphate polyacrylamide gel electrophoresis
(SDS-PAGE, Section 2.9.a.), followed by autoradiography.
2.5.c. IL-1 receptor binding
A 3T3 fibroblast cell line was used for IL-1 receptor cross-linking
studies. Cells were cultured in RPMI-1640 with 5% FCS, antibiotics and
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glutamine, and grown as adherent monolayers. Cultures were maintained at a
subconfluent level by passaging every 3-4 days. They were first washed in
2
serum free medium then 1ml of lx trypsin (NBL) was added to each 75cm flask
until cells began to lift from the surface. To this 9ml of media with 5%
serum was added, cells were centrifuged and the cultures divided 1:10 into
fresh flasks.
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To test the receptor binding activity of I IL-1 alpha, cross-linking
studies were performed on a 3T3 fibroblast line as described (Dower, 1985).
Solutions used are described in Section 9.2. Monolayers of cells were washed
in PBS and then incubated with lng/ml labelled IL-1, with or without 100 fold
excess cold cytokine as described (Section 2.5.a.). Interleukin 1 was
prepared in binding buffer and was added to cells for 4 hours at 8° C in a
volume of 5ml. Cells were then washed three times in ice cold binding buffer
to remove unbound label. A further 5ml of buffer was added with DSS at a
concentration of lmg/ml as cross-linker, this was left on ice for 45 minutes.
Cross-linker was replaced by 5ml of quenching solution, and cells scraped off
the flask using a rubber policeman. These were centrifuged at 200xg for 10
minutes at 4° C and lysed by resuspending the pellet in lOOul lysis buffer
containing protease inhibitors. Samples were analysed by SDS-PAGE (Section
2.9.a.).
2.5.d. Characterisation of the IL-1 beta binding protein
2.5.d.i. Binding kinetics
The kinetics of binding of IL-1 beta to plasma proteins was studied by
incubating iodinated IL-1 beta with plasma for various time periods. Binding
was carried out at 4° C and room temperature for 0.5, 1, 1.5, 2, 2.5, and 3
hours. A control sample was incubated overnight. The reaction was stopped by
cross-linking and adding SDS-PAGE loading buffer (Section 9.5.), samples were
then stored at -20p C.
2.5.d.ii. Effect of reducing agents
To analyse the effect of reducing agents on plasma binding proteins
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samples were prepared as described (Section 2.5.b.). Before loading on SDS-
PAGE gels an equal volume of loading buffer and dithiothreitol ((DTT) lOOmM,
Sigma) was added. These were then heated at 100° C for 10 minutes.
2.5.d.iii. Temperature stability of IL-1 binding proteins
Temperature stability of the binding protein was determined by heating
samples to 37° , 40° , 50° , 60° and 70° C for 10 minutes prior to incubation
125with I IL-1 beta, and cross-linking. Samples had EDTA added to a
concentration of 5mM to prevent clotting during treatment.
2.5.e. N-Glycanase treatment of IL-1 beta binding protein
Glycosylation of the partially purified protein was assessed by treatment
with N-Glycosidase F (N-Glycanase) purified from Flavobacterium meningoseptum
(Genzyme, Maidstone). Fifty microlitres of the ion exchange purified protein
preparation (Section 2.7.b.) was incubated with IL-1 beta and cross-linked.
The reaction was treated with 5ul of quencher (Section 9.2.), and boiled for
3 minutes in the presence of 0.5% SDS and 0.1M 2-mercaptoethanol. Twenty
microlitres of this solution was made to 0.2M with sodium phosphate pH 8.6
(Section 9.3.a.), to lOmM with 1, 10 phenanthroline (diluted in methanol,
BDH), and 1.25% with Nonidet P-40 (Sigma). N-Glycanase was added to a
concentration of lOU/ml, in a total volume of 60ul. The reaction was
incubated overnight at 37° C, and results analysed by SDS-PAGE (Section
2.9.a.).
2.6. PLASMA FRACTIONATION
To test for bioactive and immunoreactive IL-1 in plasma, extracted and
unextracted (Section 2.3.d.) samples were fractionated by gel filtration
before assay. A Sephacryl S-200 (Pharmacia- L KB Biotechnology,
Buckinghamshire) matrix was used with a PBS buffer at pH 7.4 (Section
9.3.a.). The column was 100cm in length with an internal diameter of 16mm
(Pharmacia), a flow rate of lml/minute was used and fractions were collected
over 2 minutes. Twelve millilitres of sample were allowed to load onto the
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column under gravity and proteins were then eluted. The protein concentration
was determined in each sample by OD measurement at 280nm, fractions were
stored at -20p C prior to use in IL-1 assays. The column was calibrated using
standard gel filtration molecular weight markers ranging from 12-200 kDa,
supplied in kit form (Sigma, MW-GF-200).
Plasma previously incubated with 500ng iodinated IL-1 alpha or beta was
also analysed by gel filtration. Three millilitre samples were loaded onto
the column under gravity and eluted in PBS. Fractions of 2ml were collected
and the amount of radiolabel was measured by counting for 1 minute in a gamma
counter. Results were expressed as a percentage of total counts. For one
experiment IL-1 beta/protein complexes from gel filtration were pooled,
cross-linked, concentrated, and analysed by SDS-PAGE (Sections 2.3.C. and
2.9.a.).
2.7. PURIFICATION OF IL-1 BETA BINDING PROTEIN
2.7.a. Wheat germ agglutinin column purification
Wheat germ Lectin-Sepharose 6MB (Pharmacia) was used for partial
purification of the binding protein from plasma. A column of length 65mm and
internal diameter 16mm was prepared with Wheat germ Sepharose in PBS. Twenty
millilitres of plasma was dialysed overnight at 4° C in PBS and loaded onto
the column at a flow rate of 4ml/hour. The column was washed in 2 volumes
(40ml) of PBS/0.3M NaCl (Sigma) followed by PBS/10% (v/v) ethylene glycol
(Sigma). Glycosylated proteins were eluted from the column with 2 volumes of
PBS/500mM N-acetyl-glucosamine (Sigma)/0.3M NaCl, two millilitre fractions
were collected from each step. The column was regenerated as described in
Section 9.3.b.
Fractions were assessed for protein concentration by measurement of the
OD at 280nm, and for the presence of binding protein (Section 2.5.b.).
2.7.b. Ion-exchange chromatography
For large scale purification of IL-1 beta binding protein from synovial
fluid a DEAE Sephacel (Pharmacia) anion exchange column was used. Initial
49
experiments were done to establish binding and elution characteristics.
Aliquots of 1.5ml of DEAE Sephacel were washed ten times in 10ml of 0.5M
Tris-HCl (Sigma) each at a different pH, ranging from pH 5-9. They were then
equilibrated to a lower salt concentration, by washing five times in 0.01M
Tris-HCl, at the same pH as the previous step. One millilitre of synovial
fluid, diluted 1:5 in the respective buffer, was added to each tube and mixed
for 10 minutes. The supernatant was removed and assayed for binding protein.
The lowest pH at which all binding activity had been removed from the fluid
was selected as starting buffer.
Secondly, the salt concentration required to elute the protein was
established. Aliquots of Sephacel were washed as described above, in 0.5M
Tris-HCl, at the selected pH, and then in starting buffer. Gel was then
equilibrated with a range of salt concentrations, between 0.01M and 0.3M, by
washing as before. Sample was added and the supernatant assayed for binding
activity, the lowest salt concentration in which activity was present was
used, to determine the range of the elution gradient.
The DEAE Sephacel column used was 500mm in length and 50mm in diameter,
and was equilibrated with 0.01M Tris-HCl at pH 5.5 (starting buffer).
Synovial fluid was prepared as described (Section 2.3.b.), using a starting
volume of 750ml/run. Sample was loaded at a flow rate of lml/minute at 8° C,
and the column was washed overnight in starting buffer. Proteins were eluted
with a continuous gradient of 0.01M-0.5M NaCl. Ten millilitre fractions were
collected after a 250ml void volume had eluted, 1ml aliquots were taken for
measurement binding activity, the remainder was stored at -7CP C. The column
was regenerated as described in Section 9.3.b. Pooled fractions containing
binding protein were concentrated as described (Section 2.3.c.) before
further purification steps.
2.7.C. IL-1 beta affinity chromatography
Concentrated eluate from the ion-exchange column was further purified by
IL-1 beta affinity chromatography. The matrix was prepared using Activated
Thiol Sepharose-4B (Pharmacia) which was obtained as a freeze dried powder.
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The gel was hydrated before use (Section 9.3.b).
The ligand used was an altered form of human IL-1 beta with a
substitution at position 138, where a lysine was replaced by a cysteine to
facilitate binding to thiol groups. Protein was provided as a 3.44mg/ml
solution in lOOmM Tris-HCl, ImM DTT and ImM EDTA at pH 7.5 by the Glaxo
Institute for Molecular Biology SA (Geneva).
Dithiothreitol was removed from the IL-1 prior to coupling by gel
filtration over Sephadex G25 (Pharmacia) in lOOmM sodium phosphate buffer at
pH 8 (Section 9.3.a.). Fractions containing protein, as measured by OD at
280nm, were pooled and loaded immediately onto the activated Sepharose
column. The resulting gel contained 5mg mutein IL-l/ml of matrix.
The concentrated binding protein sample was passed over the column twice
and washed in twenty column volumes of starting buffer, followed by three
high stringency washes (Section 9.3.a.). Binding protein was eluted with a
4ml pulse of 0.1M glycine (Sigma) at pH 3. The pH of fractions were tested,
any that were acidic were neutralised immediately with 0.1N sodium hydroxide
(NBL). The column was washed after use with Tris-HCl at pH 7.5. Fractions
were tested for binding activity as described (Section 2.5.b.).
2.7.d. HPLC of IL-1 beta binding protein
The semi-purified protein preparation was concentrated by vacuum
centrifugation and loaded onto a reverse phase, RP300 Aquapore 30 x 2.1mm C8
column (Applied Biosystems). Sample was eluted with a 10-70% acetonitrile
gradient with 0.3% trifluoroacetic acid over 45 minutes, at a flow rate of
200ul/minute. Optical density was measured at 220nm and protein peaks were
12Scollected by hand. Individual peaks were analysed for I IL-1 beta binding
activity.
2.8 MOLECULAR BIOLOGY TECHNIQUES
All experiments were done using RNAse free techniques and reagents
(Section 9.4.a.).
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2.8.a. cDNA probe preparation
Cytoplasmic mRNA was detected using cDNA probes. An interleukin-1 beta
cDNA encoding amino acids 5-269 was obtained from Dr D Carter (The Upjohn
Company, Kalamazoo, MI). This was an insert in a pBR322 plasmid that had been
transformed into E. coli HB101, and conferred tetracycline resistance. As a
control for mRNA loading a 7B6 cDNA (Dr U Torelli, Univ Modena, Italy) coding
for a cell cycle independent mRNA was used. This was propagated in E coli in
pBR322 and comprised a 708 base pair fragment. It has previously been
established by Northern analysis that the IL-1 beta cDNA probe binds to a
1.8kb mRNA species from stimulated peripheral blood mononuclear cells (E
Thornton, personal communication).
Plasmid DNA was prepared using standard growth and alkaline lysis
techniques as described by Sambrook et al (1989). The 7B6 DNA was prepared by
E Thornton. Interleukin-1 beta cDNA was restricted using Pst I, and 7B6 with
Pst I and Dra I enzymes (Gibco-BRL). Preparations were run on low melting
point agarose gels and the required fragment cut out, following staining with
ethidium bromide.
Probes were labelled from agarose gel preparations using a random primer
oligolabelling reaction. The cDNA preparation was denatured by boiling for 10
minutes followed by incubation for at least 10 minutes at 37° C. One hundred
nanograms of DNA was added to lOul oligolabelling buffer (Section 9.4.b.),
2ul of lOmg/ml BSA and 50uCi of "^P labelled dCTP (DuPont). One microlitre of
large fragment DNA polymerase I (Klenow, Gibco-BRL) was then added and the
volume made up to 50ul with water. The reaction was incubated overnight at
room temperature and then stopped by addition of 200ul of 500ug/ml calf
thymus DNA (Sigma). Probe was separated from free label by passing down a
Sephadex G-50 (Pharmacia) column and eluted in Tris-EDTA pH 8.1 (TE, Section
9.4.b.). The column was monitored using a Geiger counter and the first
radiolabeled peak collected. Specific activity of the probe was estimated by
counting a lul aliquot, the reaction gave at least 10^-10^ cpm for lOOng of
DNA added.
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2.8.b. Slot blot analysis of mRNA
Slot blot analysis was performed according to the method of White and
Bancroft (1982). Solutions used are described in Section 9.4.b.. Cell
suspensions containing 1x10^ cells were centrifuged at 400xg and the pellet
washed in PBS. The cells were then resuspended in 45ul ice cold TE and 5ul of
5% Nonidet P-40 was added. Preparations were mixed on ice for 5 minutes and a
further 5ul of Nonidet was added. Nuclei were removed by spinning for 3
minutes at 1500xg, 50ul of the supernatant was taken and added to a 1.5ml
tube containing 30ul of 20x saline sodium citrate (SSC) and 20ul of 37% (v/v)
formaldehyde. This was heated to 60° C for 15 minutes, and then stored at
-7CP C if required. Samples were diluted 1:2, 1:5 and 1:25 with 15x SSC,
relevant denatured cDNAs were prepared as hybridisation controls at
concentrations between 0.1 and O.OOlng/ml. Cytoplasmic mRNA and control DNA
were transferred to Hybond N (Amersham) membranes using a slot blot
apparatus. One hundred microlitres was added to each slot, and then washed
through with lOx SSC. RNA was fixed by exposing to UV light for 5 minutes at
305 nm, the filter was allowed to dry.
The membrane was prehybridised overnight at 37° C in 50% (v/v) formamide,
4x phosphate buffered saline sodium citrate (SSCP), lx Denharts and 0.1% SDS
(w/v) in a volume of 100ml. Radiolabelled cDNA probe was prepared as
described (Section 2.8.a.). Twenty millilitres of hybridisation buffer, 50%
formamide, 4x SSCP, lx Denharts was prepared on ice. Probe and sufficient
sheared calf thymus to give a 50ug/ml final concentration were boiled for 10
minutes, rapidly chilled on ice and added to hybridisation buffer. The
membrane was incubated for 20 hours at 37° C in hybridisation mix, and then
washed in 2x SSC/0.1% SDS, lx SSC/0.1% SDS, 0.5x SSC/0.1% SDS, and O.lx
SSC/0.1% SDS. Membranes were autoradiographed for 3-4 days at -7(P C with
Hyperfilm-MP (RP N6, Amersham), using intensifying screens.
To reprobe a filter the membrane was first stripped by incubating at
65° C for 1-2 hours in 0.005M Tris-HCl at pH 8.0 with 0.002M Na2EDTA and O.lx
Denharts. Autoradiography was used to confirm that stripping was effective.
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2.9. ANALYSIS OF PROTEINS
2.9.a. Western Blotting
Protein samples were analysed on 10% or 15% SDS-PAGE gels according to
the method of Laemmli (1970). A discontinuous system that stacks at pH 6.8
and resolves at pH 8.8 was used. Samples were treated by adding an equal
volume of 2x loading dye (Section 9.5.), if run under reducing conditions
lOOmM DTT or 1% 2-mercaptoethanol were added before boiling for 10
minutes. Ten microlitres of rainbow markers/well (Molecular weight 14.3-200
kDa; Amersham) were treated in the same way. Gels were run at 25mA in an SDS-
Tris glycine buffer, and were then transferred onto nitrocellulose membranes
(Bio-Rad, Hertfordshire) at 220mA for two hours.
2.9.b. Protein detection
Radiolabeled samples were detected directly from gels using
■j AC
autoradiographic techniques. Preparations containing I-label were wrapped
and directly autoradiographed.
2.9.c. Immunochemical IL-lbeta detection
Interleukin 1 beta in samples blotted onto nitrocellulose filters was
analysed using two immunochemical detection schemes; the first was used when
recombinant pro IL-1 beta was the substrate of reactions, the second, a more
sensitive avidin-biotin system was used when THP-1 cell lysates served as a
source of the IL-1 precursor. Solutions used are described in Section 9.5..
In the former method filters were first blocked in a 5% (w/v) BSA (RIA
grade; Sigma) solution for an hour at room temperature. This was followed by
an overnight incubation in sheep anti-IL-1 beta antiserum at 1:2000 dilution
(Glaxo Group Research), in blocking buffer. Blots were washed three times,
for five minutes each wash, in a 20mM Tris/0.15M NaCl solution with 0.05%
Tween 20, followed by a detergent free wash. Second antibody, alkaline
phosphatase conjugated anti-sheep IgG (Sigma), was diluted 1:2000 in second
antibody buffer and filters incubated for 4 hours. This was followed by
further washing. Both substrates were prepared at a concentration of 20mg/ml
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immediately before use in substrate buffer: Fast Blue RR was obtained as a
crystalline salt (Sigma, F 0500) and Napthol AS-MX phosphate as the sodium
salt (Sigma, N 5000). Solutions were mixed and added to filters for up to 15
minutes, the reaction was stopped by washing blots several times in PBS
(Section 9.3.a.).
The alternative method followed the Vector (Peterborough) kit protocol
issued with reagents. Filters were blocked for 30 minutes at room temperature
in a Tris/NaCl/Tween 20 solution (TTBS), this was also used for antibody
dilution and washing. Primary antibody, sheep anti-IL-1 beta antiserum
(NIBSC), was incubated in the same manner at a 1:500 dilution, this was
followed by three 5 minute washes in TTBS. Biotinylated rabbit anti-sheep
antibody (Vector) was added at a 5ug/ml concentration. The avidin-biotin
alkaline phosphatase complex (Standard ABC-AP kit, Vector) was prepared 30
minutes before use, by adding lOOul of reagents A and B to 20ml of TTBS.
Three drops each of substrate solution A, B, and C (Vector Red, Kit 1) were
added to 20ml of 0.1M Tris-HCl at pH 8.2, this was mixed and added to the
washed filters until bands had developed. The reaction was stopped by washing
in distilled water.
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3. RESULTS: Plasma interleukin 1 measurement
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3.1. INTRODUCTION
The measurement of IL-1 in biological fluids is known to be subject to
inaccuracies due to the presence of specific and non-specific cytotoxic and
inhibitory factors that affect bioassays. Other growth factors eg IL-2, IL-4,
IL-6 can also give false positive readings. Much of the data concerning ex
vivo IL-1 measurement has been obtained from fluids after partial
purification, usually by gel filtration.
In synovial fluid from rheumatoid arthritis patients, inhibitory activity
in the LAF assay can be removed by gel filtration which allows the detection
of an IL-l-like activity (Miossec et al, 1986). Recent results show both IL-1
forms in synovial fluid as measured by immunoassay, and demonstrate
inhibitory activity on D10 murine T cells at dilutions less than 1:1000 (di
Giovine et al, 1990). Tamatani et al (1988) used gel filtration to
characterise IL-1 bioactivities in amniotic fluid. Attempts to measure IL-1
in urine have shown inhibitory effects in the majority of samples (Kimball et
al, 1984), probably due to the subsequently well characterised IL-1 inhibitor
(Balavoine et al, 1986).
In serum IL-1 has been demonstrated by a D10 bioassay, thymocyte
proliferation and LEM assay (Cannon and Kluger, 1983; Cannon and Dinarello,
1985), all require fractionation before assay. Gahring et al (1984)
identified IL-1 in a low molecular weight fraction of plasma (<25 kDa), this
activity could be completely inhibited if reconstituted with the high
molecular weight fraction. Serum IL-1 suppressor activity has been
demonstrated at a size of 50 kDa or larger, this can be separated to reveal
IL-1 bioactivity even in samples from normal individuals (Luger et al, 1986;
Cannon and Dinarello, 1984).
More confident measurement of blood IL-1 levels can now be made due to
the commercial availability of immunoassays specific for IL-1 alpha and beta.
However there is still the possibility that high protein and lipid levels in
plasma and serum samples may interfere with IL-1 detection in some assays.
This may be further complicated in disease states. A recent report describes
an extraction protocol designed to overcome these problems, by means of a
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chloroform extraction step (Cannon et al, 1988).
The accurate determination of circulating IL-1 levels is important to
the understanding of the in vivo role of IL-1 in both normal and disease
states. The present study describes the measurement of plasma IL-1 alpha and
beta by immunoassay, and the effect of extraction on detection systems. The
concentrations of circulating IL-1 in normal individuals and rheumatoid
arthritis patients were also compared.
3.2. PLASMA INTERLEUKIN 1 BETA MEASUREMENT
3.2.a. Assay validation
3.2.a.i. Interleukin 1 beta recovery
Control and rheumatoid arthritis patient plasma samples were prepared as
described in Section 2.3.a.. They were then spiked with 200pg/ml IL-1 beta
standard either before or after chloroform extraction (Section 2.3.d.),
recovery of added IL-1 was determined by measurement in the Cistron IL-1 beta
ELISA (Section 2.4.a.i.). The percentage recovery of added IL-1 is shown in
Table 3.2.1., mean values were above 80% for both populations irrespective of
when the standard was added.
3.2.a.ii. Dilution characteristics
Plasma samples were serially diluted in the ELISA buffer before assay.
Dilution curves are shown in Figure 3.2.1., the samples showed parallel
dilution characteristics.
3.2.a.iii. Interassay variability
Duplicate samples were tested for IL-1 beta levels in separate Cistron
ELISA kits, and the mean plasma concentrations were compared. As shown in
Table 3.2.2. the difference between assays was less than 12%.
3.2.a.iv. Plasma effects on IL-1 detection























Table 3.2.1. Recovery of added IL-1 beta from plasma
A — % recovery of 200pg/ml IL-1 beta added to plasma before
chloroform extraction.
















Figure 3.2.1. Dilution characteristics of plasma IL-lbeta
Three plasma samples were serially diluted in buffer before assay in















Table 3.2.2. IL-lbeta ELISA assay variability
IL-1 beta pg/ml







Table 3.2.3. Sample collection validation
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IL-1 preparation dilutions were made in either the Cistron BSA-phosphate
buffer or in a plasma sample known to contain little endogenous IL-1 beta
(<20pg/ml). The resultant standard curves (Figure 3.2.2.) showed similar
profiles but plasma appeared to reduce the level of detection at higher
concentrations.
3.2.a.v. Effect of rheumatoid factor
To ensure that rheumatoid factor was not influencing the assay, the mean
plasma IL-1 beta concentrations were compared with rheumatoid factor titre in
the patient group. Those patients with detectable rheumatoid factor had
slightly higher mean IL-1 levels (162pg/ml compared with 130pg/ml), but no
correlation was seen between antibody titre and IL-1 beta concentration
(Figure 3.2.3.).
3.2.a.vi. Validation of sample collection
The effect of delayed sample preparation was assessed by allowing blood
samples to stand at 4° C for up to three hours either with or without addition
of lOOpg/ml of LPS (Section 2.3.a.). The results are shown in Table 3.2.3..
Samples left for more than thirty minutes lost considerable IL-1 beta
immunoreactivity (from an initial concentration of 115pg/ml to a mean value
of 26pg/ml after 1 hour). However the presence of LPS in the collection tube
led to a rapid increase in levels at between 2-3 hours (from 35pg/ml at 2
hours to lOOpg/ml after 3 hours incubation).
3.2.b. Effect of plasma extraction
Eleven control and 35 RA patient plasma samples were measured in the
IL-1 beta assay both before and after chloroform extraction. The mean values
for each group were compared using Students T-test. As shown in Table 3.2.4.
extraction significantly increased the amount of detectable IL-1 beta in both
groups. In the control group detectable IL-1 beta levels rose from a mean of
20.3pg/ml to 33.4pg/ml following extraction. The assay sensitivity limit was
20pg/ml, so negative samples were allocated a value of 19pg/ml to calculate a
62
IL1p(pg/ml)
Figure 3.2.2. The effect of plasma on the IL-1 beta ELISA standard curve
The IL-1 beta standard curve was prepared in both assay buffer ( ) and
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Figure 3.2.3. Correlation of plasma IL-1 beta levels with rheumatoid factor
titre
Rheumatoid factor titre in patients was correlated with plasma IL-1 beta








Table 3.2.4. Effect of extraction on IL-1 beta detection
in plasma







Control vs RA f=4.28; p<0.0001
Table 3.2.5. Interleukin 1 beta in extracted plasma
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group mean. RA patients showed a rise in plasma IL-1 beta from 54.4pg/ml to
85.6pg/ml after chloroform treatment.
3.2.c. Plasma IL-1 beta levels
3.2.c.i. Comparison of control and RA groups
The mean plasma IL-1 beta concentration following extraction was
compared for patients and controls. The group of 21 normals showed
significantly lower mean IL-1 beta values (44.7pg/ml) than 51 age matched
rheumatoid patients (98.2pg/ml), as assessed by Students T-test (Table
3.2.5.).
3.2.c.ii. IL-1 beta correlation with disease activity
The correlations between plasma IL-1 beta levels and various measures of
disease activity were determined. Figure 3.2.4. shows a significant
cross-sectional correlation between Ritchie articular index and plasma IL-1
beta, in an RA population of 37 (r= 0.572, p<0.001). Cross-sectional
correlations were also seen with erythrocyte sedimentation rate (r= 0.358,
p<0.05; Figure 3.2.5.), duration of morning stiffness (r= 0.473, p<0.005) and
pain score (r= 0.605, p<0.001). A negative correlation with haemoglobin
concentration was seen (r= -0.53, p<0.001; Figure 3.2.6.). Significance was
not reached in correlations with platelet count or white cell count.
3.2.c.iii. Serial IL-1 beta measurement
Serial blood samples were taken from hospitalised RA patients and
longitudinal IL-1 beta measurements compared with disease assessment. Figure
3.2.7. shows three individuals with their plasma IL-1 beta levels correlated
against Ritchie score, platelet count, and ESR. In each case the patient was
admitted with active disease that subsided over the first few days. This was
subsequently followed in each of these cases by an increase in disease
activity. Patient A shows correlations between IL-1 beta and ESR (r= 0.74,
p<0.02), and platelet count (r= 0.745, p<0.02). In patient C there are





Figure 3.2.4. Correlation between plasma IL-1 beta and Ritchie articular
index
Plasma IL-1 beta concentration was correlated with Ritchie articular




Figure 3.2.5. Correlation between plasma IL-lbeta and ESR
Plasma IL-1 beta level was compared with ESR, as a laboratory measure of
disease activity. IL-1 beta results were plotted on a natural log scale. A
significant correlation was seen n= 35, r= 0.358, p<0.05.
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PLASMA IL16 (pg/ml)
Figure 3.2.6. Negative correlation between plasma IL-1 beta and haemoglobin
concentration
Blood haemoglobin concentration showed a significant negative
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p<0.005), white cell count (r= 0.806, p<0.005), pain score (r= 0.794, p<0.01)
and ESR (r= 0.618, p<0.05). Patient B showed similar trends but no
significant correlations.
3.2.d. Comparison of IL-1 beta immunoassays
To assess the validity of the Cistron ELISA, extracted plasma IL-1 beta
measurements were compared with those values obtained for the same samples in
a Roussel ELISA (described in Section 2.4.a.ii.). The Cistron ELISA read
slightly higher (mean levels 96.5pg/ml and 70.9pg/ml) but correlated with the
Roussel assay results in the majority of samples (n= 42, r= 0.711, p<0.001
(Figure 3.2.8.). However several samples gave very high readings in the
Roussel kit (350-2000pg/ml) but comparatively low ones in the Cistron ELISA
(20-258pg/ml). The reason for this was unclear.
3.3. PLASMA INTERLEUKIN 1 ALPHA MEASUREMENT
3.3.a. Assay validation
3.3.a.i. IL-1 alpha recovery
Plasma was extracted and 200pg/ml of standard IL-1 alpha was added. The
recovery was tested in an Amersham radio-immunoassay (Section 2.4.b.). The
results are shown in Table 3.3.1.. The mean level of recovery of exogenous
IL-1 alpha was 88.1±7.5%.
3.3.a.ii. Dilution characteristics
Plasma samples were diluted serially in assay buffer before RIA. The
dilution characteristics are shown in Figure 3.3.1., linear dilution of
endogenous IL-1 alpha was seen.
3.3.a.iii. Assay variability
Duplicate plasma samples were tested for immunoreactive IL-1 alpha
levels in different assays, the mean values from each were compared. As shown
in Table 3.3.2. the interassay variability was 9.8%.
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Roussel ELISA ILip (pg/ml)
Figure 3.2.8. Comparison of plasma IL-1 beta detection by two ELISAs
Plasma IL-1 beta levels were measured, following extraction, in Cistron
and Roussel ELISAs. All the plasma samples tested are shown. A selected
population was compared for correlation between ELISAs. The population
included all samples that gave a value of less than 325 pg/ml in the Roussel











Table 3.3.1. Recovery of added IL-1 alpha
IL-1 alpha pg/ml












Table 3.3.2. Variability of IL-1 alpha RIA
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Figure 3.3.1. Dilution characteristics of plasma IL-1 alpha
Plasma samples were serially diluted in assay buffer before being
analysed by IL-1 alpha RIA. Sample dilutions are expressed as percentage
(v/v) plasma.
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3.3.a.iv. Validation of sample collection
Blood samples were allowed to stand for up to three hours at 4° C, with
or without added LPS (lOOpg/ml) as described in Section 2.3.a.. Plasma was
prepared, extracted and tested for IL-1 alpha immunoreactivity. The results
are shown in Table 3.3.3.. The initial level of IL-1 alpha dropped during the
first hour (from a mean of 95pg/ml to 80pg/ml) and then rose to considerably
higher concentrations after 1.5 hours. Addition of LPS resulted in a greater
peak IL-1 alpha level at this time point (125pg/ml without and 200pg/ml with
LPS). In both cases by the third hour IL-1 immunoreactivity had fallen to
around the detection limit of the assay.
3.3.b. Effect of plasma extraction
Plasma samples from both control and RA patient groups were tested in
the IL-1 alpha RIA before and after extraction. The results are shown in
Table 3.3.4.. A group of 17 normal individuals showed a non-significant
increase in plasma IL-1 alpha after extraction (from 222pg/ml to 249pg/ml).
The group of 44 patients, however, showed a slight but significant increase
in IL-1 alpha levels (from 192pg/ml to 238pg/ml).
3.3.c. Plasma IL-1 alpha levels
3.3.c.i. Comparison of control and RA groups
The mean plasma IL-1 alpha levels were compared between age matched
patient and control groups (Table 3.3.5.), similar concentrations were seen
in the two groups (control mean 239pg/ml, patient mean 245pg/ml). There was
no significant difference in plasma IL-1 alpha concentrations as determined
using Students T-test.
3.3.c.ii. IL-1 alpha correlation with disease activity
The plasma IL-1 alpha concentration was compared with various measures
of disease activity within the patient group. In contrast to IL-1 beta no
correlation was seen with clinical or laboratory measures of disease
activity, apart from a correlation reaching slight significance with ESR, the
75
Plasma IL-1 alpha pg/ml














Table 3.3.4. Effect of extraction on plasma IL-1 alpha
detection
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Controls vs RA, t=0.338, p=0.736
Table 3.3.5. Interleukin 1 alpha levels in extracted plasma
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results (n= 48, r= 0.29, p<0.05) are shown in Figure 3.3.2..
3.3.c.iii. Serial IL-1 alpha measurement
Serial plasma samples were taken from hospitalised RA patients, and
plasma IL-1 alpha measurements compared to conventional measures of disease
activity. Results from three patients are shown in Figure 3.3.3.. In Patient
A correlations were found with Ritchie joint index (r= 0.678, p<0.005), pain
score (r= 0.59, p<0.02), duration of morning stiffness (r= 0.538, p<0.5) and
haemoglobin concentration (r=-0.49, p<0.05). Patient B showed significant
correlations with duration of morning stiffness (r= 0.587, p<0.02) and
platelet count (r= 0.719, p<0.005). In Patient C similar trends were
observed, with decreased IL-1 alpha levels corresponding to clinical
improvement, though correlations did not reach statistical significance.
3.4. DISCUSSION
The results show that chloroform extraction significantly increased the
amount of detectable plasma IL-1 beta immunoreactivity in both normal and RA
groups. The mean concentration of plasma IL-1 beta in the patient population
was significantly higher than that in controls. Furthermore plasma IL-1 beta
also correlated with various measures of disease activity, in both the whole
patient population and in individuals tested at regular intervals during a
period of hospitalisation. Use of an alternative IL-1 beta ELISA showed that
the assays were comparable for the majority of samples, but that the second
ELISA gave unexpectedly high readings in some cases. These levels are
considerably higher than those seen using other assays in our group.
In contrast, plasma IL-1 alpha levels in most individuals were
unaffected by extraction, and no difference was seen in the mean
concentrations between patient and control groups. The patient population as
a whole showed little correlation between IL-1 alpha and indices of disease
activity. However, examination of serial samples from particular individuals
























Figure 3.3.2. Comparison of plasma IL-1 alpha levels with ESR in RA patients
Extracted plasma samples were tested for IL-1 alpha level and the values
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and laboratory disease assessments.
Examination of blood collection methods showed that both IL-1 alpha and
beta rapidly degraded if plasma was not prepared soon after collection and
LPS contamination could result in raised levels after longer time periods.
The importance of careful blood sampling techniques was emphasised by Cannon
et al (1988), who suggested that plasma samples give more accurate
representations of the in vivo levels than serum samples, as IL-1 may be
released during the clotting process. The importance of including protease
inhibitors to prevent degradation of IL-1 has also been discussed. The
combination of aprotinin and EDTA has been previously described (Dinarello et
al, 1984). However, even when protease inhibitors are included during blood
collection a loss of immunoreactive IL-1 is observed if samples are not
prepared rapidly. If allowed to stand for longer than two hours even at 4° C
IL-1 may be released from cells, this may be further complicated by the
presence of LPS.
Chloroform extraction was seen to be important in unmasking IL-1 beta
immunoreactivity in both patient and control groups. The initial description
of this protocol, using a specific IL-1 beta RIA, showed that extraction
removed the influence of non-specific factors that interfere with immunoassay
in the plasma of malarial patients (Cannon et al, 1988). The latter report
described comparable IL-1 beta levels in normal individuals (mean= 62pg/ml)
to those reported here.
Using other assays it has been reported that chloroform extraction of
plasma samples does not improve detection of IL-1 beta (Fontaine et al,
1989). We therefore decided to compare IL-1 levels in extracted plasma as
measured by the Roussel and Cistron ELISAs. The majority of samples showed
comparable IL-1 beta levels in both assays, indicating that while extraction
may not be absolutely necessary, it was certainly not detrimental to
detection in the Roussel ELISA. This assay did however, show unexpectedly
high levels in some samples (>2000 pg/ml). Plasma beta IL-1 concentrations at
these levels have not been reported in other systems. It is reasonable to
assume that these extremely high levels are artefactual. Other commercially
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available immunoassays are unable to measure IL-1 beta in extracted or
unextracted plasma (J A Symons personal communication). This suggests that
plasma IL-1 immunoreactivity may be masked at certain epitopes and that
extraction uncovers some but not all of these sites. Thus the success of
immunodetection depends upon the particular epitopes of IL-1 that are
recognised by the antibodies employed and an ideal system can only be
designed when the epitope structure of natural IL-1 is fully resolved. In
contrast to IL-1 beta, IL-1 alpha detection is not increased by chloroform
extraction in the majority of samples.
Other extraction protocols have been described including a silica
elution method (Series et al, 1988). This however, results in only 30%
recovery of IL-1 added to blood, and detection of levels in the range of 0.3-
0.6 pg/ml.
The measurement of IL-1 in plasma from rheumatoid arthritis patients
shows that their mean plasma IL-1 beta level is raised compared to a normal
population. It is known that during active RA IL-1 immunoreactivity is found
in the joint fluid (Symons et al, 1989) and that the mRNA can be identified
in the synovial lining (Duff et al, 1988). It may be, therefore, that plasma
IL-1 beta is seen as a result of a local inflammatory activation within the
joint. The correlation between IL-1 beta concentration and laboratory
measures of disease activity, such as ESR, indicate a role for the former in
the activation of the acute phase response. Interleukin 1 is also known to
have effects on both iron metabolism (Dinarello, 1984) and on the a
suppressive action on the development of erythroid progenitor cells (Maury et
al, 1988). The negative correlation between IL-1 and blood haemoglobin
concentration provides further evidence that the cytokine may play a part in
the refractory anaemia often seen in chronic inflammatory disease. An
involvement for IL-1 in the RA disease process has often been suggested when
considering its ability to activate synovial cells, cause resorption of bone
and cartilage and act as a chemoattractant for cells involved in the
inflammatory response. Therefore, evidence of raised plasma IL-1 levels in
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active stages of the disease lends considerable support to this idea.
It has been suggested that individuals can be divided into high and low
producers of IL-1 (Molvig et al, 1988). It is suggested that these inter-
individual differences are related to HLA haplotype (Santamaria et al, 1989).
This difference was also observed at the plasma IL-1 beta level, the control
population having low levels presumably due to minimal cellular activation,
whereas serial measurements from some patients eg. Patient A, showed
variations within a small range of IL-1 beta concentrations but others eg.
Patient C showed a high levels of production. This variation in the IL-1 beta
levels produced by particular individuals may explain the scatter seen in
IL-1 population data. In contrast IL-1 alpha remained at comparable levels in
individuals tested serially.
Immunoassay of IL-1 may detect biologically inactive IL-1 in the form
of: pro IL-1 beta, partial degradation products and complexes of IL-1 with
other proteins. The in vivo effects of inhibitors can also not be determined
by immunoassay. Recent evidence suggests that extracellular precursor IL-1
molecules are likely to be processed rapidly in vivo by proteolytic enzymes
produced, particularly at an inflammatory site (Hazuda et al, 1990).
The correlations found in the RA population suggest that immunoreactive
blood IL-1 beta levels do, indeed, reflect production of bioactive IL-1,
within the joint.
Plasma interleukin 1 alpha levels showed no difference between control
and patient groups, and no population correlations with measures of disease
activity. Individuals undergoing serial measurement did however show
correlations between plasma IL-1 alpha and assessment of disease activity. It
is therefore suggested that the basal level of IL-1 alpha production is high
and may be derived from an organ such as the skin. It has been shown that
human keratinocytes produce predominantly IL-1 alpha and that this is
secreted from the cells in vitro (Kupper et al, 1986). Schmitt et al (1986)
have also suggested that the epidermis represents a large pool of IL-1 that
may arise in response to continual exposure of keratinocytes to stimuli such
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as UV light. This pool could contribute to the high IL-1 alpha levels seen in
all individuals. Any further IL-1 alpha produced from activated sites, such
as the synovium in arthritis patients, would not result in a significant rise
above basal levels. However, consideration of one individual, by longitudinal
assessment, would allow detection of small fluctuations in plasma levels
corresponding to changes in disease activity.
Recent studies in which plasma IL-1 has been measured, show increased
IL-1 beta levels in a number of disease states, including infectious purpura
(Girardin et al, 1988), experimental endotoxin fever (Cannon et al, 1990) and
renal transplant recipients (Maury and Teppo, 1988). The IL-1 alpha however
appears to remain at levels comparable to those in normal individuals (Cannon
et al, 1990).
We have shown the benefit of using the chloroform extraction protocol
when measuring plasma IL-1 beta but not alpha and, by immunoassay, have
demonstrated detectable levels of both cytokines in normal individuals and RA
patients. Levels of IL-1 beta could be correlated with disease activity in
the RA population and in longitudinal studies. Interleukin 1 alpha was also
related to disease activity when serial measurements from individuals were
examined.
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RESULTS: Characterisation of plasma IL-
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4.1. INTRODUCTION
To confirm that the plasma IL-1 immunoreactivity measured corresponded to
the presence of bioactive cytokine, plasma was separated by gel filtration
before assay. This also enabled a preliminary identification of IL-1
inhibitory activity in the EL4/CTLL costimulator assay.
Early analysis of IL-1 activity in ex vivo biological fluids involved an
initial fractionation step followed by bioassay. In other studies, this has
resulted in the finding of IL-1 bioactivity at high molecular weights. In
amniotic fluid Tamatani et al (1988) indicate that IL-1 activity was present
in fractions eluting between 60-90 kDa and was neutralisable by antisera to
the IL-1 beta form only. Concentration of this activity peak followed by
rechromatography resulted in IL-1 activity eluting at 15-20 kDa, suggesting
that in amniotic fluid, IL-1 beta is associated with a higher molecular
weight protein.
During the isolation of IL-1 activity from stimulated cells it has
occasionally been noted that the use of serum in culture media results in the
appearance of high molecular weight complexes. Furukawa et al (1987) have
shown IL-1 activity at above 70 kDa in supernatants from a monocytic line.
Togawa et al (1979) could identify secreted thymocyte stimulatory activity at
50-70 kDa derived from mononuclear cells, and demonstrated that if low
molecular weight LAF was added to human serum the activity rechromatographed
as the high molecular weight form. Treatment of large intracellular IL-1
species with detergent has resulted in generation of forms with sizes
characteristic of the mature molecule (Lepe-Zuniga et al, 1985; Kimball et
al, 1985).
The initial report describing the IL-1 extraction procedure also
analysed the molecular sizing of plasma IL-1 beta immunoreactivity and of
bioactive material (Cannon et al, 1988). This showed that fractionated
extracted plasma contained IL-1 beta immunoreactivity at 17 kDa with minor
higher peaks at above 150 kDa. Bioactivity analysis also identified a 17 kDa
IL-1 molecule and higher molecular weight material. The first bioactive peak
co-eluted with the largest immunoreactive moiety. Another study on
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fractionated plasma indicated that both IL-1 alpha and 1L-1 beta
immunoreactivity are present as high molecular weight (>66 kDa) forms (Capper
et al, 1990).
Many groups have identified inhibitors of IL-1 bioactivity in serum
following fractionation studies (Luger et al, 1986; Tamatani et al, 1988).
These usually appear at molecular weights between 50-70 kDa, the specificity
of these IL-1 inhibitors is often not well characterised.
We aimed to identify IL-1 bioactivity in extracted and unextracted human
plasma using gel filtration. This could then be compared with a similar
immunoreactivity profile. This technique would also facilitate the
preliminary identification of specific inhibitors of IL-1 alpha and beta in
the EL4/CTLL bioassay.
4.2. PLASMA FRACTIONATION
A large scale normal plasma sample (~30ml) was taken and prepared as
described previously. Half was then extracted (Sections 2.3.a. and 2.3.d.)
and twelve millilitres of extracted or unextracted plasma were
chromatographed on a Sephacryl S-200 gel filtration column and 2ml fractions
were collected (Section 2.6.).
4.2.a. Protein elution profile
The protein content of individual fractions was determined by measuring
the OD at 280nm. Both unextracted and extracted plasma samples gave similar
broad protein peaks, eluting immediately after the void volume (Figure
4.2.1.). Extraction considerably reduced the size of the peak, indicating
removal of a considerable amount of protein across a broad molecular weight
range.
4.2.b. Plasma IL-1 alpha profile
Unextracted plasma showed low IL-1 alpha immunoreactivity (Section
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Figure 4.2.1. Plasma protein profile before and after chloroform extraction
The protein profile (OD 280nm) of fractionated normal human plasma
before (—) and after ( ) chloroform extraction is shown. The position
of molecular weight markers, expressed in kDa, are indicated.
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2.4.b.) following fractionation, small peaks were seen at above 66 kDa and
above 150 kDa (Figure 4.2.2.). In extracted plasma a comparable lower
molecular weight peak was seen, whereas fractions from the >150 kDa peak were
of much higher IL-1 alpha concentration. No immunoreactivity was seen at
around 17 kDa. This individual showed a small increase in detectable IL-1
alpha levels in whole plasma from 420 to 460pg/ml following extraction.
4.2.c. Plasma IL-1 beta profile
Unextracted plasma samples showed little IL-1 beta immunoreactivity in
the Cistron ELISA (Section 2.4.a.i.). Small peaks were observed migrating
above the 12 kDa and 29 kDa markers and within the void volume (Figure
4.2.3.). Extraction, however, resulted in detection of a large peak of IL-1
beta activity that eluted immediately after the void volume, and of a
considerable amount of low molecular weight material (<12.4 kDa). A small
peak of activity at "20 kDa (Fraction 33) was apparent. This individual
showed <20pg/ml immunoreactive IL-1 beta in whole unextracted plasma, but
following extraction the level rose to 61pg/ml.
4.3. PLASMA IL-1 BIOACTIVITY
4.3.a. Antisera inhibition of IL-1 bioactivity
Anti IL-1 alpha and IL-1 beta antisera were tested to determine the
titre required to inhibit IL-1 bioactivities in the EL4/CTLL assay (Sections
2.1.b. and 2.I.e.). A 1:1000 dilution of each antiserum or pre-immune serum
was tested for its ability to inhibit the response to lOOpg/ml of each IL-1.
Figure 4.3.1. shows that the antibodies completely neutralised the respective
IL-1 species, no cross reactivity was seen and pre-immune serum did not
affect the biological response.
4.3.b. Plasma IL-1 bioactivity profile
Column fractions were tested in the IL-1 bioassay as described in
Section 2.1.b., the results shown represent samples tested at a concentration
of 10%. Unextracted plasma showed minimal IL-1 bioactivity, the largest peak
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Figure 4.2.2. Plasma IL-1 alpha profile
The IL-1 alpha immunoreactivity profile of fractionated normal human
plasma, before (—) and after ( ) chloroform extraction is shown. The
position of molecular weight markers expressed in kDa are indicated. The
shaded area represents the detection limit of the assay.
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Figure 4.2.3. Plasma IL-lbeta profile
The IL-1 beta immunoreactivity profile of fractionated normal human
plasma, before (—) and after ( ) chloroform extraction is shown. The
position of molecular weight markers expressed in kDa are indicated. The
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Figure 4.3.1. Anti-sera neutralisation of recombinant IL-1 activity
The neutralisation of 100 pg/ml of IL-1 alpha or beta by anti IL-1
antisera or pre-immune serum at 1:1000 titre is shown. The dashed line
represents the background OD.
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giving less than lpg/ml response as compared to standard (Figure 4.3.2.).
Extraction identified a bioactive peak at >150 kDa, positive fractions read
>100pg/ml compared to recombinant IL-1. All the IL-1 bioactivity shown was
completely neutralised by 1:1000 titre of a combination of both anti IL-1
antisera.
4.3.c. Plasma IL-1 inhibitor profile
Unextracted plasma column fractions were incubated at room temperature
for 1 hour with lOpg/ml of either IL-1 alpha or beta prior to assay by EL4
cells (Section 2.1.d.). The inhibition profile is shown in Figure 4.3.3.. The
results represent the activity of 1% final sample concentration, none of the
samples showed cytotoxicity at this concentration. The IL-1 alpha inhibitory
activity was never greater than 10%. However inhibition of recombinant IL-1
beta bioactivity showed a peak within the void volume that reduced IL-1 beta
bioactivity by 75%.
4.4. DISCUSSION
Fractionation of normal plasma identified little immunoreactive IL-1
alpha or beta unless the sample had previously been chloroform extracted. The
procedure revealed high molecular weight IL-1 alpha and beta, the major peak
in each case being at >200 kDa. A considerable amount of low molecular weight
IL-1 beta was also detected, this may however be due to proteolysis of larger
IL-1 species. Bioactivity analysis again identified IL-1 only following
extraction. Large molecular weight species were seen with no low molecular
weight bioactivity. The IL-1 activity was neutralisable by a combination of
antisera to both IL-1 alpha and beta. Chloroform extraction was shown to
remove a considerable amount of protein at a range of molecular weights
throughout the protein peak.
Specific IL-1 beta inhibitory activity was identified in normal,
unextracted plasma at high molecular weights, eluting near the void volume.
No corresponding IL-1 alpha inhibitory activity was seen.
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Figure 4.3.2. Plasma IL-1 bioactivity profile
The profile of fractionated plasma IL-1 bioactivity before (—) and
after ( ) chloroform extraction is shown. Samples are all tested at 10%
concentration and the activity shown is neutralisable by anti IL-1 antisera.
Molecular weight markers in kDa are indicated.
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Figure 4.3.3. Plasma IL-1 inhibitor profile
The profile of IL-1 inhibitory activity in unextracted fractionated
plasma is shown. The lines represent inhibition of 10 pg/ml of either human
recombinant IL-1 alpha (—) or IL-1 beta ( ). Samples are tested at 1%
concentration. The positions of molecular weight markers in kDa are
indicated.
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From immunoreactivity data it appears that both IL-1 molecules are
present in the circulation as high molecular weight complexes, and that the
associated proteins mask epitopes recognised by antibodies in the assays
used. Unexpectedly, extraction of plasma revealed high IL-1 alpha
concentrations in this individual after fractionation. However examination of
plasma showed that in this case chloroform extraction did increase the amount
of the detectable IL-1 alpha. Capper et al (1990) identify high molecular
weight plasma IL-1 alpha without extraction using the same immunoassay; the
levels they detected were, however, considerably lower with a peak of 150
pg/ml at >66 kDa. This could correspond to the peak observed in our
unextracted plasma run, eluting close to the 66 kDa marker. In monocyte
culture supernatants high molecular weight IL-1 alpha (>150 kDa) has been
demonstrated when serum is included in culture media (Ferrua et al, 1988).
The plasma IL-1 beta profile identified minimal immunoreactivity in
unextracted plasma, but a high molecular weight peak was apparent following
extraction. Plasma IL-1 beta has also been demonstrated by Capper et al
(1990) using a different immunoassay system that is not dependent on prior
extraction. The study did not, however, find low molecular weight IL-1 beta
species, indicating that this material may be a result of proteolytic
breakdown of higher molecular weight material during extraction or
fractionation. A high molecular weight species (>150 kDa) of IL-1 beta has
also been found in the supernatants of blood monocytes cultured in the
presence of serum (Ferrua et al, 1988).
In contrast to previous studies our bioactivity data indicate that
fractionation alone is not sufficient to identify plasma IL-1. This may be
due to differences in the assays used. The majority of other reports use the
thymocyte proliferation assay known to respond to murine TNF, IL-6, IL-2 and
murine IL-4. However the EL-4/CTLL assay does not recognise either human TNF
or human IL-6, and when tested on CTLL cells alone positive fractions did not
cause proliferation indicating the absence of human IL-2. The use of specific
antibodies to both IL-1 forms completely inhibited the IL-1 response. In
extracted plasma, high molecular weight IL-1 activity was again detected in
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fractions shown to contain immunoreactivity. Interleukin 1 bioactivity was
not seen at 17 kDa.
Initial description of the chloroform extraction identified IL-1 beta
immunoreactivity at high molecular weights and at 17 kDa (Cannon et al,
1988). Pooling and rechromatography of the larger material resulted in the
appearance of 17 kDa IL-1. Capper et al (1990) showed that IL-1 beta/protein
complexes could be dissociated at acid pH to give high levels of
immunoreactivity at <30 kDa.
The data suggest that rather than being present as an isolated molecule,
circulating IL-1 exists in complexes with other proteins. Binding to a high
molecular weight factor (>200 kDa) is seen, this interaction does not appear
to affect biological activity. However the association of another molecule,
that is removable by chloroform extraction, inhibits biological responses to
IL-1 and blocks the recognition of certain epitopes by immunoassay.
The inhibitory effect of fractionated normal plasma on IL-1 bioactivity
was assessed, we added exogenous IL-1 to fractions to show specific anti IL-1
effect rather than examining the cellular response to fractions alone.
Inhibition of IL-1 beta but not IL-1 alpha bioactivity was demonstrated at
high molecular weights (>200 kDa). This may represent the association of IL-1
beta with high molecular weight proteins or masking factors described.
Alternatively, this could be the effect of a specific IL-1 inhibitor such as
those previously described. If inhibition was a result of IL-1 beta binding
to the high molecular weight factors seen in this study, the lack of effect
with IL-1 alpha could imply that different moieties mask epitopes on IL-1
alpha and beta, or that IL-1 alpha less readily associates with the available
molecules. This could also explain why IL-1 alpha is less consistently
affected by extraction than IL-1 beta.
There are various candidate high molecular weight proteins that may act
as carriers or inhibitors of IL-1 action. Alpha 2 macroglobulin (alpha 2M) has
been shown to bind to IL-1 beta (Borth and Luger, 1989) and other cytokines
(James, 1990). The IL-1 beta/alpha 2^ complex was shown to migrate at >160 kDa
by HPLC molecular sieve chromatography and to retain biological activity in
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the thymocyte co-stimulator assay. Complexes were also shown between alpha 2M
and iodinated IL-1 beta in plasma and serum. Complex formation between
alpha 2M and IL-6 has been shown to protect the cytokine from the action of a
number of proteolytic enzymes, while not altering its receptor binding or
biological activity (Matsuda et al, 1989). The binding of TGF beta to alpha 2M
has been shown to be in part acid labile (O'Conner-McCourt and Wakefield,
1987). The sensitivity of high molecular weight IL-1 complexes to acid
treatment (Capper et al, 1990) suggests that this may represent a similar
type of binding.
Autoantibodies to IL-1 alpha have been identified in the sera of about
10% of normal individuals. This is proposed to account for the binding of
iodinated IL-1 alpha to 100-200 kDa factors in pooled serum (Svenson et al,
1989). Autoantibodies were shown to inhibit the bioactivity of IL-1 alpha in
the EL-4 assay. Preliminary studies to identify autoantibodies to IL-1 beta
in the course of the work reported here showed some activity in the serum of
individuals with systemic lupus erythymatosus (data not shown).
The IL-1 binding factors seen in normal human plasma could serve two
purposes: to protect the local and systemic environment from the potentially
damaging effects of free IL-1, and to facilitate the cytokine's removal from
the circulation. Alpha is known to effect the removal of bound proteases.
Alternatively, they could serve a carrier function, allowing retention of
biological activity and perhaps even protecting IL-1 from the action of
proteases in both the circulation and at the local site of inflammation.
Radiolabeled IL-1 beta has been shown to clear from plasma in a biphasic
manner, with an initial rapid half life and a second slower one of about 4
hours (Klapproth et al, 1989). It has also been shown that IL-1 beta
associates with the plasma fraction in blood (Newton et al, 1988). The second
slower clearance phase is consistent with IL-1 associating with a plasma
protein.
Our studies show that plasma IL-1 exists in the circulation as complexes
with large proteins rather than as the free molecule. This is demonstrated
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for IL-1 alpha, beta and the bioactive form. Binding to the high molecular
weight material does not prevent the detection of bioactivity, however some
factor is present that is able to mask both immunoreactive epitopes and
bioactivity. A high molecular weight moiety is also demonstrated in plasma
that is able to inhibit the bioactivity of IL-1 beta but not IL-1 alpha.
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5. RESULTS: The interleukin 1 beta binding protein
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5.1. INTRODUCTION
Local production of IL-1 at sites of inflammation is potentially
damaging to surrounding tissue. The extensive tissue destruction often seen
at sites of inflammatory disease may be attributed, at least in part, to the
effects of local IL-1 synthesis. The presence of circulating IL-1 in normal
individuals suggests that factors are present to regulate the in vivo effects
of the cytokine.
Though high molecular weight factors have been shown to bind plasma
IL-1, investigation of the best characterised of these, alpha 2 macroglobulin,
suggests that association is not sufficient to prevent biological activity
(Borth and Luger, 1989; Teodorescu et al, 1988). Cytokine autoantibodies may
have a role in the regulation of IL-1 effects but are not found in all
individuals (Bendtzen et al, 1990).
Various inhibitors of IL-1 in vitro action have been described (Larrick,
1989). Only one of these has been cloned (Eisenberg et al, 1990) allowing
study of its in vivo effects. This molecule acts by binding to the 80 kDa IL-
1 receptor and therefore preventing interaction with any IL-1 present. The
inhibitor is produced by monocytes (Hannum et al, 1990) and has been
identified in both serum and urine (Prieur et al, 1987), indicating that it
has a role in modulating the effects of circulating IL-1. The physiological
importance of the receptor antagonist has been shown by Carter et al (1990),
who describe its inhibition of IL-1 induced corticosteroid production. An
inhibition of IL-1 induced hypotension and acute phase response has also been
reported by Ohlsson et al (1989).
For a number of other cytokines soluble receptors have been identified,
some of which are seen to inhibit biological response to ligand. Soluble
receptor forms have been commonly described as constitutive components of
serum or urine from normal animals or individuals (Novick et al, 1989;
Fernandez-Botran and Vitetta, 1990). They have high affinity for ligand and
can be shown to inhibit in vitro biological responses (Symons et al, 1988;
Kondo et al, 1988).
Though a naturally occurring soluble IL-1 receptor has not been
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identified previously expression of a truncated cDNA clone for the 80 kDa
molecule produces a protein with high affinity for IL-1 alpha (Dower et al,
1989), that is able to inhibit in vitro and in vivo responses (Maliszewski et
al, 1990; Fanslow et al, 1990).
In this study we aimed to identify IL-1 binding proteins in human ex
vivo fluids. We report the presence and partial purification of an IL-1 beta
binding protein from human plasma and synovial fluid.
5.2. IDENTIFICATION OF IL-1 BINDING FACTORS
5.2.a. Identification by gel filtration
Iodinated IL-1 alpha and beta were added to unextracted and extracted
human plasma as described (Sections 2.3.d. and 2.5.a.). Samples were then
separated by Sephadex S-200 gel filtration chromatography (Section 2.6.).
Figure 5.2.1. shows the association of IL-1 alpha with plasma proteins. In
unextracted plasma IL-1 alpha was predominantly found as the free molecule
eluting at approximately 17 kDa. However following chloroform extraction IL-1
alpha was seen to associate with a high molecular weight factor at >200 kDa.
When iodinated IL-1 beta was added to untreated plasma a proportion
eluted as the free molecule at 17 kDa, but a considerable amount ("6% of the
total counts) migrated at a higher molecular weight of "100 kDa (Figure
5.2.2.). Following chloroform extraction, association of IL-1 beta with a
high molecular weight factor was seen within the void volume, this was
comparable with the IL-1 alpha binding molecule. Extraction did not appear to
alter binding in the 100 kDa complex.
To analyse the specificity of IL-1 association with plasma proteins, the
sample was incubated with iodinated IL-1 beta, with or without lOOx excess
cold IL-1 alpha or beta (Figure 5.2.3.). Two IL-1 binding complexes were seen
125with iodinated cytokine alone, IL-1 alpha competition did not affect I IL-
1 beta binding but cold IL-1 beta reduced the amount of binding in the 100
kDa complex (from "5.1% to "4.5% of total counts). In plasma preparations,



















Figure 5.2.1. Gel filtration of IL-1 alpha in human plasma
Extracted (—) and unextracted ( ) human plasma were incubated with
iodinated IL-1 alpha and analysed on a gel filtration column. The percentage
of total counts in each 2ml fraction are shown. The position of molecular
weight markers in kDa, on the same column, are indicated.
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Figure 5.2.2. Gel filtration of IL-1 beta in human plasma
Extracted (—) and unextracted ( ) plasma were incubated with
iodinated IL-1 beta and analysed by gel filtration. The percentage of total
counts in each 2ml fraction are shown. The position of molecular weight
markers, expressed in kDa, are indicated.
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Figure 5.2.3. Specificity of IL-1 beta association with the 100 kDa plasma
protein
The binding of iodinated IL-1 beta to plasma proteins is shown (•—•).
Specificity of binding was assessed by including lOOx excess cold IL-1 alpha
(m—■) or beta ( ) in the incubation reaction. The percentage of total
counts in each 2ml fraction are shown. The position of molecular weight
markers in kDa are indicated.
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Using synovial fluid samples, however, effective competition of iodinated
IL-1 beta by unlabelled IL-1 beta could consistently be demonstrated (Figure
5.2.4., courtesy of J A Symons).
5.2.b. Identification by SDS-PAGE
Plasma samples were incubated overnight with iodinated IL-1, and the
associated complexes were cross-linked covalently as described (Section
2.5.b.). Cold competition experiments were done (prior to cross-linking) to
examine the specificity of binding. Samples were run on SDS-PAGE gels, as
described in Section 2.9.a.. Figure 5.2.5. shows the cross - linking of
iodinated IL-1 alpha (A) and beta (B) to plasma samples. Minimal binding was
seen with IL-1 alpha, the cytokine being associated with high molecular
weight material (>200 kDa). However iodinated IL-1 beta showed specific
cross-linking to a complex migrating at about 60 kDa. Binding was competable
by excess cold IL-1 beta but not IL-1 alpha or TNF. High molecular weight
IL-1 beta binding was also seen at >200 kDa, this appeared to be partially
competed by each cold cytokine.
A comparable gel showing the IL-1 beta binding proteins present in
synovial fluid is shown in Figure 5.2.6. (courtesy of J A Symons). Cross-
linking again shows a band at about 60 kDa indicating a protein of
approximately 43 kDa that binds specifically to IL-1 beta.
The binding characteristics of the 43 kDa protein using a second cross-
linking reagent are shown in Figure 5.2.7.. The use of EGS identified a
similar molecular weight complex with iodinated IL-1 beta, that could be
competed by excess cold IL-1 beta but not alpha.
5.2.c. Binding of IL-1 alpha to cell surface receptors
To confirm that the iodinated IL-1 alpha preparation retained receptor
binding ability, the cytokine was cross-linked to surface receptors on 3T3
cells as described in Section 2.5.C.. The results are shown in Figure 5.2.8..
Interleukin 1 alpha was able to bind to 3T3 receptors resulting in a complex
that migrated at approximately 97 kDa. Binding was competable with excess
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Figure 5.2.4. The association of labelled IL-1 alpha and IL-1 beta with
synovial fluid proteins
The binding of iodinated IL-1 alpha ( B...o) or IL-1 beta ( o—o) to
synovial fluid proteins is shown. Specificity was assessed by including lOOx
excess cold IL-1 beta (• • ) in the incubation reaction. The percentage of














Figure 5.2.5. Analysis of plasma IL-1 binding proteins by SDS-PAGE
Plasma was cross-linked to either iodinated IL-1 alpha (A) or beta (B)
and the labelled complexes were analysed by SDS-PAGE (lane 1). The
specificity was determined by addition of 100 fold excess of cold IL-1 alpha
(lane 2), IL-1 beta (lane 3), or TNF alpha (lane 4). The position of








Figure 5.2.6. Analysis of synovial fluid IL-1 binding proteins by SDS-PAGE
Synovial fluid was cross-linked to iodinated IL-1 beta, the products
were analysed using SDS-PAGE (lane 1). Specificity was determined by the
addition of 100 fold excess of cold IL-1 (lane 2), beta (lane 3) or TNF alpha
(lane 4). The figure was provided courtesy of J A Symons. The positions of
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Figure 5.2.7. Analysis of plasma IL-1 beta binding proteins using EGS as the
cross-linking agent
The binding and specificity of association of iodinated IL-1 beta with
plasma proteins was compared using ethylene glycolbis(succinimidyl succinate)
as the cross-linking reagent. Lane 1 shows the binding of IL-1 beta alone and
lanes 2 and 3 show competition with excess cold IL-1 alpha and beta







Figure 5.2.8. Cross-linking of IL-1 alpha to the 3T3 cell line
The ability of iodinated IL-1 alpha to bind to the IL-1 receptor on 3T3
cells is shown (lane 1). Specificity is shown by the addition of excess cold
IL-1 alpha (lane 2), beta (lane 3) and TNF alpha (lane 4). The position of
molecular weight markers in kDa are indicated.
Ill
cold IL-1 alpha and IL-1 beta but not with TNF alpha. Thus the iodinated IL-1
alpha bound the cell surface 80 kDa receptor.
5.2.d. Analysis of IL-1 beta binding activities
Fractions containing the 100 kDa IL-1 beta binding protein from Sephadex
S-200 column runs were pooled, cross-linked with DSS, concentrated (Section
2.3.c.) and analysed by SDS-PAGE (Figure 5.2.9.). The products of two
independent column runs are presented. Both show that the 100 kDa gel
filtration complex migrates at approximately 60 kDa in non-reducing
polyacrylamide gels.
5.3. PURIFICATION OF THE IL-1 BETA BINDING PROTEIN
5.3.a. Wheat germ agglutinin column
Partial purification of the IL-1 beta binding protein was achieved using
a wheat germ agglutinin column. The plasma sample was loaded and eluted from
the column as described in Section 2.7.a.. The protein elution profile is
shown in Figure 5.3.1.. The majority of the protein did not bind to the
column or was eluted in the initial wash steps. Specific elution using
N-acetylglucosamine recovered a small protein peak. The binding protein was
identified in Fractions 90-92.
Figure 5.3.2. shows the elution of the binding protein from the column
by N-acetylglucosamine. Fraction 1 represents the start of the elution step.
Fractions were incubated with iodinated IL-1 beta and cross-linked as before.
Figure 5.3.3. shows the binding characteristics of the eluted protein.
Fraction 8 from the previous figure was incubated with labelled IL-1 alpha
(A) or beta (B) with excess cold cytokine to test specificity. Reducing
conditions did not alter the mobility of the binding protein by SDS-PAGE. The
results demonstrate that the protein only associates with iodinated IL-1 beta







Figure 5.2.9. The migration on SDS-PAGE of the 100 kDa iodinated peak from
gel filtration
The 100 kDa peak isolated by gel filtration was cross-linked,
concentrated and analysed by SDS-PAGE. Lanes 1 and 2 represent pooled















Figure 5.3.1. Protein profile of plasma eluted from a lectin affinity
column
The OD at 280nm of plasma fractions collected from a wheat germ
agglutinin column were measured. Arrow 1 represents the start of the salt
wash, 2 the ethylene glycol wash, 3 PBS and 4 the N-acetyl glucosamine
elution step. Arrow 5 marks the peak of binding protein activity.
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Figure 5.3.2. The IL-1 beta binding activity eluted from the lectin affinity
column
Iodinated IL-1 beta was cross-linked to fractions from the N-acetyl
glucosamine elution from the wheat germ agglutinin affinity column. The
fractions represent numbers 84-93 on the previous figure. Molecular weight
markers in kDa are shown.
115
1 2 3 4 5 1 2 3 4 5
Figure 5.3.3. Specificity of association of IL-1 with the lectin affinity
purified binding protein
Iodinated IL-1 alpha (A) and beta (B) was cross-linked to the wheat germ
agglutinin purified binding protein (lane 1). Lanes 2, 3, and 4 show the
effect of cold competition with IL-1 alpha, beta and TNF alpha respectively.
Lane 5 shows the protein run under reducing conditions, and lane 6 a
comparable plasma sample. Molecular weight markers in kDa are shown.
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5.3.b. Ion exchange purification
5.3.b.i. Binding and elution characteristics of IL-lbeta binding protein
Before purification the conditions required for binding to and elution
from DEAE Sephacel were determined. The pH at which the protein bound to the
matrix was first established (Section 2.7.b.). Synovial fluid diluted with
Tris-HCl at different pH values was incubated with DEAE Sephacel and then
tested to determine whether binding protein had been removed from the
supernatant. Figure 5.3.4. shows the levels remaining in synovial fluid
following incubation with DEAE Sephacel. The results show that at pH 5.0 the
protein is still present in the supernatant, whereas at pH 5.5 no 60 kDa
complex is evident.
The salt concentration required for elution of protein was then
determined. As described in Section 2.7.b. DEAE Sephacel was washed in
starting buffer and then equilibrated at a range of salt concentrations.
Synovial fluid was added, and the supernatant assayed for binding activity.
As shown in Figure 5.3.5. the 60 kDa protein bound to the column at
concentrations below 0.1M saline, but above this concentration all activity
was recovered in the supernatant.
Therefore 0.01M Tris-HCl at pH 5.5 was selected as the starting buffer
and a continuous elution gradient of 0.01-0.5M NaCl was used.
5.3.b.ii. Purification of the IL-1 beta binding protein
The elution profile of the IL-1 beta binding protein, recovered from 3
litres of synovial fluid in 500ml aliquots, is shown in Figure 5.3.6.. The
factor eluted as two distinct bands (shaded) at salt concentrations of 0.15
and 0.25M. The cross-linking of associated bands is shown in Figure 5.3.7..
Active fractions were then pooled, concentrated and used for further
purification or characterisation.
5.3.C. Affinity purification
An IL-1 beta affinity column was prepared using a modified IL-1 molecule
in which a lysine residue was substituted for a cysteine, allowing the
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Figure 5.3.4. The effect of pH on the association of binding protein with
DEAE Sephacel
The supernatant from synovial fluid incubated with DEAE Sephacel at a
range of PH values was tested for loss of binding protein activity. Lane 1
shows whole synovial fluid, and lanes 2-10 supernatants removed from the
Sephacel following incubation at a pH range of 5.0-9.0 at intervals of 0.5 pH
units. Molecular weight markers in kDa are shown.
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Figure 5.3.5. The effect of salt concentration on association of binding
protein with DEAE Sephacel
The supernatant from synovial fluid incubated with DEAE Sephacel at
increasing salt concentrations was tested for IL-1 beta binding activity.
Lanes 1-7 represent incubation at 0.01, 0.05, 0.1, 0.15, 0.2, 0.25 and 0.3M
sodium chloride concentrations. Molecular weight markers in kDa are shown.
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Figure 5.3.6. The protein elution profile from a DEAE Sephacel column
The OD at 280nm of fractions eluting from the ion exchange column are
shown, and the salt concentration gradient indicated. Fractions showing IL-1









Figure 5.3.7. IL-1 beta binding activity of fractions eluted from the ion
exchange column
The cross-linking of IL-1 beta to alternate fractions from the ion
exchange column are shown. Positions of molecular weight markers in kDa are
indicated.
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formation of disulphide bonds with an activated Thiol Sepharose column.
Coupling using the protocol described (Section 2.7.C.), resulted in 97%
efficiency of binding.
The elution profile of binding protein from the affinity column is shown
in Figure 5.3.8.. Binding protein was not eluted by the high stringency salt
wash, but strong binding activity was found in the fractions at low pH when
coming off the column. Binding specificity in these fractions is also shown,
formation of iodinated complex is effectively competed only by cold IL-1
beta.
5.3.d. Reverse phase HPLC of partially purified binding protein
The elution of binding protein with a 10-70% acetonitrile gradient is
shown in Figure 5.3.9.. The fractions exhibiting activity by cross-linking on
SDS-PAGE gels are shown.
5.4. CHARACTERISATION OF THE IL-1 BETA BINDING PROTEIN
5.4.a. IL-1 beta binding kinetics
The kinetics of association of iodinated IL-1 with the plasma binding
protein were examined at 4° C and room temperature (Section 2.5.d.i.). Figures
5.4.1. and 5.4.2. show the respective results. At 4° C little binding was seen
in the first three hours, however, overnight incubation at the same
temperature resulted in high levels of complex formation. At room temperature
considerable binding occurred within the first hour. The sample treated
overnight showed much greater binding to the >200 kDa high molecular weight
material.
5.4.b. Temperature sensitivity of IL- beta binding protein
Plasma samples were heated to the described temperatures (Section
2.5.d.ii.) before overnight incubation at 4° C with iodinated IL-1 beta.
Association of the 60 kDa complex was not greatly affected by heating, only
at 70° C was there any reduction of the intensity of the cross-linked band
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Figure 5.3.8. Elution of binding protein from the IL-lbeta affinity column
Fractions from the salt wash and acid glycine elution, from the
immobilised IL-1 beta column, are assessed for binding protein (A). The
specificity of binding is also demonstrated (B), lane 1 shows association
with iodinated IL-1 beta alone, and lanes 2, 3 and 4 competition with cold
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Figure 5.3.9. HPLC analysis of IL-1 beta binding protein activity
The elution profile from the HPLC column, protein OD at 220nm in
fractions was determined. The cross-linking of iodinated fractions is shown.
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Figure 5.4.1. The kinetics of association of IL-1 beta with the binding
protein at 4°C
The association of iodinated IL-1 beta with the binding protein is shown
after different incubation times at 4° C. Lanes 1-7 represent incubation
overnight, for 0.5, 1.0, 1.5, 2.0, 2.5 and 3.0 hours. Molecular weight
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Figure 5.4.2. The kinetics of association of IL-1 beta with the binding
protein at room temperature
The association of iodinated IL-1 beta with binding protein is shown
after different incubation times at room temperature. Lanes 1-7 represent
incubation overnight, for 0.5, 1.0, 1.5, 2.0, 2.5, 3.0 hours. Molecular
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Figure 5.4.3. The temperature sensitivity of the IL-1 beta binding protein
Plasma samples were heated to 37° C, 40° C, 50° C, 60° C and 70° C (lanes 1-
5) before incubation with IL-1 beta, and cross-linking. Molecular weight
markers in kDa are shown.
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binding following heating at 70° C.
5.4.c. N-Glycanase treatment
The partially purified binding protein prepared by ion exchange, was
incubated with labelled IL-1 beta and the complex cross-linked. This was
treated with N- Glycosidase F as described (Section 2.5.e.). The treated
sample was then analysed by SDS-PAGE (Figure 5.4.4.). Treatment with N-
Glycanase resulted in the appearance of a band migrating at about 47 kDa,
suggesting that the unglycosylated protein has a molecular weight of around
30 kDa.
5.5. DISCUSSION
The results demonstrate the presence in both plasma and synovial fluid
of a specific IL-1 beta binding protein. Interleukin 1 alpha is unable to
bind or compete for sites of IL-1 beta binding to this protein. The protein
associates with IL-1 beta to give a complex of molecular weight of
approximately 100 kDa by gel filtration and 60 kDa by SDS-PAGE. The protein
shows specific binding to a wheat germ agglutinin column, and following
deglycosylation the molecular weight of the cross-linked complex is reduced
to 47 kDa. The data suggest the presence of a 43 kDa binding factor, that
following deglycosylation exhibits a molecular weight of 30 kDa. The binding
protein appears to associate with other factor(s) under physiological
conditions.
The protein has been partially purified from pooled synovial fluid
samples. An initial ion-exchange separation step was followed by affinity
chromatography on an IL-1 beta thiol Sepharose column. The binding protein
could then be identified as a peak on reverse phase HPLC. Characterisation of
the binding protein showed that association with IL-1 beta was slow at 4° C
but rapid binding could be demonstrated at room temperature. The molecule was
insensitive to heat inacti vation, showing only slight loss of binding
activity at 70° C.
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Figure 5.4.4. The effect of N-Glycanase on migration of the binding protein
Partially purified binding protein was incubated with labelled IL-1 beta
and cross-linked. The complex was then treated with N-Glycosidase F and the
molecular weight analysed by SDS-PAGE. Lanes 1 and 2 show untreated and
deglycosylated binding protein respectively. Molecular weight markers in kDa
are shown.
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Gel filtration analysis of proteins that associate with iodinated IL-1
identified a high molecular weight species common for both IL-1 forms. This
binding activity was not detected in unextracted plasma, but is revealed
following the described chloroform treatment. It is possible that the high
molecular weight factor may represent alpha -> macroglobulin. It has been
suggested that the binding of TGF beta to alpha 2M may occur through both
covalent and non-covalent linkages (O' Conner-McCourt and Wakefield, 1987),
and that some is readily removed by either acid or urea treatment (Huang et
al, 1988). It is possible that chloroform denaturation results in removal of
some molecules associated with alpha 2M, in this way uncovering sites suitable
for IL-1 binding.
The second factor identified by gel filtration of plasma was able to
bind only IL-1 beta resulting in a 100 kDa complex. The specificity of this
association was tested by addition of 100 fold excess of unlabelled cytokine
in the reaction. Using plasma, cold IL-1 alpha showed no competition of
binding, but beta was able to reduce the size of the 100 kDa peak, this
competition however was not completely effective. When synovial fluid was
used as the source of binding molecule, excess unlabelled IL-1 beta removed
all iodinated IL-1 beta binding at 100 kDa. It is therefore possible that the
large amounts of alpha 2M present in serum and plasma are able to bind much of
the cold cytokine thus reducing the pool available to compete for specific
sites on other proteins.
Using cross-linking and SDS-PAGE analysis of plasma an IL-1 beta/binding
protein complex was demonstrated at 60 kDa suggesting the presence of a 43
kDa factor. Specificity of association could be demonstrated. A comparable
molecule was also identified in synovial fluid samples. When the pooled gel
filtration peak was analysed by SDS-PAGE the complex migrated at 60 kDa,
indicating that in physiological situations the 43 kDa binding protein
associates with another factor(s) resulting in the larger iodinated peak seen
by gel filtration. The inclusion of a reducing agent in the sample did not
appear to alter the size of the band. However using af finity - purified
material, reduction increased the size of the complex to about 70 kDa (J A
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Symons, personal communication), suggesting that internal disulphide bonding
was involved in maintaining the conformation of the molecule. A second cross-
linking reagent was used to confirm that bands seen were not artefacts due to
the system used.
The binding protein was partially characterised with regard to the
binding kinetics and heat sensitivity. The rate of association with labelled
IL-1 beta was slow at 4° C but at room temperature significant binding was
demonstrable within an hour. The binding protein exhibited little temperature
sensitivity even up to 70° C.
A recent report supports this finding of the association of iodinated
IL-1 beta but not alpha with a high molecular weight binding protein (>66
kDa). A very slow rate of association of the factor with IL-1 beta at 4° C was
also shown (Capper et al, 1990).
The presence of a band of broad molecular weight suggested that the
factor may be glycosylated and we therefore used a lectin affinity column as
an initial purification technique. Binding and specific elution of the
protein from the wheat germ affinity column indicates that the molecule is
glycosylated with carbohydrate containing N-acetyl glucosamine. Treatment of
a partially-purified preparation of binding protein with N-Glycosidase F
results in a complex with IL-1 beta that migrates at about 47 kDa. This
indicates that the molecular weight of the unglycosylated molecule is
approximately 30 kDa.
To enable large scale purification of the binding protein from pooled
synovial fluid samples, ion exchange chromatography was used as an initial
fractionation step. Binding protein eluted as two peaks at 0.15 and 0.25M
sodium chloride, this may indicate differential glycosylation of the two
forms.
The binding activity from the ion exchange purification was concentrated
and further purified on an IL-1 beta affinity column. The column was prepared
using an IL-1 beta mutein, with a cysteine replacing the lysine at residue
138. The characteristics of this IL-1 beta form have been studied (Wingfield
et al, 1989). The molecule shows similar conformation to the native form, as
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assessed by NMR, and has comparable receptor binding affinity and biological
activity. Binding protein eluted from the column with pH 3 glycine, and
showed similar specificity to the unpurified molecule.
HPLC analysis of the preparation indicated the presence of multiple
protein peaks, one of the major ones demonstrating high levels of IL-1 beta
binding activity.
There are a number of reports demonstrating the release of receptor
molecules in vivo, resulting in soluble, high-affinity, ligand binding
moieties. As discussed, various soluble cytokine receptors have been
described, many of which show an inhibitory effect on the bioactivity of the
ligand by preventing receptor binding. It is possible that the IL-1 beta
binding protein described here is a soluble IL-1 receptor molecule.
Further studies concerning the cellular source of the binding protein
have been carried out, they indicate that it is produced by PHA stimulated
peripheral blood mononuclear cells (Symons et al, 1990), and the Raji B cell
line (Symons and Duff, 1990). From cell surface cross-linking experiments the
latter study indicates that the molecule may be a solubilised form of the
Raji IL-1 receptor that is released following cleavage by a cell surface
protease.
Studies on the IL-1 receptor have suggested that two distinct forms
exist, the 80 kDa molecule found predominantly on T cells and fibroblasts and
the 60 kDa form characterised on B cells (Chizzonite et al, 1989). The 60 kDa
molecule shows preferential binding to IL-1 beta (Scapigliati et al, 1989).
Recent evidence, however, suggests a more complicated model in which many B
cell lines possess two receptor forms. The Raji line appears to be uncommon
in having only the smaller molecule (Benjamin and Dower, 1990; Symons and
Duff, 1990).
The cloned 80 kDa (type 1) IL-1 receptor has been expressed as a
truncated 62 kDa molecule and shown to retain IL-1 alpha binding activity
(Dower et al, 1989). This soluble receptor has IL-1 inhibitory activity in
both in vivo and in vitro assays (Maliszewski et al, 1990; Fanslow et al,
1990). However no comparable natural molecule has yet been described in
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biological fluids.
The preferential IL-1 beta binding characteristics of the Raji IL-1
(type 2) receptor adds further evidence that the soluble binding protein
described in the present work may be a soluble form of this cell-surface IL-1
receptor.
The association of IL-1 beta with the synovial fluid binding protein has
been shown by Scatchard analysis to be of comparable affinity to that with
the 80 kDa receptor on EL4 cells, suggesting a potential ability to compete
for IL-1 binding with the cell surface receptor (Symons et al, 1990). Recent
studies show that the affinity purified protein from Raji cell supernatants
inhibits the binding of iodinated IL-1 beta to the receptor on EL4 and Raji
cells, but does not affect IL-1 alpha binding (J A Symons, personal
communication). The binding protein may, therefore, act as a significant
physiological regulator of IL-1 beta activity in vivo.
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6. RESULTS: Interleukin 1 beta processing
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6.1. INTRODUCTION
Cleavage of the inactive IL-1 beta precursor to the biologically active
mature molecule is a potential site for the pharmacological modulation of
IL-1 activity. As the IL-1 alpha precursor exhibits receptor binding and is
active biologically, inhibition of its processing to the mature form is
unlikely to have a major effect on the overall biological response.
Interleukin 1 alpha is also thought predominantly to be a cell associated
molecule, therefore inhibition of its activity or production may have less
impact in vivo than alterations in bioaclive IL-1 beta levels.
The IL-1 beta processing event is poorly characterised, it has been
suggested that a cell surface or secreted enzyme is responsible for
proteolytic cleavage, as mature IL-1 beta is rarely found intracellularly
(Black et al, 1988). However attempts to isolate the processing enzyme have
also identified factors in cytosolic (Black et al, 1989b; Kostura et al,
1989) and membrane preparations (Black et al, 1988). The cytosolic processing
activities described are shown to result in the correct cleavage product as
determined by N-terminal sequencing, and to increase the bioactivity of the
IL-1 beta preparation.
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The importance of processing at the correct site, Asp -Ala , has
been shown by Black et al (1988) who used a variety of well characterised
enzymes to cleave the IL-1 beta propeptide. This showed that enzymic
activities resulting in slightly larger mature IL-1 molecules, even
elongation by only a few amino acids at the N-terminus, resulted in a
considerable loss of bioactivity. This led to the suggestion that the factor
responsible for production of the optimal mature IL-1 beta molecule was a
specific enzyme with an unusual substrate specificity.
A recent report however has indicated that in vivo, particularly in the
inflammatory, state another mechanism may operate. Hazuda et al (1990) showed
that enzymes present in inflammatory exudate fluids cleave recombinant pro
IL-1 beta to a biologically active form. The specificity of this processing
reaction was not determined, but it was demonstrated that enzymes such as
elastase, collagenase and cathepsin G are all able to increase the level of
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lower molecular weight IL-1 products. It is therefore postulated that
precursor IL-1 beta may be released either as a result of specific secretion
or cellular damage, at the site of an inflammatory reaction. This could then
be cleaved by proteolytic enzymes derived from inflammatory leukocytes to
give increased local IL-1 bioactivity.
The aim of the present study was to identify factors capable of
processing the IL-1 beta propeptide, and then to attempt to inhibit the
reaction with either common protease inhibitors or synthetic peptides
constructed from sequences around the cleavage site of the precursor molecule
as shown in Figure 6.1.1..
6.2. CELLULAR PROCESSING OF IL-1 BETA
6.2.a. Sources of IL-1 beta propeptide and processing activity
To determine a suitable source of IL-1 beta propeptide and of processing
enzyme activity various monocytic cell lines were stimulated as described
(Section 2.I.e.). The supernatants and cell lysates were separated by SDS-
PAGE followed by Western blotting (Sections 2.9.a.), and immunoreactive IL-1
beta visualised using the avidin biotin detection system (2.9.C.). Figure
6.2.1. shows IL-1 levels in cell lysates and supernatants of THP-1, HL-60 and
U937 cells, production by stimulated and unstimulated cells are shown. The
production of 31 kDa propeptide in cell lysates was enhanced by PMA and
zymosan in each cell line tested. The HL-60 and U937 lines showed minimal
propeptide levels when unstimulated, and LPS did not significantly induce
production. In culture supernatants propeptide was found in media from THP-1
and U937 cells cultured with PMA. However mature IL-1 beta, co-migrating with
the recombinant 17 kDa form, was only detected in THP-1 supernatants.
6.2.b. Inhibition of processing in whole cell culture
THP-1 cells were cultured with PMA to stimulate IL-1 beta production.
Protease inhibitors were also added in an attempt to inhibit processing of
the precursor molecule (Section 2.1.f.). Figure 6.2.2. shows Western blots of
136
Met Ala Glu Val Pro Glu Leu Ala Ser Glu Met Met Ala Tyr Tyr Ser Gly Asn Glu
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Asp Asp Leu Leu Phe Glu Ala Asp Gly Pro Lys Gin Met Lys Cys Ser Phe Gin Asp
38
Leu Asp Leu Cys Pro Leu Asp Gly Gly lie Gin Leu Arg lie Ser Asp His His Tyr
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Ser Lys Gly Phe Arg Gin Ala Ala Ser Val Val Val Ala Met Asp Lys Leu Arg Lys
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Met Leu Val Pro Cys Pro Gin Thr Phe Gin Glu Asn Asp Leu Ser Thr Phe Phe Pro
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Phe He Phe Glu Glu Glu Pro He Phe Phe Asp Thr Trp Asp Asn Glu Ala Tyr Val
y - 114
His Asp Ala Pro Val Arg Ser Leu Asn Cys Thr Leu Arg Asp Ser Gin Gin Lys Ser
T33
Leu Val Met Ser Gly Pro Tyr Glu Leu Lys Ala Leu His Leu Gin Gly Gin Asp Met'
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Glu Gin Gin Val Val Phe Ser Met Ser Phe Val Gin Gly Glu Glu Ser Asn Asp Lys
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He Pro Val Ala Leu Gly Leu Lys Glu Lys Asn Leu Tyr Leu Ser Cys Val Leu Lys
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Asp Asp Lys Pro Thr Leu Gin Leu Glu Ser Val Asp Pro Lys Asn Tyr Pro Lys Lys
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Lys Met Glu Lys Arg Phe Val Phe Asn Lys He Glu He Asn Asn Lys Leu Glu Phe
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Glu Ser Ala Gin Phe Pro Asn Trp Tyr He Ser Thr Ser Gin Ala Glu Asn Met Pro
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Taken from Auron et al, 1984.
Peptide a, amino acids 102-138 MWt= 4.3 kDa
Peptide b, amino acids 111-122 MWt= 1.36 kDa
Peptide c, amino acids 101-112 MWt= 1.48 kDa
Arrow represents the IL-1 beta propeptide cleavage site





Figure 6.2.1. Production and processing of IL-lbeta by whole cells
Production of IL-1 beta in lysates (A) and culture supernatants (B) of
THP-1, HL-60 and U937 cells. Cells were cultured alone (lane 1), with
lOOng/ml or lOug/ml LPS (2 and 3), lmg/ml zymosan (4) and 0.1 or lug/ml PMA
(5 and 6). The last lane in panel B shows recombinant IL-1 beta. Molecular
weight markers in kDa are indicated.
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Figure 6.2.2. Inhibition of cellular IL-1 beta processing in whole cells
Detection of IL-1 beta in lysates (A) and culture supernatants (B) by
Western blotting. THP-1 cells were cultured in media alone (lane 1),
stimulated with lOOng/ml PMA (2), or PMA with; aprotinin (3), pepstatin (4),
PMSF (5), leupeptin (6), lOOng/ml 3,4 DC (7), lOOng/ml 1,10 PA (8), lOng/ml
3,4 DC (9) and lOng/ml 1,10 PA (10). The position of molecular weight markers
in kDa are indicated.
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the cell lysates (A) and culture supernatants (B) to determine the production
and size of IL-1 beta protein. The figure shows that similar levels of the
precursor are produced in all cultures apart from that containing 1,10
phenanthroline (1,10-PA, lOOng/ml; lane 8). Cells cultured with this
concentration of 1,10-PA exhibited reduced viability by trypan blue
exclusion. Lower concentrations did not affect the amount of propeptide in
the cell lysate (lane 10). In culture supernatants aprotinin (lane 3) and
leupeptin (lane 6) reduced the appearance of mature IL-1 beta but not the
propeptide indicating inhibition of enzyme processing. PMSF reduced the
levels of both molecules (lane 5). The other protease inhibitors had no
effect on the level of processed IL-1 beta.
6.2.c. The effect of protease inhibitors on IL-1 beta mRNA levels
The IL-1 beta mRNA levels in THP-1 cells following culture with protease
inhibitors were determined by slot blot analysis (Section 2.8.b.) and are
shown in Figure 6.2.3.. Low levels of IL-1 beta mRNA (A) were seen in
unstimulated cells (lane 1), but levels were raised following culture with
PMA (lane 2). Aprotinin, pepstatin or 3,4 dichloroisocoumarin did not alter
IL-1 beta mRNA levels. However PMSF, leupeptin and 1,10-PA considerably
reduced IL-1 beta mRNA compared to stimulated cells. To ensure that the
results did not reflect differences in sample loading between wells, the
filter was stripped and reprobed with 7B6 cDNA, which encodes a cell cycle-
independent message. When hybridised with 7B6 (6.2.3.B), sample loading was
shown to be comparable between wells.
The effect of protease inhibitors on pro IL-1 beta processing and mRNA
levels in the whole cell system is summarised in Table 6.2.1..
6.3. PROCESSING OF CELL LYSATE (NATURAL) PRO IL-1 BETA
Stimulated THP-1 cell lysate was prepared as a source of 31 kDa IL-1
beta as described in Section 2.2.a.. The ability of a membrane preparation,
whole cells and the cell lysate itself to effect processing were examined
over a 1-24 hour time period. The inhibitory activity of both aprotinin and
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Figure 6.2.3. mRNA levels in cells cultured with protease inhibitors
Slot blots were probed with cDNA coding for IL-1 beta (A) or 7B6 (B)
mRNA. THP-1 cells were cultured in media alone (lane 1), stimulated with PMA
(2), or PMA with; aprotinin (3), pepstatin (4), PMSF (5), leupeptin (6),
lOOng/ml 3.4 DC (7), 100 ng/ml 1,10 PA (8), lOng/ml 3,4 DC (9), or lOng/ml
1,10 PA (10). Lane 11 shows IL-1 beta cDNA as a positive control. Dilutions
of 1:2, 1:5 and 1:25 of the mRNA preparations are shown.
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Protease Extracellular IL-1 beta levels
inhibitor Pro IL-1 beta 17 kDa IL-1 beta IL-1 beta mRNA
Aprotinin Y
Pepstatin — — —
Phenyl methyl Y Y Y
sulphonyl fluoride
Leupeptin — Y Y
3,4 dichloro- — - —
isocoumarin
1,10 phenanthroline — — -
Table 6.2.1. The effect of protease inhibitors on the cellular processing
of IL-1 beta
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the synthetic 37 amino acid peptide (Peptide a), shown in Figure 6.1.1., was
tested.
The lysate preparation (Figure 6.3.1.A) showed IL-1 beta processing
ability at late time points (12 and 24 hours; lanes la-5a), but these bands
were not seen when aprotinin (lanes lb-5b) or synthetic peptide (lanes lc-5c)
were present in the reaction. Addition of membrane preparations resulted in a
faint band co-migrating with recombinant IL-1 beta at the 6 hour time point
(Figure 6.3.l.B), no comparable bands were seen in the reaction with
aprotinin or peptide added. When fresh whole cells were used as processing
activity more distinct 17 kDa bands were seen particularly at 6 and 12 hours
(Figure 6.3.1.C). Again no bands were seen if aprotinin or peptide was added.
6.4. PROCESSING OF RECOMBINANT PRO IL-1 BETA
6.4.a. Cellular localisation of processing activity
To make a preliminary assessment of processing activity, cell lysate and
membrane preparations were tested for their ability to cleave recombinant pro
IL-1 beta (Section 2.2.b.). Two different monocytic lines were tested and the
effect on processing of heating to 50° C, to destroy enzyme activity, was also
determined (Figure 6.4.1.). The figure shows that recombinant IL-1 beta
propeptide migrates above the 30 kDa marker. It undergoes little degradation
during the course of the incubation (lane 10), the only smaller bands in the
preparation migrate slightly faster than the recombinant propeptide. The
addition of membranes from either THP-1 or HL-60 (lanes 5 and 3 respectively)
cells resulted in the appearance of a number of bands at >17 kDa, and a band
that co-migrated with recombinant mature IL-1 beta. Cell lysates showed some
processing activity (lanes 2 and 4). Stimulation of the cells with PMA did
not increase the intensity of the processed ~17 kDa band (lanes 6 and 7),
heating of the membrane and lysate preparations reduced the level of the 17
kDa form (lanes 8 and 9).
The processing ability of THP-1 cell lysates, membrane preparations and
culture supernatant was assessed with and without prior stimulation by LPS or
PMA (Section 2.2.a.). Figure 6.4.2. demonstrates that none of the
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Figure 6.3.1. Processing of IL-1 beta in cell lysates
THP-1 cell lysates were used as pro IL-1 beta source. Lysates were
incubated alone (A), with membrane preparation (B) or fresh cells (C). The
reaction was incubated for 1, 2, 6, 12, and 24 hours (lanes 1-5). Aprotinin
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Figure 6.4.1. Processing of recombinant pro IL-1 beta
Recombinant pro IL 1 beta was incubated for 2 hours at 37° C with various
cell lysate and membrane preparations. Lane 1 shows propeptide alone without
incubation, lanes 2 and 3 propeptide incubated with HL-60 lysate and
membranes respectively, lanes 4 and 5 THP-1 cell lysates and membranes, lanes
6 and 7 PMA stimulated THP-1 cell lysates and membranes, lanes 8 and 9 heat
treated THP-1 lysates and membranes and lane 10 propeptide alone incubated
for 2 hours at 37° C. Lane 11 shows recombinant 17 kDa IL-1 beta. Molecular
weight markers in kDa are shown.
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Figure 6.4.2. The processing ability of cell lysates, membranes and culture
supernatants
The ability of THP-1 cell lysates (lanes 2-7), membrane preparations
(lanes 8-13) and culture supernatants (lanes 14-19) to process the IL-1
precursor. Lane 1 shows recombinant pro IL-1 beta alone and lanes 2-4, 8-10
and 14-16 show lysates, membranes and supernatant alone. Lanes 2, 5, 8, 11,
14 and 17 represent unstimulated cells; 3, 6, 9, 12, 15 and 18 cells
stimulated with lOOng/ml LPS; 4, 7, 10, 13, 16, 19, cells stimulated with
lOOng/ml PMA. Lane 20 shows recombinant 17 kDa IL-1 beta.
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preparations alone showed intrinsic IL-1 beta activity at 17 kDa, but that
addition of cell lysates resulted in multiple bands of IL-1 immunoreactivity
one of which co-migrated with the mature molecule. When membrane preparations
were used as the source of processing activity many intermediate IL-1 forms
were seen, the intensity of the precursor band was much lower than in other
reactions and an increase in intensity of the "17 kDa molecule is observed
when compared to the reaction using cell lysates. Culture supernatants showed
a different pattern of bands when compared to the other enzyme sources, a
very faint band was seen co-migrating with the mature IL-1 beta molecule.
Stimulation of the cells before fractionation did not appear to alter their
processing ability.
6.4.b. Time course of production of processed IL-1 beta
The rate of production of the 17 kDa IL-1 form was determined by
stopping the reaction at various time points up to five hours (Section
2.2.c). The results are shown in Figure 6.4.3.. The first panel (A) shows the
degradative products of the incubation of the propeptide alone at 37° C, very
little low molecular weight material was seen though an obvious decrease in
the level of intensity of the 33 kDa band was observed. Incubation with THP-1
cell lysates (panel B) showed little processing in this experiment, though a
faint band was seen at "17 kDa at later time points. Panel C shows the effect
of membranes in the processing reaction, the 17 kDa band was evident within
30 minutes and was most intense at 1.5-2 hours. After this time point there
appeared to be some degradation of the products. From the time course it was
not apparent whether the higher molecular weight bands were processing
intermediates or products of other enzyme activities present in the membrane
preparation.
6.4.c. Inhibition of the processing reaction
Peptides a, b and c (Section 2.2.e.) were tested for their ability to
inhibit the processing reaction, using membrane preparations as a source of










Figure 6.4.3. Time course of pro IL-1 beta processing
Recombinant IL-1 beta propeptide was incubated with tissue culture media
(A), THP-1 cell lysate (B) or membrane preparation (C) Aliquots of incubation
were taken at the start of reaction (lane 1), 15 mins (2), 30 mins (3), 45
mins (4), 1 hr (5), 1.5 hr (6), 2 hr (7), 2.5 hr (8), 3.0 hr (9), 4 hr (10),
and 5 hr (11). Lane 12 on panel C shows the inhibition of antibody binding by
including 100 fold excess of mature IL-1 beta in the primary antibody
incubation. Molecular weight markers in kDa are shown.
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beta immunoreactivity (lanes 13-22; Figure 6.4.4.). The peptides were not
able to inhibit the appearance of the IL-1 band co-migrating with the mature
form, b and c however did alter the intensity of higher molecular weight
bands. Using this system aprotinin did not inhibit the production of the ~17
kDa molecule but did alter the banding pattern at higher molecular weights.
Protease inhibitors were tested for their ability to inhibit the
processing of pro IL-1 beta (Section 2.2.d.). None of the protease inhibitors
alone showed any cross-reacting bands by Western analysis (Figure 6.4.5.). In
some cases protease inhibitors altered the intensity of certain IL-1 beta
immunoreactive bands, but only 3,4 DC at lOug/ml was able to prevent the
appearance of the ~17 kDa molecule (lane 12).
The effect of elastatinal on processing is shown in Figure 6.4.6.. The
inhibitor did not affect the appearance of any band at 1 or lOmM, whereas 3,4
DC again prevented processing to the ~17 kDa form.
6.5. BIOACTIVITY OF PROCESSED IL-1 BETA
The bioactivity produced by the processing reaction was determined by
EL4/CTLL assay (Section 2.1.b.). The results are shown in Table 6.5.1..
Sample concentrations above 1% showed some cytotoxicity in the assay, the
values presented are from preparations tested at 0.1%. Propeptide alone
resulted in no detectable activity, but when spiked with the recombinant
mature form showed >100% recovery of bioactivity. Processed IL-1 was readily
detectable in the EL4 assay. From the amount of propeptide used in the
initial reaction (275ng) it was estimated that about 34.5% had been converted
to a bioactive form.
6.6. DISCUSSION
Stimulated THP-1 cells were shown to produce the IL-1 beta propeptide
molecule intracellularly, the precursor could be detected extracellularly as
could the mature 17 kDa molecule. The cellular processing event was prevented
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Figure 6.4.4. The effect of synthetic peptides on the processing reaction
The jprocessing of pro IL-1 beta by THP-1 membranes alone (lane 2) or
with 10" , 10 or 10 M peptide a (lanes 3-5), peptide b (lanes 6-8),
peptide c (lanes 9-11) or 0.67 U/ml aprotinin (lane 12) is shown. Lanes 13-22
show the peptides alone. Lane 1 shows recombinant precursor IL-1 beta and
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Figure 6.4.5. The effect of protease inhibitors on recombinant pro IL-1 beta
processing
Recombinant pro IL-1 beta was incubated alone (lane 1), with THP-1
membranes (2), and with membranes plus lx and lOx concentrations of protease
inhibitors; aprotinin (3 and 9), pepstatin (4 and 10), leupeptin (5 and 11),
3,4 DC (6 and 12), 1,10 PA (7 and 13) and PMSF (8 and 14). Lanes 15-20 show
lOx concentrations of protease inhibitors alone. Lane 21 shows recombinant
mature IL-1 beta. Molecular weight markers in kDa are shown.
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Figure 6.4.6. The effect of elastatinal on IL-1 beta processing
Recombinant pro IL-1 beta was incubated alone (lane 1), with THP-1
membranes (2), and membranes with lx and lOx elastatinal (3 and 4) or 3,4 DC
(5). Lane 6 shows recombinant 17 kDa IL-1 beta.
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Sample IL-1 bioactivity pg/ml
1:1000 dilution Recovery
Propeptide alone <0.1pg/ml
Propeptide + 3pg/ml -
lng/ml mature IL 1
Propeptide + 95pg/ml 95ng/ml
membrane preparation 34.5%
Table 6.5.1. Bioactivity of processed pro IL-lbeta molecule
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intracellular precursor or IL-lbeta mRNA levels was seen.
Stimulated THP-1 cells were used as the source of IL-1 beta propeptide.
Processing activity by the lysates themselves, added whole fresh cells or
membrane preparations was detected. Inhibition of the appearance of the "17
kDa form was demonstrated using aprotinin and the synthetic, 37 amino acid
peptide that spans the cleavage site.
When recombinant pro IL-1 beta was used as reaction substrate,
processing activity was found predominantly in membrane preparations. Prior
stimulation of the cells did not alter their processing ability. The optimum
time for the reaction was shown to be 1.5-2 hours. Synthetic peptides were
unable to inhibit the production of "17 kDa IL-1 beta in this system. Of a
range of protease inhibitors only 3,4 dichloroisocoumarin was effective. The
bioactivity produced during the processing reaction was determined in the
EL4/CTLL assay, approximately 35% of the recombinant molecule was recovered
as bioactive IL-1.
Cell lines were initially stimulated to establish a source of natural
propeptide and of IL-1 beta processing activity. It was found that though
each line was able to produce propeptide the mature molecule was only
detectable in THP-1 cell supernatants following stimulation with PMA. From
previous studies of IL-1 production by this line it has been shown that the
secreted IL-1 beta form has a comparable N-terminal amino acid sequence to
the native protein of untransformed cells (Matsushima et al, 1986b). Western
analysis was performed on cells cultured for 24 hours. The U937 line has
been described as only producing secreted IL-1 bioactivity at time points
after 48 hours (Palacios et al, 1982).
The THP-1 line was therefore used for cellular IL-1 processing studies,
and was stimulated with lOOng/ml PMA. The effects of characterised protease
inhibitors on processing were determined. 1,10 phenanthroline at high
concentrations reduced the level of IL-1 beta propeptide, this corresponded
to a reduction in IL-1 beta message but not the mRNA of a cell cycle-
independent gene. In culture supernatants aprotinin and leupeptin inhibited
the appearance of the 17 kDa but not the 31 kDa IL-1 beta form. Inhibitory
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activity was also seen with PMSF that reduced the extracellular levels of
both IL-1 beta molecules. When protease inhibitors were tested for their
effect on IL-1 beta message both PMSF and leupeptin treated cultures showed a
reduction in the intensity of the IL-1 beta mRNA bands but not a cell cycle
independent mRNA species, aprotinin did not affect IL-1 beta mRNA levels.
It is possible that the inhibitory effect on the production of 17 kDa
IL-1 seen with PMSF and leupeptin is due to slower accumulation of the
precursor resulting in reduced secretion, though lower cell-associated levels
are not apparent by Western blotting. Aprotinin however appears specifically
to reduce the extracellular levels of mature IL-1 beta, without affecting
propeptide or mRNA levels. When the synthetic 37 amino acid peptide was
tested in this system no inhibition of processing was seen (data not shown).
Aprotinin is a broad spectrum serine protease that acts to inhibit
proteolytic activity at the cell surface or in the culture supernatant
(Hewlett, 1990). As serum was not used in cultures it is likely that
aprotinin inhibited a membrane or secreted protease derived from the cells
themselves. Extracellular serine protease activity has previously been
suggested to be involved in the processing of IL-1 beta propeptide (Auron et
al, 1987). The presence of IL-1 beta precursor in the culture supernatant
suggests that secretion precedes the processing event, but it cannot be
absolutely established, with current techniques, that propeptide release is
not a result of cell damage or death.
When the stimulated THP-1 cell lysate preparation was used as the source
of IL-1 beta propeptide, freshly added cells gave the best processing. Low
levels of processing were seen both by membrane preparations and the cell
lysates. In all cases aprotinin inhibited the processing reaction as did the
synthetic 37 amino acid peptide. This suggests that the processing enzyme may
be secreted from live cells. Alternatively a membrane protease may be present
that loses activity on disruption of the cells.
Using cell lysates as the source of propeptide IL-1 resulted in very low
levels of "17 kDa product that were difficult to detect even using a
sensitive avidin-biotin system. We therefore continued the study using
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recombinant pro IL-1 beta as the reaction substrate.
Using recombinant pro IL-1 beta little processing activity could be
demonstrated in culture supernatants. Cell lysates showed some activity but
the highest level of processing was found with membrane preparations. Using
sonication to disrupt the cells it is possible that small liposome-like
structures may form that would not sediment under the centrifugation
conditions we used. Contamination of the lysate preparation with these
liposomes may account for the low level of processing seen in this fraction.
Processing activity was seen in membrane preparations from two myeloid
cell lines, THP-1 and HL-60. As it had been described that processing
activity is co-inducible with the IL-1 beta propeptide (Black et al, 1989b),
we compared the levels of "17 kDa product in PMA stimulated and unstimulated
THP-1 cells. Our enzyme preparation was not affected by cell stimulation, and
therefore appears to be constitutively expressed at least in this cell line.
The membrane processing activity was shown to be sensitive to heating
consistant with the notion that processing is enzyme-mediated.
A number of immunoreactive IL-1 beta bands were seen following the
processing reaction, one of which co-migrated with mature recombinant IL-1
beta. That the co-migrating band represents the mature IL-1 beta molecule
cannot be established by Western blotting. Differences of a few amino acids
at the N-terminus would not necessarily result in observed differences in the
migration of the bands. To confirm the identity of the "17 kDa form N-
terminal sequencing would be required.
A time course reaction was performed to establish the optimum time for
appearance of the "17 kDa band. Recombinant material in tissue culture medium
slowly degraded during the course of the incubation. The cell lysate
preparation showed some processing activity, evident at around 3 hours. The
processing reaction by membrane preparations showed the optimum time of
incubation to be 1.5-2 hours, after this the product gradually degraded.
Inhibition of recombinant pro IL-1 beta processing by membranes was not
seen using any of the synthetic peptides. A number of the protease inhibitors
were seen to alter the intensity of some of the high molecular weight IL-1
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beta intermediates, but only 3,4 dichloroisocoumarin prevented the production
of the "17 kDa band. 3,4 DC is a potent inhibitor of serine protease enzymes
(Harper et al, 1985).
It has been suggested that elastase may account for much of the IL-1
beta processing in membrane preparations, we therefore used a specific
inhibitor (elastatinal) to remove its activity. Elastatinal did not, however,
alter the intensity of the "17 kDa IL-1 beta band when included in the
reaction.
The relationship of the different sized IL-1 beta bands seen is not
clear. It is possible that some of the high molecular weight material may
represent intermediates in the production of the "17 kDa form, or that these
are the end products of other enzyme activities present. Inclusion of
protease inhibitors or synthetic peptides in the reaction resulted in altered
banding patterns at high molecular weights, this may be due to the inhibition
of non-specific proteolytic activity. Further studies in which groups of
protease inhibitors are included may identify any intermediates in the
specific processing reaction, and reduce the production of non-specific
cleavage products. This may also prevent the spontaneous degradation of the
"17 kDa product.
Analysis of the bioactivity produced as a result of processing was
determined by EL4/CTLL assay. The IL-1 beta propeptide showed no activity,
but a considerable biological response was seen with its processed products.
How much of the bioactivity was due to mature 17 kDa IL-1 beta could not be
established, as processing at sites slightly upstream of the authentic N-
terminus has been shown to result in recovery of some bioactivity (Black et
al, 1988). The level of bioactivity in processed IL-1 is dependent on how
near to the optimal N-terminus (between residues 116 and 117) the precursor
is cleaved. It has been reported that cleavage between Val^^-His*^ can also
result in full biological activity in the EL-4 thymoma assay (Hazuda et al,
1989).
There are various reports concerning the identity of the processing
enzymes that act on pro IL-1 beta. An early report isolated the precursor
157
molecule and showed that its degradation to lower molecular weight forms was
effected by a serine protease that was sensitive to the action of PMSF (Auron
et al, 1987). More recent studies have used recombinant pro IL-1 beta as the
substrate for reactions. An initial report suggested that techniques used for
isolation of the recombinant precursor may result in loss of the native
conformation of the molecule (Black et al, 1988). This was shown by the
sensitivity of precursor to complete degradation by membrane preparations
within the incubation period. According to these criteria our pro IL-1
preparation would appear to be in its usual conformation as two hour
incubation with processing preparations led to the production of distinct
bands recognisable by Western blotting.
In contrast to our results Hazuda et al (1988) were not able to detect
processing activity by whole monocytic cells, but from cell fractionation
experiments localised activity to the cell lysate or peripheral membranes.
Black et al (1988) have demonstrated IL-1 beta processing activity in
isolated KG-1 membrane, that results in two distinct products one of which
co-migrates with mature IL-1 beta. The activity was only found in cells of
myeloid lineage. This group (Black et al, 1989b) have also reported a
cytosolic protease in THP-1 cells that is co-induced with IL-1 beta. This
activity could be inhibited by iodoacetate but not by other factors including
PMSF and pepstatin, suggesting the presence of a cysteine protease activity.
Kostura et al (1989) have also identified a cytosolic enzyme able to cleave
pro IL-1 beta at the correct site, as determined by amino acid sequencing.
The enzyme was not able to cleave a modified IL-1 beta precursor in which
Asp^^ was converted to an Ala residue.
Other processing activities have been shown to cleave the propeptide
slightly upstream of the authentic site, it has however been suggested that
these may have biological relevance particularly in an inflammatory
environment (Hazuda et al, 1990). Collagenase, cathepsin G and elastase all
generate a considerable amount of biological activity from pro IL-1 beta, and
are known to be produced at sites of inflammation. Release of IL-1 beta
precursor in vivo may lead to the rapid generation of a bioactive form as a
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result of extracellular proteolytic activity. Black et al (1989a) have
described a secreted processing activity in monocyte culture supernatants.
The enzyme is a pre-aspartate specific protease, that leaves one additional
amino acid at the N-terminus. Such a cleavage event would be expected to
result in significant levels of bioactive IL-1 beta.
We have identified two processing activities, one is seen to cleave IL-1
beta in whole cell cultures and cell lysate preparations. This activity is
only demonstrable when using a highly sensitive avidin - biotin detection
system for IL-1 beta. The activity appears to be either secreted or
associated with the cell surface, and is likely to be a serine protease that
exhibits sensitivity to aprotinin. The second factor is a THP-1 membrane
activity that is able to process the recombinant pro IL-1 beta molecule. The
enzyme is also likely to be a serine protease but with different protease
inhibitor sensitivity.
Only the secreted processing activity was sensitive to the inhibitory
effect of a synthetic peptide that spans the processing site. It is possible
that the peptides do not share the epitopes required for binding of the
membrane associated enzyme activity. Small peptide molecules, however, are
known to adopt a number of different conformations in vitro. It may be that
sufficient levels of peptide in the correct conformation are not available to
inhibit the processing enzyme by substrate competition. When using cell
lysate as the source of pro IL-1 beta factors such as chaperon proteins may
be able to retain the conformation of synthetic peptides in a suitable state
to interact with the processing molecule. Small peptide molecules of 8-12
residues have been shown to bind to hsc70 and BiP, two members of the heat
shock protein family (Flynn et al, 1989).
Other studies using synthetic peptides as substrates and inhibitors of
proteolytic processing reactions have shown that alteration of an amino acid
residue at the cleavage site results in a considerably better affinity for
the enzyme involved. One group designed peptides in an attempt to inhibit the
processing activity of the HIV-1 protease (Moore et al, 1989). Use of the
modified peptide in vitro has been effectively shown to prevent processing of
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structural proteins of the virion core and of a number of essential
replicative enzymes (Meek et al, 1990). It is possible that modification of
the synthetic IL-1 beta peptides may also increase their inhibitory
effectiveness.
It has been suggested that IL-1 alpha and beta precursors are post-
translationally modified in vitro by either phosphorylation or myristylation
(Kobayashi et al, 1988; Bursten et al, 1988). Interleukin 1 alpha has been
reported to show greater phosphorylation and this has been linked to either
enhanced stability or protease susceptibility by two different groups
(Kobayashi et al, 1988; Beuscher et al, 1988). Myristylation has been
suggested to direct proteins to particular intracellular locations, this may
bring IL-1 molecules into the proximity of particular processing enzymes or
secretory pathways. The potential effects of post-translational modifications
on IL-1 beta processing have as yet not been addressed.
We have described two pro IL-1 beta processing activities that are
distinguishable by their sensitivities to common protease inhibitors. Both
however appear to be serine proteases. The secreted enzyme form could also be
inhibited by a synthetic 37 amino acid peptide designed around the pro IL-1
beta processing site. The other processing activity could be localised to
isolated membrane preparations.
The membrane processing activity described may be involved in the normal
IL-1 beta secretory process. It has be shown by many workers that mature IL-1
beta is not found intracellularly and it has, therefore, been suggested that
IL-1 beta processing and secretion are closely linked (Black et al, 1988). A
processing activity situated at the plasma membrane may be able to promote
both cleavage and secretion, accounting for the lack of intracellular mature
IL-1.
The activity that is found predominantly in culture supernatants may be
involved in cleaving pro IL-1 beta that is released from the cell. It is not
apparent whether IL-1 precursor molecules are normally released as part of
the secretory process, or as a result of damage to the plasma membrane. The
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extracellular enzyme activity may be involved in the processing of IL-1 beta
propeptide at a localised inflammatory site, such as in RA synovial fluid, in
a way similar to that described by Hazuda et al (1990). The enzymes secreted
at an inflammatory locus may also have a broader role in the destructive
processes seen in inflammatory diseases. By converting released, inactive
IL-1 to a bioactive form further amplification of the inflammatory state may
occur, causing further damage that may exceed the reparative capacity of the
tissues involved. Specific inhibitory factors such as the synthetic peptide
described here are, therefore, potentially important molecular models for the
design of novel anti-inflammatory medicines.
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CONCLUDING DISCUSSION
The development of reliable techniques for measurement of IL-1 in
biological fluids has only recently become possible with the availability of
immunoassays. The presence of IL-1 in the plasma of some normal individuals
provides support for the suggestion that this cytokine is involved in normal
physiological processes.
The source of circulating IL-1 in healthy individuals is unknown. The
reported changes in IL-1 levels following exercise (Cannon and Kluger, 1983),
and during the menstrual cycle suggest some regulated activation of a
population of IL-1 producing cells. However it is possible that "normal"
plasma IL-1 may be produced as a result of a sub-clinical inflammation or
immune activation in a healthy individual.
Many reports have been published showing raised plasma or serum IL-1
levels, particularly of the beta form, in various disease states. The
increase in circulating levels may result from systemic activation of the
immune response or production at a localised site. In the case of RA a
localised inflammatory reaction in the synovium may result in high
concentrations of IL-1 in the joint. Some of this may then enter the
circulation and trigger the systemic changes seen in rheumatoid disease.
The role of individual cytokines in the local inflammatory reaction is
difficult to establish. It is becoming increasingly apparent that the effects
of one particular cytokine in vitro are highly susceptible to the modulating
effects of others. The in vivo environment is likely to be considerably more
complicated, the network of interacting cytokines and other inflammatory
mediators being difficult to analyse with current techniques.
In most cases the triggering event that leads to the production of
sufficient IL-1 to result in localised destructive effects is unknown. It is
possible that the damage seen in inflammatory disease is a result of a
susceptibility in certain individuals to high IL-1 production based on
cellular control mechanisms or inadequate negative feedback mechanisms.
Production of IL-1 in the course of normal physiological processes must
be subject to control mechanisms that are able to regulate its potentially
destructive effects. Feedback inhibition of IL-1 production has been
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described in the case of the glucocorticoid system (Knudsen et al, 1987).
Interleukin 1 has also been shown to prevent its own synthesis (Manson et al,
1988) and to be regulated by factors such as prostaglandins (Knudsen et al,
1986).
Factors able to modify IL-1 action following its production and
secretion are also likely to play an important role in protecting biological
systems from the unwanted actions of the cytokine. Our results show that
plasma IL-1 is associated with factors that prevent detection of bioactivity
and the recognition of certain immunoreactive epitopes. Assessment of the
molecular weight of circulating IL-1 also indicates an interaction with other
protein moieties.
We have described a circulating binding protein that is now known to
prevent IL-1 beta binding to both the 80 kDa and 60 kDa IL-1 receptors, and
is therefore a candidate molecule for modulating the cytokine's action in
vivo. Little is known about the production the IL-1 binding protein, that the
factor is released following stimulation of peripheral blood mononuclear
cells (Symons et al, 1990) and its presence in plasma is indicative that it
may have a role in the regulation of the systemic effects of IL-1 beta. The
molecule is also found in inflammatory joint fluid suggesting a role in the
control of the local inflammatory response.
Many soluble receptor molecules, both in vitro and in vivo, have been
studied. Soluble receptors represent a readily available source of inhibitory
activity. They may either be synthesised specifically as an alternative
receptor form or cleaved from the surface in response to suitable stimuli. As
yet little is known concerning the enzymes responsible for releasing membrane
bound receptors in this manner, or the particular stimuli that activate the
cleavage event. Surface receptors, however, may represent a rapidly
mobilisable source of inhibitory activity.
A solubilised receptor is likely to represent a highly specific
antagonist molecule to its ligand. That the soluble IL-1 beta binding
protein retains comparable ligand affinity to the membrane receptor and
inhibits the IL-1 beta/receptor interaction in vitro, suggests that it will
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compete effectively for the cytokine in an in vivo situation. The presence of
the binding protein in the plasma of healthy individuals indicates that it
may take part in the normal regulatory processes controlling the actions of
IL-1 beta.
The activities of IL-1 are likely to be regulated at multiple levels and
another potential means of control is through the cloned inhibitor molecule.
The role of the cloned IL-1 inhibitor (receptor antagonist) in vivo has been
better characterised. The receptor antagonist has been shown to have
inhibitory effects in various systems. However little is known concerning the
regulation of its production. In vitro, the IL-1 inhibitor is secreted by
aged monocytes (Roux - Lombard et al, 1989) indicating that the tissue
macrophage may be a likely source in vivo. Monocytes activated by immune
complexes also produce the factor (Arend et al, 1989b), indicating the
possibility of a systemic cellular source following immune activation.
The involvement of non-specific factors such as alpha 2M need also to be
considered. Though the interaction with IL-1 does not appear directly to
inhibit biological activity, complexes may be more rapidly removed from the
circulation. One report suggests that IL-1 preferentially binds to the "slow"
form of alpha 2M (James et al, 1990). Activation to the "fast" form reveals a
specific binding site recognised by macrophages and facilitates removal from
the circulation. This suggests that the IL-1 interaction with alpha 2M does
not promote clearance of this cytokine. There are reports of alpha -,M
protecting cytokines from the destructive effects of proteolytic enzymes
(Matsuda et al, 1989). Alpha 2M is a major serum protein and is produced
predominantly by the liver. It is found in extravascular fluids such as lymph
(James, 1990) and may therefore have a major role in modulating the systemic
effects of IL-1. At a local level alpha -,M is produced by macrophages and so
also has the potential to act as a regulatory molecule and control localised
inflammatory processes at a site of tissue injury.
It has been demonstrated that radiolabeled IL-1 administered
systemically is rapidly cleared from the circulation and localises in various
tissues. The main organ of clearance is thought to be the kidney (Klapproth
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et al, 1989). The role of factors such as alpha 2M and the IL-1 beta binding
protein in tissue localisation and systemic clearance has not yet been
determined.
Inhibition of the damaging effects of IL-1 by pharmacological agents
could be effected by a number of mechanisms. An inhibitor could act by
interacting with IL-1 itself to prevent association with the receptor, as
appears to be the case with the IL-1 beta binding protein. The potential
pharmacological properties of the engineered soluble 80 kDa receptor have
been investigated (Fanslow et al, 1990), systemic administration of the
sIL-lR was shown to prolong the survival of heart allografts in mice by
neutralisation of the effects of endogenously produced IL-1. In a similar
manner to the described physiological IL-1 inhibitor a factor could bind to
the receptor molecule itself. The sequence of the IL-1 inhibitor shows 26%
homology to IL-1 beta (comparable to the homolgy between the two IL-1 forms,
Eisenberg et al, 1990). It is likely that the inhibitor bears a structural
motif common also to the ligand molecules, that mediates interaction with the
receptor. Another potential site for inhibition would be at the signal
transduction level as has been reported for the synthetic peptide designed
around the retroviral envelope protein pl5E (Gottleib et al, 1989).
Efficient inhibition of IL-1 action could be effected by blocking its
production, secretion or post-translational processing. As IL-1 beta is
thought to be the predominant released form and is not active as the
precursor molecule it is the more obvious target for pharmacological
modulation. The cellular release of IL-1 is a poorly characterised event. As
it appears possible that IL-1 precursors are released following cellular
damage, blocking the action of a specific cellular processing event may not
be sufficient to achieve a pharmacological effect. There is evidence that
other proteolytic enzymes are able to cleave the IL-1 beta propeptide in a
non-specific manner resulting in the recovery of different IL-1 molecules
with some bioactivity. To be effective a potential inhibitor may need to
block the processing of IL-1 beta by both a cellular enzyme and a variety of
different extracellular proteolytic activities, often found a sites of
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inflammation.
Though much is now known about the in vitro effects of IL-1 little is
understood concerning the factors affecting its in vivo actions or the
control of potentially damaging effects. The recent production of the
recombinant receptor antagonist molecule will be a helpful tool in future
studies as will the further characterisation of factors such as the soluble
receptor molecules for IL-1 beta described here. What seems clear is that we
are now only at the threshold of understanding the complex system of
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Cell lines were regularly tested for mycoplasma contamination using a
'l
Gen-probe detection system (Laboratory Impex). The test used a H-labelled
DNA probe specific for Mycoplasma and Acholeplasma ribosomal RNA. Briefly, 3
day culture supernatants were centrifuged at 200xg to remove cells, 2ml was
then respun at 12000xg for 10 minutes and the media discarded. Two hundred
microlitres of probe was added to the pellet and vortexed. At the same time
positive and negative controls were prepared by adding 50ul of the solutions
provided to 200ul of tritiated probe. During the hybridisation reaction tubes
were floated in a water bath at 72° C overnight. The contents of each tube
were then transferred to 7ml screw-cap scintillation vials (ICN
Radiochemicals, High Wycombe) with 5ml of separation suspension, these were
vortexed and incubated for a further 5 minutes at 72° C. Vials were
centrifuged at 500xg, the supernatant discarded and the pellet washed twice:
this involved adding 5ml of wash solution, resuspending the pellet and
incubating at 72° C, the reaction was spun and decanted as previously
described. The pellet was resuspended in 5ml of scintillant and each vial
counted for 1 minute.
To determine total counts 5ml of separation solution was centrifuged and
the pellet retained, as described for samples. Fifty microlitres of probe was
added followed by scintillant and the vial was counted. Background counts
were determined using 5ml of scintillation solution alone.
Any cell lines found to be contaminated with mycoplasma were treated
using an antibiotic, BM-Cycline (Boehringer Mannheim). The antibiotics were
supplied as two preparations; BM-Cycline 1 and BM-Cycline 2 which were
dissolved in 10ml sterile PBS, this stock solution was stored at -20°C. A
three cycle treatment protocol was used, as recommended, in which 40ul of BM-
Cycline 1 was added to each 10ml culture for three days and replaced by
medium containing 40ul BM-Cycline 2 for a further four days. This was
repeated three times with cultures being passaged as necessary at the start
of each treatment. It was found that some lines were sensitive to the toxic
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effects of the antibiotics, in these it was helpful to maintain cells at a
slightly higher density than usual.
9.1.b. T Cell Growth factor production
The spleens were removed from young adult Wistar rats and the cells were
dissociated into RPMI 1640 using two sterile frosted glass slides, The
suspension was decanted, avoiding any large tissue clumps, and was
7
centrifuged at 200xg for 10 minutes. Splenocytes were cultured at 1x10 with
5ug/ml concanavalin A (Sigma) in serum free RPMI for 24 hours. The
supernatant was harvested and the cells spun down. Conditioned media was
recentrifuged at 1800xg. Aliquots of TCGF were stored at -20p C, and before
use were filtered through a 0.22um filter.
9.2. CHEMICAL CROSS-LINKING SOLUTIONS
Binding buffer - lx RPMI-1640, 1% bovine serum albumin, 0.1% sodium azide
(Sigma), 20mM N-(2-hydroxyethyl)piperazine-N'-(2-ethanesulphonic
acid) (Hepes, Sigma) at pH 7.4.
Quenching solution - lOmM Tris-HCl at pH 7.5, ImM Na2EDTA.
Lysis buffer - 1% SDS, with protease inhibitors; lOmM PMSF, 2mM EDTA, 2mM
pepstatin, 2mM 1,10 PA.
9.3. PROTEIN PURIFICATION COLUMNS
9.3.a. Purification column buffers
Phosphate buffered saline - made up as lOx concentrated stock; 1.3M NaCl,
0.07M disodium phosphate (Na-,HPO^, BDH) and 0.03M monosodium
phosphate (NaH BDH).
lOOmM sodium phosphate buffer - lOOmM solutions of both Na2HPO^ and NaH-,PO^
were prepared and the di-sodium preparation taken to the required
pH using the mono-sodium solution.
IL-1 beta affinity column wash steps - 10 column volumes was used each of;
0.1M Tris-HCl pH 7.5/ 1.0M NaCl, 1.0M Tris-HCl/ 0.1M NaCl/ 10%
ethylene glycol, and 0.1M Tris-HCl/ 0.1M NaCl.
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9.3.b. Treatment of purification columns
Regeneration of wheat germ agglutinin column- The column was first washed
with 10 volumes of 0.1M Tris-HCl/ 0.5M NaCl at pH 8.5, followed by 0.1M
sodium acetate (BDH)/0.5M NaCl at pH 4.5 and was then re-equilibrated with
PBS.
Hydration of Thiol Sepharose-4B - One gram of freeze dried gel was
prepared by washing in lOOmM sodium phosphate buffer (200ml/g of gel) at pH
8.0. The wash was done on a scintered glass filter at room temperature over
15 minutes.
9.4.a. MOLECULAR BIOLOGY TECHNIQUES
All techniques were done using sterile tissue culture plastics or
glassware that had been either baked for 4 hours at 250° C, or treated by an
overnight soak in diethyl pyrocarbonate (DEPC) water and then autoclaved.
Experiments were done using gloves and care was taken to prevent RNAse
contamination.
Water was prepared by adding 5ml of DEPC (Sigma) to each litre of
distilled water and stirring overnight. To remove remaining DEPC, which may
interfere with subsequent reactions, treated water was autoclaved.
9.4.b. Reagents
Oligolabelling buffer - Prepared by mixing solutions A, B, and C at a ratio
of 100: 250: 150. Solution O, 1.25M Tris-HCl, 0.125M magnesium
chloride (MgCl, BDH) at pH 8.0. Solution A, 1ml solution O, 18ul 2-
mercaptoethanol, 5ul of each triphosphate solution (Boehringer
Mannheim). Solution B, 2M Hepes (free acid) to pH 6.6 with 4M
sodium hydroxide. Solution C, hexadeoxyribonucleotides (Pharmacia)
in TE at 90 OD units/ml.
Tris-EDTA (TE) - lOOmM Tris-HCl pH 7.4, lOmM EDTA.
Saline sodium citrate (SSC) - 20x solution; 0.3M sodium citrate (BDH), 3M
NaCl.
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Phosphate buffered saline sodium citrate (SSCP) - 20x solution; 0.3M sodium
citrate, 2.4M NaCl, 0.4M sodium dihydrogen phosphate dihydrate to
pH 7.4 with sodium hydroxide.
Denharts - 50x solution; 1% BSA, 1% Ficoll (Sigma), 1% polyvinyl pyrolidine
(Sigma).
9.5. PROTEIN ANALYSIS SOLUTIONS
Loading buffer - 60mM Tris-HCl, 20% glycerol (Sigma), 4% SDS, 20% saturated
bromophenol blue (Sigma).
Blocking buffer - 20mM Tris-HCl pH 7.4, 0.15M NaCl, 5% BSA, 0.2% Tween 20.
Second antibody buffer - PBS, 1% BSA, ImM magnesium chloride (BDH), 0.1%
Tween 20.
Substrate buffer - 0.1M Tris-HCl pH 8.8, ImM magnesium chloride, 0.1M zinc
chloride (Sigma).
Tris/Tween buffered saline (TTBS) - lOOmM Tris-HCl pH 7.5, 0.15M NaCl, 0.1%
Tween 20.
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Summary The mean plasma level of interleukin 1 beta
(IL-1 beta), measured by immunoassay,
was significantly higher in 51 patients with rheumatoid
arthritis (RA) than in 21 healthy controls of similar age.
Further, in the RA group, plasma IL-1 beta correlated
positively with Ritchie joint index, pain score, and
erythrocyte sedimentation rate and correlated negatively
with haemoglobin concentration. In individual patients
with active disease who had serial measurements, plasma
IL-1 beta also correlated with clinical disease activity. These
results support the idea that IL-1 beta has a central role in
the pathogenesis of RA.
Introduction
IL-1 molecules are polypeptides with many biological
activities related to host defence and tissue remodelling,' and
interest has arisen in the pathogenic potential of IL-1 in
inflammatory and immune diseases.2 Two forms of human
IL-1 (alpha and beta) are encoded by seoarate genes with
inducible expression in macrophages, lymphocytes,
endothelial cells, and other cell types. The initial product of
each is a propeptide of 31 kD from which mature peptide of
17 kD is processed.3-5 IL-1 alpha and beta have only 26%
aminoacid homology but compete equally for receptors on
target cells6 and have similar biological activities.5 In resting
blood monocytes IL-1 mRNA is undetectable but after
cellular activation it accumulates rapidly and IL-1 beta is
usually the predominant form.3,5
Many activities of IL-1 are relevant to rheumatoid
arthritis (RA).7 IL-1 increases the release from synovial cells
of vasoactive agents and mediators of tissue damage (eg,
prostaglandins, proteinolytic enzymes, and reactive oxygen
molecules)1,5 and is a powerful stimulus of bone58 and
cartilage15 9 resorption. It also induces the acute-phase
response1" and fever1,511 and may potentiate chronic
inflammation by induction of lymphocyte growth factors
such as interleukin 2 and its receptor.12
Much evidence13 has implicated IL-1 in the pathogenesis
of RA: high levels are found in synovial exudates;14 16 RA
synovial cells spontaneously produce biologically active
IL-1 in vitro;17 in-situ hybridisation of mRNA shows that
IL-1 gene expression is activated in vivo in RAi synovial
cells;16 and in laboratory animals a single intra-articular
2
injection of IL-1 produced synovial fluid leucocytosis and
increased proteoglycan breakdown.18
Despite the weight of circumstantial evidence for IL-1 as
a pathogenic mediator in RA, it has not previously been
possible to correlate IL-1 levels in vivo with clinical disease
activity in patients because IL-1 measurement in blood and
other biological fluids has been complicated by interfering
factors.1415 By means of a sensitive immunoassay combined
with a single plasma extraction procedure we have now been
able to measure circulating levels of immunoreactive IL-1
beta in patients with RA.
Methods
Patients with definite or classical rheumatoid arthritis1" attending
a rheumatology outpatient department or admitted to a
rheumatology ward were graded for disease activity by Ritchie joint
index,20 duration of early morning stiffness, and visual analogue:
pain score. At the same time, blood was taken for haemoglobin
concentration, white cell count, platelet count, erythrocyte
sedimentation rate (ESR), and rheumatoid factor titre as part of the
normal management. Blood samples for plasma preparation were
taken into EDTA (5 x 10 3 mol l) tubes (Labco) containing
aprotinin (bovine lung 15-30 U ml; Sigma) at 0-67 U ml. Plasma
was separated from cells and platelets immediately by
centrifugation at 400 g and then at 10 000 g and stored in 500 pi
samples at — 20°C until tested for IL-1 beta content. All patients
received non-steroidal anti-inflammatory drugs (NSAID), and
some received second-line antirheumatic drugs, including intra¬
articular steroids.
IL-1 beta Measurement
Before IL-1 measurement, samples were treated according to the
method of Cannon et al.21 Plasma samples were thawed and
extracted twice with chloroform (BDH, Paisley) by addition of 2
volumes of chloroform to 1 of plasma, mixing for 5 minutes, and
then centrifugation at 10 000 g and removal of the aqueous phase for
IL-1 beta testing in an enzyme-linked immunoabsorbent assay
(IL-1 beta ELISA; Cistron Biotechnology Laboratory Impex). In
our laboratory,16 this assay is sensitive to 20 pg ml IL-1 beta, and
has parallel dilution characteristics, less than 12% interassav
variation, and detection recovery of added IL-1 beta in RA plasma
of 82% after extraction (n = 10; mean 82-2 SEM 2-7%; difference
from recovery in extracted normal plasma not significant). There is
no cross-reactivity with IL-1 alpha. The ELISA test is
commercially available. To 94-well microtitre plates coated with
monoclonal antibody specific for IL-1 beta were added either
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*Controls vs RA: t = 4-28: p = <0 0001.
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extracted plasma or 1L-1 beta standards, with incubation at 37°C for
2 hours. After washing, a polyclonal rabbit anti-human IL-1 beta
antiserum was added, with a further 2 hours of incubation.
Horseradish-peroxidase-labelled goat anti-rabbit IgG was added,
followed by enzyme substrate (o-phenylenediamine) to produce a
chromogenic reaction. For colorimetry we used a scanning
spectrophotometer (micro ELISA reader; Dvnatech) at 490 nm.
Concentrations of IL-1 beta were obtained from a standard curve
derived from homogeneous human recombinant IL-1 beta.
Statistical Methods
Mean values were compared by Student's f-test and correlations
were assessed with the Spearman rank correlation coefficient.
Results
IL-1 beta Levels in Plasma
In 51 patients with RA (age 26-63, mean 40 years) the
mean IL-1 beta level in extracted plasma was significantly
higher than in 21 healthy individuals (age 26-54, mean 38
years) (table). In 35 outpatients with RA and 11 healthy
subjects, plasma IL-1 beta was measured both before and
after the extraction procedure. In the RA patients, the
unextracted mean was 54-5 pg ml, increasing to 85-6 pg/ml
after extraction (p< 0-001), and in the controls it was 20-3
pg, ml (below detection, an arbitrary value of 19 pg/ml was
assigned) increasing to 33-4 pg ml after extraction (p < 0 05).
There was no obvious relation between plasma IL-1 beta
level and therapy with any particular agent but the variety of
antirheumatic drugs used in these patients precluded
confident analysis.
Having seen that the extraction procei lure increased the
detection of plasma IL-1 beta both in FA patients and in
controls and that plasma IL-1 levels were higher in patients,
we then sought correlations between plasma IL-1 beta
PLASMA IL1H (pg ml)
Fig 1—Correlation between plasma IL-1 beta concentration and
Ritchie articular index in patients with RA.
n = 37, r = 0 572; p<0 001.
4
concentration and conventional indices of disease activity in
the RA patients.
Plasma IL-1 beta Correlations with Disease Activity
In samples from different RA patients, IL-1 beta
concentration in extracted plasma correlated significantly
with: Ritchie joint score (fig 1; r= +0-572, p <0-001);
duration of morning stiffness (r = + 0-473, p < 0 005); pain
log PLASMA IL1I3 (pg/ml)
Fig 2—(Correlation between plasma IL-1 beta (natural log scale) and
ESR in patients with RA.
n = 35; r = 0-358; p< 0 05.
PLASMA IL1I3 (pg/ml)
Fig V—Negative correlation between plasma II.-1 beta and
haemoglobin concentration in patients with RA.
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tested at different times over several weeks, IL-1 beta levels
were related to clinical disease activity. For example, fig 4A
shows serial plasma IL-1 beta, Ritchie index, platelet count,
and ESR in a patient admitted with acute exacerbation of
RA. After initial improvement there was an increase in joint
pain, stiffness, and swelling as reflected in the Ritchie index.
In this individual, concurrent plasma IL-1 beta levels
correlated significantly with ESR (p = 0 02) and platelets
(p = 002). The correlations with Ritchie index (p = 008)
and pain score (p = 0-07) were not statistically significant.
Fig 4 B and C shows similar results when the same indices
were measured serially in two further patients. There were
no statistically significant correlations in patient B but, in
patient C, plasma IL-1 level correlated with: platelets
(p< 0-005); white cell count (p< 0-005); pain score
(p<0-01); and ESR (p<0-05).
Discussion
We have shown that, in patients with RA,
immunoreactive levels of IL-1 beta in extracted plasma are
higher than in healthy volunteers. More importantly, the
concentration correlated with clinical (Ritchie index,
morning stiffness, pain score) and laboratory (ESR,
haemoglobin) evidence of disease activity within the group
of patients. In individuals tested at different times,
correlations were found with pain score, white cell count,
platelet concentration, and ESR and similar trends were
seen in the Ritchie index.
Immunoreactive IL-1 beta is not necessarily biologically
active since forms of the molecule (both larger and smaller
than the mature peptide) may fail to bind the IL-1 receptor
but retain sites for antibody recognition. Further, it seems
that inhibitory molecule(s) may mask the immunoreactivity
and bioactivity of IL-1 in unextracted samples.21-22
Recently, an inhibitor of IL-1 bioactivity was reported in
serum and urine ofchildren with juvenile chronic arthritis.23
However, the clinical correlations in our study suggest that
plasma levels of immunoreactive IL-1 reflect production of
biologically active IL-1 at sites of inflammation.
Transcription of the IL-1 gene seems not to be
constitutive but occurs with cellular activation in most
mesenchymal cell-types tested.3-5 We have found mRNA for
IL-1 beta, IL-1 alpha, and tumour necrosis factor by in-situ
hybridisation in synovial sections from RA joints,16 and
others have identified IL-1 mRNA in synovial extracts.24
These observations indicate that IL-1 gene expression is
activated in vivo within the rheumatoid lesion.
The raised concentrations of IL-1 in RA are of particular
interest in view of the biological responses that IL-1
stimulates. These include: chemotaxis and activation of
inflammatory cells;25 release of prostaglandins and
collagenase from synovial cells;26 stimulation of synovial
cell mitogenesis17 and hepatocyte acute-phase protein
7
synthesis;27 resorption of bone and cartilage;89 and potent
effects on the immune system through induction of
lymphokines and their receptors.12-28 While some of these
effects may represent a direct action on target cells, others
are probably mediated by different cytokines (eg,
interleukin 6) stimulated by IL-1,29 These biological actions
of IL-1 seem relevant not only to the chronic proliferative
synovitis and cartilage/bone erosion of RA but also to the
systemic acute-phase response and increased symptoms
associated with exacerbation of disease.
Of interest also is the negative correlation reported here
between plasma IL-1 beta and haemoglobin concentration.
In RA, as in other chronic diseases, a refractory anaemia is
common. For some time IL-1 has been known to have
effects on iron metabolism that could contribute to
anaemia,1 but other effects of IL-1 might lead to inhibition
of erythropoiesis. For example, IL-1 has been reported to
suppress in-vitro colony formation of erythroid progenitor
cells.30
The present study does not address the extent to which
IL-1 beta accumulation is itself a reaction to increased
inflammation, but sustained or high IL-1 release could be
pathogenic irrespective of when it occurs in the chain of
events that results in clinical disease.
Though the kinetics of distribution are not fully known,
we have found (Eastgate J, Symons JA, Wood NC, Duff
GW, unpublished) that the blood level of the related
cytokine IL-1 alpha was not comparable with that of IL-1
beta in terms of correlations with disease indices in RA
The interactions with synergistic and antagonistic factors
are likely to be complex, but taken together with its
arthritogenic, catabolic, and immunoregulatory activities,
the clinical correlations reported here support the idea that
IL-1 is an important pathogenic mediator in RA and give
impetus to the task of developing agents to manipulate its
production or biological activities in vivo.
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Identification of an interleukin-1 beta binding protein in human plasma
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A covalent cross-linking technique was used to bind iodinated interleukin-1 (IL1) alpha and beta to plasma proteins. One specific IL1 beta binding
protein was observed, that when cross-linked to 125I-IL1 beta migrated to approximately 60 kDa on SDS-PAGE. The protein did not bind IL1
alpha. The 43 -kDa protein was partially purified using a wheat germ agglutinin affinity column. The isolated factor again specifically bound IL1
beta, and appeared to consist of single chain glycoprotein. The protein was heat stable and had a rapid association time with IL1 beta. This protein
may be an important carrier molecule for IL1 beta in vivo.
Interleukin 1 alpha; Interleukin 1 beta; Soluble binding protein; Interleukin 1 receptor
1. INTRODUCTION
Interleukin 1 (IL1) is a polypeptide produced by ac¬
tivated leukocytes and other cells. It mediates a wide
range of biological activities relevant to host defence. It
increases production of T and B lymphocyte growth
factors and stimulates other cells involved in inflam¬
matory and immune responses. Additionally, it plays a
role in connective tissue remodelling, haematopoiesis
and is an important factor in the induction of fever and
acute phase protein synthesis [1].
Two distinct forms of IL1 (IL1 alpha and IL1 beta)
have been described [2], Although the two peptides
have only 26% homology, they compete for the same
cellular receptor with equal affinity [3,4]. The murine
IL1 receptor (IL1R) has recently been sequenced and
cloned [5] and is a member of the immunoglobulin gene
superfamily. The 319-amino-acid extracellular domain
consists of two beta-pleated sheets connected by disul-
phide bonds and seven potential N-linked glycosylation
sites, which account for the described size heterogeneity
of the IL1R.
High expression of IL1 peptides appears to be a com¬
mon phenomenon in many inflammatory diseases
leading to extensive tissue damage [6], Therefore,
regulatory pathways must exist to limit IL1-mediated
responses. 1L1 -stimulated prostaglandin E2 production
post-transcriptionally blocks monocyte expression of
IL1 activity [7], In addition, a large number of IL1 in¬
hibitory molecules have been described (reviewed by
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Larrick [8]), although the mechanism of inhibition in
most cases is largely unknown. The most highly char¬
acterised IL1 inhibitor described is produced by
macrophages in response to GM-CSF [9] and immune
complexes [10] and has a molecular mass of approx¬
imately 26 kDa. This inhibitor blocks both IL1 alpha
and IL1 beta but not TNF alpha binding to cell-surface
receptors. Other proteins may control the distribution
and bioavailability of IL1 in vivo by acting as carrier
molecules. For example, treatment of plasma with tryp¬
sin or methylamine allows complex formation between
alpha 2 macroglobulin and IL1 beta through disulphide
bonding [11].
In this paper we describe the presence of a novel IL1
binding protein in normal human plasma. Unlike the
previously known IL1 inhibitors and IL1 receptor pro¬
tein, the ILl-binding protein described here appears to
have affinity specifically for IL1 beta and does not bind
IL1 alpha.
2. MATERIALS AND METHODS
2.1. Reagents
Radioiodinated hr IL1 alpha and hr IL1 beta proteins were obtain¬
ed from Du Pont (NEN Products; Hertfordshire, England). IL1
alpha was radioiodinated using the chloramine-T procedure to a
specific activity of 90.4 /iCi//ig (3.35 mBq//ig). IL1 beta was labelled
with Bolton Hunter reagent to a specific activity of 158^Ci//ig (5.85
mBq//ig). Cold human recombinant IL1 peptides were a gift from
Biogen S.A., human recombinant TNF alpha was a gift from Dr
Guenther Adolf (Ernst Boehringer Institut fur Arzneimittel For-
schung, A-1121 Wien, Austria). Covalent cross-linking reagents
disuccinimidyl suberate (DSS), disuccinimidyl tartarate (DST) and
ethylene glycolbis (succinamidyl succinate) (EGS) were obtained from
Pierce and Warriner, Chester, England.
2.2. Cell culture
Murine 3T3 fibroblasts were cultured in RPMI-1640 containing
Published by Elsevier Science Publishers B. V. (Biomedical Division)
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penicillin (100 U/ml), streptomycin (100 ,«g/ml), glutamine (2 mM)
and 5% foetal calf serum (FCS; heat inactivated; 56°C, 30 min). All
cell culture reagents were obtained from Northumbria Biologicals
(Northumbria, England).
U.,-
2.3. Covalent cross-linking and PAGE analysis
Plasma or semi-purified protein (50 pi) was incubated overnight at
4°C with 10 ng/ml of 125I-IL1 alpha or IL1 beta, with or without
100-fold excess of cold IL1 alpha, IL1 beta or TNF alpha. Subse¬
quently, covalent cross-linker, DSS, DST or EGS (final concentration
1 mg/ml) freshly prepared in DMSO, was added and incubated at 4°C
for 30 min. Cross-linked complexes were identified in 10%
polyacrylamide gels according to Laemmli [12]. Samples to be tested
under reducing conditions were treated with dithiothreitol (100 mM;
DTT) and boiled for 10 min.
Monolayers of 3T3 fibroblasts in 25 cm3 flasks were incubated for
4 h at 8°C with 1 ng/ml labelled IL1 alpha or IL1 beta in RPMI 1640
containing 1% BSA, 0.1% sodium azide and 20 mM Hepes, pH 7.4
(binding buffer) in a final volume of 5 ml. Specificity of binding was
controlled by the addition of excess cold cytokine as above. Unbound
radioactivity was removed by washing three times in protein-free, ice-
cold binding buffer. Five mililitres of this buffer was then added to
each flask, cross-linker (DSS) was added to a final concentration of
1 mg/ml and incubated on ice for 45 min. The cross-linker was then
removed and replaced with 5 ml of quenching solution (10 mM Tris-
HC1, pH 7.5, 1 mM EDTA). The cells were scraped using a rubber
policeman into the buffer and centrifuged at 800 xg for 10 min at
4°C. The cells were subsequently dissolved in 100yl of 1% (w/v) SDS
containing protease inhibitors PMSF (10 mM), EDTA (2 mM),
pepstatin (2 mM) and 1,10 phenanthroline (2 mM). Samples were
analysed by SDS-PAGE as described above, lodinated cytokines were
routinely assessed for self-association in cross-linking experiments.
2.4. Partial purification and characterisation
IL1 binding proteins were partially purified using a wheat-germ ag¬
glutinin sepharose 6MB column (Pharmacia LKB Biotechnology,
England). Briefly, plasma was equilibrated by extensive dialysis
against PBS and then loaded on the column using a flow rate of
4 ml/h. The column was subsequently washed with PBS/0.3 M NaCl,
PBS/10% (v/v) ethylene glycol and finally PBS. Specifically bound
glycoproteins were then eluted from the column with PBS containing
500 mM A'-acetyl-glucosamine and 0.3 M NaCl. Two-millilitre frac¬
tions were collected and screened for 1L1 bindig activity by covalent
cross-linking.
Heat stability of the partially purified binding protein was tested by
incubating aliquots for 30 min at temperatures ranging from 4°C to
70°C. Treated samples were then incubated with iodinated 1L1 beta
and cross-linked as previously described. Kinetics of binding of IL1
beta to the protein was tested by incubating labelled cytokine with
binding protein for various lengths of time at 4°C, room temperature












Fig.l. 125I-1L1 alpha (A) and 125I-IL1 beta (B) cross-linked to plasma






Binding proteins were identified by cross-linking
plasma previously incubated with iodinated IL1. When
IL1 alpha cross-linked to human plasma was analysed
by SDS-PAGE, no specific binding was observable
(fig.lA). A small amount of material that just entered
the gel showed binding, but this appeared to be non¬
specific. To demonstrate that I25I-IL1 alpha retained
receptor binding activity, we cross-linked it to 3T3
fibroblasts. Fig.2 shows that IL1 alpha specifically




Fig.2. Cross-linking of iodinated IL1 alpha to 3T3 cells (lane 1) with
excess cold IL1 alpha (lane 2), IL1 beta (lane 3) and TNF alpha (lane
4).
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Fig.3. Cross-linking of 125I-IL1 beta to fractions eluted from a WGA
column.
In contrast when 125I-IL1 beta was cross-linked to
plasma, an IL1 beta/protein complex was observed to
migrate at approximately 60 kDa (fig.IB). This binding
was displacable by 100-fold excess of cold IL1 beta but
not IL1 alpha or TNF alpha, and was seen with all three
cross-linkers used. Some non-specific binding was also
seen to high-molecular mass material.
3.2. Purification and biochemical characterisation
The 60 kDa IL1 beta/binding protein complex
migrated as a broad band from 50-70 kDa suggesting
the possibility of variable glycosylation. We therefore
used lectin affinity chromatography for partial purifi¬
cation of the binding protein. Experiments revealed
that the binding protein could be specifically eluted
from a wheat germ agglutinin (WGA) affinity column.
The result of this purification is shown in fig.3. The bin¬
ding protein eluted from the column with W-acetyl
glucosamine and when cross-linked to 125I-IL1 beta,
migrated at the same molecular mass as the unpurified
plasma protein. The specificity of this protein for IL1
beta was retained (fig.4) as it failed to bind 125I-IL1
alpha. Further 125I-IL1 beta binding was only competed
by 100-fold excess cold IL1 beta. Separation of plasma
on the WGA column resulted in a 25-fold purification.
12 3 4 5 6
Fig.4. 125I-IL1 alpha (A) and 125I-IL1 beta (B) cross-linked to fraction
8 of the affinity column (lane 1), with excess cold 1L1 alpha (lane 2),
1L1 beta (lane 3) and TNF alpha (lane 4) and also under reducing con¬
ditions (lane 5) iodinated proteins are also cross-linked to plasma
(lane 6).
Reducing SDS-PAGE resulted in the 125I-IL1 beta/
binding protein complex migrating at the same mole¬
cular mass as in non-reducing conditions (fig.4). Fleat
treatment of semi-purified binding protein before
cross-linking showed that the 125I-IL1 beta binding
ability was retained even at 70°C (data not shown). In¬
cubation of labelled IL1 beta with binding protein for
various lenghts of time at 4°C, room temperature and
37°C indicated that rapid association occurred, with
maximal binding after 30 min at 37°C (data not
shown).
4. DISCUSSION
SDS-PAGE analysis of plasma cross-linked with
iodinated ILls shows an IL1 beta/binding protein com¬
plex of molecular mass 60 kDa suggesting the presence
of a 43 kDa factor in human plasma capable of specific
association with IL1 beta and not IL1 alpha. Partial
purification using a WGA column isolated a protein
that bound IL1 beta and was not affected by reducing
conditions, suggesting the presence of a single polypep¬
tide chain. The binding factor is thought to be a heat-
stable glycoprotein with rapid association kinetics with
IL1 beta. A high-molecular-mass factor is also seen to
bind both labelled IL1 alpha and IL1 beta; this appears
to be non-specific.
Vairous factors have been described as IL1 inhibitors
[8], most of which are assayed by their ability to in¬
terfere with the co-mitogenic activity of IL1 on thymo¬
cytes. A well-characterised 23 kDa inhibitor affects
both IL1 alpha and IL1 beta stimulation of fibroblast
prostaglandin production and blocks iodinated IL1
alpha binding to its receptor [9], Uromodulin, an im¬
munosuppressive glycoprotein, inhibits ILl-induced T
cell proliferation. This activity depends on intact
glycosylation and it appears that IL1 itself binds to
uromodulin through lectin-like binding [13], It is
unlikely that either of these inhibitors are comparable
to the binding protein described here, due to molecular
mass and specificity differences. A granulocyte-derived
45-70 kDa molecule [14] and a 40 kDa immunosup¬
pressive protein from epidermal cells have been de¬
scribed to inhibit ILl-induced thymocyte co-mito-
genesis and fibroblast proliferation [15]. However,
none of these factors have been shown to be specific for
either IL1 alpha or IL1 beta alone.
Some groups have suggested that the proteinase in¬
hibitor alpha 2 macroglobulin (alpha 2M) may, in an
activated form, bind IL1, accounting for its various im¬
munosuppressive actions in vitro [11]. Activated alpha
2M has been found at high levels in synovial fluid of
rheumatoid arthritis patients and also acts as a binding
protein for IL6 [16], Alpha 2M may account for the
high-molecular-mass factor seen to bind non-speci-
fically both IL1 alpha and IL1 beta in the present study.
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The 43 kDa specific IL1 beta binding protein describ¬
ed here may represent a solubilised form of the IL1
receptor, but a recombinant form of the murine IL1R
comprising only the extracellular domain retains equal
affinity for IL1 alpha and beta [17]. Radiolabelled IL1
beta has a half-life in vivo of approximately 5-10 min
following i.v. injection [18]. Despite the presence of
IL1R on many cells circulating in the blood, IL1 beta is
almost entirely associated with the plasma. Distribution
studies indicate that apart from the liver and kidneys,
IL1 beta distributes into all tissues to approximately the
same extent. The specific binding protein described here
may therefore act as a carrier molecule for IL1 in body
fluids and may be an important determinant of tissue
distribution and bioavailability in vivo. It may also ex¬
plain in part the difficulty of measuring IL1 in body
fluids. With the increasing interest in the potential of
recombinant IL1 beta as a therapeutic molecule or as a
target for pharmacological intervention, it becomes im¬
portant to understand the factors that control its handl¬
ing in vivo.
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A SOLUBLE BINDING PROTEIN SPECIFIC FOR
INTERLEUKIN 1/3 IS PRODUCED BY ACTIVATED
MONONUCLEAR CELLS
Julian A. Symons,* Julie A. Eastgate, Gordon W. Duff
Soluble interleukin 1 (IL 1) binding proteins were identified by gel filtration and covalent
cross-linking of ,25I IL 1 in normal human serum and inflammatory exudate. High molecular
weight l25I IL 1 protein complexes occurred with both IL la and IL 1/8, however, high molecular
weight binding appeared to be non-specific. One specific IL 1/8 binding protein was observed to
elute at approximately 100 kDa on gel filtration when bound to 125I IL 1/8. This complex migrated
as a broad band at 60 kDa when covalently cross-linked and analyzed by SDS-PAGE. The
protein did not bind 125I IL la and ,25I IL 1/8 binding was only displaceable by excess cold IL-1/8.
The production of the specific IL 1/8 binding protein was assessed in a number of cell populations.
Unstimulated peripheral blood mononuclear cells (PBMNC) did not produce the binding protein,
but stimulation with phytohemagglutinin (PHA) caused production within 24 hr and binding
protein levels remained elevated for up to 7 days. Stimulation with lipopolysaccharide (LPS) and
IL 1 a did not consistently induce synthesis of the binding protein. Ligand-binding studies were
performed to compare solubilized EL 4 NOB.l cell membrane IL 1 receptor (sIL 1R) with
semi-purified IL 1/8 binding protein from pooled synovial fluid. The sIL 1R preparation bound
ligand with an affinity of 168 pM while the IL 18 binding protein bound 125IIL 18 with an affinity
of 370 pM. This protein may function as an important carrier molecule for IL 18 and determine
its distribution and kinetics in vivo.
© 1990 by W.B. Saunders Company.
Interleukin 1 (IL l)a and IL 18 are polypeptides
involved in the regulation of immune and inflammatory
responses.1 Although the two peptides have only 26%
homology,2 they compete with equal affinity for the
same major class of cellular receptor.3'4 Recently, the
murine5 and the human6 IL 1 receptor (IL 1R) mole¬
cules have been sequenced and cloned. They share a 69%
amino acid homology and are members of the immuno¬
globulin gene superfamily. In the murine IL 1R, the 319
amino acid extracellular domain consists of two 8-
pleated sheets connected by disulphide bands and seven
potential N-linked glycosylation sites, which may ac¬
count for the described size heterogeneity of the IL 1R.
IL 1 mediates a wide range of biological activities
that, if not closely regulated, may lead to extensive
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tissue damage. High levels of circulating IL 1 are often
seen by immunoassay in inflammatory diseases and
correlate with other markers of disease activity.7 In the
absence of disease, homeostatic mechanisms must oper¬
ate to limit IL 1 mediated responses. Many IL 1
inhibitory molecules have been described8 but few have
been characterized extensively. Recently, an IL 1 recep¬
tor antagonist has been sequenced9 and cloned.10 This
protein is 26% homologous with IL 18 and 19%
homologous with IL la, and binds IL 1R, but lacks IL 1
biological activity. The receptor antagonist is produced
from monocytes, in response to immune complexes,
IgG,11 and granulocyte macrophage colony stimulating
factor (GM-CSF)12 and appears identical to an IL 1
inhibitor, which was isolated from the urine of febrile
and myelomonocytic leukemia patients.13 Other regula¬
tory pathways of IL 1 include post-transcriptional con¬
trol by prostaglandin E214 and carrier molecules that
bind to IL 1. a2 macroglobulin (a2 M) forms complexes
with cytokines, including IL 1, following treatment with
trypsin or methylamine to expose free thiol groups.15
However, other plasma proteins with free thiol groups
(such as fibronectin) do not bind IL 1, so other structural
properties must be important.
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Soluble IL 1/3 binding protein / 191
In this paper, we describe a novel IL 1 binding
protein, which is present in synovial inflammatory exu¬
date and normal serum and that is produced by acti¬
vated mononuclear cells. Unlike previously described
inhibitors and binding proteins, this protein appears to
have affinity specifically for the /3 form of IL 1 and does
not bind IL la.
RESULTS
Identification of IL 1 Binding Proteins by Gel
Filtration
In order to identify IL 1 binding proteins, synovial
inflammatory exudate (SF) was incubated with 125I IL 1
peptides and then separated by Sephacryl S-200 gel
filtration (Fig. 1). When SF was incubated with 125I IL
1(3 , two identifiable complexes were formed: a small
peak of binding eluting at high molecular weight in the
void volume and a larger peak of binding at 100 kDa,
which accounted for approximately 16% of the available
125I IL I/?. When the experiment was repeated with
500-fold excess cold IL 1(3 the binding activity eluting in
the void was unchanged, however, the 100 kDa peak was
reduced significantly. Incubation of SF with 125I IL la
also resulted in the formation of the high molecular
weight complex, but no other distinct peaks were seen.
Identification ofIL 1 Binding Proteins by
Soluble Covalent Cross-Linking
A soluble covalent cross-linking procedure was used
to characterize the binding proteins. After incubation of
125I IL 1 peptides with the sample, complexes were
covalently cross-linked with disuccinimidyl suberate
(DSS) and analyzed by sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). Fig. 2A
shows that when SF was incubated with 125I IL la no
specific binding proteins were observed. I25I IL la-
associated material that occassionally entered the gel
(>500 kDa), was observed, however, this was not
affected by excess cold IL 1 peptides. In contrast, when
125I IL 1/3 was covalently crosslinked to SF proteins,
several molecular weight species were seen (Fig. 2B). As
with 125I IL la a high molecular weight band (>500
kDa) was seen but this was not displaceable with either
excess IL la, IL 1/3 or TNF a. While the major l25I IL
1(3 protein complex migrated as a broad band at approx¬
imately 60 kDa, 125I IL 1/3 binding to this complex was
not displaceable by excess cold IL la or TNF a, but was
completely displaceable by excess cold IL 1/3. A fainter
band was seen at 150 kDa, which was also displaceable
with only excess cold IL 1/3, however, this band was not
seen in reducing conditions, where the 60 kDa band was
unchanged (results not shown). Binding of 125I IL 1/3 in
Void 150 Kd
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Figure 1. Gel filtration of IL 1 binding proteins.
Synovial fluid was incubated with either 125I IL 1/3 or l25I IL la and then subjected to gel filtration through
Sephacryl S-200. Results are expressed as percentage of total counts in each fraction. Total counts loaded in each
case were for l25I IL 1/3 65,667 (O O), for l25I IL 1(3 plus 500 x excess cold IL 1/3 68,228 (•—•) and for IL la
161,844 (□—□) cpm. Results are representative of three different synovial fluid samples.
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the 60 kDa complex, but was not displaceable by a
variety of other cytokines, which include IL 2, GM-
CSF, IL 4, IL 6, TNF /?, or y I FN. The binding protein
complex, seen at 100 kDa on gel filtration of SF (Fig. 1),
was covalently crosslinked and analyzed by SDS-
PAGE, where it migrated at 60 kDa (data not shown).
Analysis of l25I IL 1/? binding to serum proteins by
covalent crosslinking was also performed (Fig. 3). A
similar pattern of binding was seen to that observed in
SF.
To confirm that the iodinated IL la, used in these
experiments, was able to bind to the receptor, we
performed cell surface IL 1-receptor crosslinking using
the murine thymoma line EL4 NOB. 1.18 Analysis
of receptor/ligand complexes (Fig. 4) revealed a major
band at approximately 95 kDa. Binding was fully
displaceable by excess cold IL 1/3 but not by cold
TNF a.
Production oJ'IL 1(3 Binding Protein by Activated
Mononuclear Cells
To identify the cell source of the soluble IL 1/3
binding protein, supernatants from resting and activated
cells were analyzed by 125I IL 1/3 covalent crosslinking
and SDS-PAGE. Results obtained with normal human
PBMNC showed that resting PBMNC did not produce
the binding protein (Fig. 5) and stimulation with concen¬
trations of LPS optimal for monocyte activation (100
ng/mL) also produced little binding activity. However,
PHA concentrations optimal for PBMNC proliferation
(1 /iig/mL) induced production of the binding protein
within 24 hr of culture and levels were maintained for up
to 7 days. Stimulation of PBMNC with IL la at
concentrations that induced both IL 1/3 and IL 6
production (10 ng/mL) failed to induce any binding
protein activity. Culture of PB neutrophils in either
1 2 3 4 1 2 3 4
Figure 2. Analysis of IL 1 binding proteins in synovial fluid by soluble covalent cross-linking and SDS-PAGE.
Synovial fluids were incubated at 4°C overnight with (A) l25I IL la or (B) 125I IL 1/3. Complexes were covalently
cross-linked with DSS and subjected to SDS-PAGE. I25I IL 1/binding protein complexes were identified by
autoradiography. In each case Lane 1 is with no competing agent, Lane 2 with excess cold IL la, Lane 3 with excess
cold IL 1/3 and Lane 4 with excess cold TNF a. Protein molecular weight markers are in kDa.








Figure 3. Analysis of IL 1 binding proteins in serum.
Serum from normal individuals was incubated with l25I IL 1/3 at 4°C
overnight. Subsequently complexes were covalently cross-linked with
DSS and subjected to SDS-PAGE. I25I IL ld/binding protein com¬
plexes were identified by autoradiography Lane 1 with no competing
agent, Lane 2 with excess cold IL-la, Lane 3 with excess cold IL-1 /S
and lane 4 with excess cold TNF a. Protein markers are in kDa.
analysis (inset) revealed an apparent kD of 370 pM
(Fig. 6B).
DISCUSSION
The present study describes the presence of a
specific binding protein for IL 1/3 in normal human
serum, inflammatory exudate and activated PBMNC
culture supernatants. We have previously described the
presence of this protein in normal human plasma.17 The
protein forms complexes with 125I IL 1/3, that elute at
approximately 100 kDa on gel filtration and migrate at
60 kDa on SDS-PAGE. The binding of 125I IL 1/3 to this
protein is only competable by the addition of excess cold
IL 1/3 and not by excess IL la or other cytokines,
suggesting it is specific for IL 1/3. To identify the cell
population that produces the binding protein we cul¬
tured PBMNC for up to 7 days with media, IL la, LPS
or phytohemagglutinin (PHA). Only stimulation with
PHA resulted in synthesis of the binding protein. Produc¬
tion occurred within the first 24 hr and levels remained
stable in the media for the 7 day culture period.
Ligand-binding studies revealed that the soluble binding
protein had a similar affinity for IL 1/3 as for the cell
surface IL 1R and solubilized 80 kDa IL 1R.
Several IL 1 inhibitory molecules have been
described,8 although the precise mechanism of inhibi-
media or with serum-treated zymosan resulted in no
production of binding protein (data not shown).
Specific Binding of1251 IL 1 to Soluble IL I
Binding Proteins
We first tested the ability of solubilized EL 4
NOB.l cell membranes to bind 125I IL la (Fig. 6A).
Maximal binding was achieved within 60 min at 22°C
(data not shown). The binding of l25I IL 1 alpha to the
solubilized receptor was specific and saturable. Figure
6A shows 125I IL la binding to a solubilized receptor as
a function of ligand concentration. Saturation was seen
at concentrations of 100 pM and above and Scatchard
analysis (inset) indicated an apparent kD of 168 pM.
Soluble IL 1/3 binding protein was semi-purified
from pooled synovial fluid by sequential DEAE-
Sephacel ion exchange chromatography and wheat germ
agglutinin affinity chromatography.16 The semi-purified
material retained the same specificity of binding as the
original unpurified protein (data not shown). Time
course studies of 125I IL 1/3 binding to the semi-purified
material revealed similar kinetics to the solubilized IL 1
receptor preparations. At 22°C maximal binding oc¬
curred within 60 min and saturation was achieved at






Figure 4. Affinity cross-linking of 125I IL la to EL 4 NOB.l cells.
EL 4 NOB.l cells (1 x 107) were incubated with iodinated IL la.
After washing, receptor-ligand complexes were crosslinked with DSS.
Cells were lysed in 1% (wt/vol) SDS containing protease inhibitors
and subjected to SDS-PAGE under reducing conditions. Lane 1 with
no competing agent, Lane 2 with excess cold IL 1/3, Lane 3 with excess
cold TNF a. Protein markers are in kDa.













Figure 5. Production of ,25I IL 10 binding proteins
by PBMNC.
PBMNC (2 x 106/mL) were cultured in serum-free
RPMI 1640 for up to 7 days. Cells either remained
unstimulated (a) or were stimulated with optimal
concentrations of (b) LPS (100 ng/mL), (c) IL la
(10 ng/mL) or (d) PHA (1 Mg/mL) cell-free superna-
tants were incubated with I IL 10, cross-linked
with DSS and analyzed by SDS-PAGE. Protein
markers are in kDa.
tion in most cases is unknown. Prostaglandin E2 inhibits
monocyte IL 1 production posttranscriptionally,14 by
increasing intracellular levels of cAMP. Recently, an IL
1-receptor antagonist (IL Ira) has been purified9 and
cloned.10 It is produced by monocytes stimulated with
IgG," has 26% amino acid homology with IL 1/3 and
blocks IL la and /3 action by binding to the 80 kDa IL 1
receptor. Unlike the binding protein described here the
IL Ira does not bind to 125I IL l.9 An independent
mechanism of IL 1 regulation may involve binding
proteins, a2 M, a major plasma proteinase inhibitor, is
involved in the binding of cytokines including IL 619 and
IL l.15 Binding to a2 M is mediated through a thiol
disulphide exchange reaction and, in each case, cytokine
binding was demonstrated to be specific. However, it
appears that a2 M does not function as a biological
inhibitor, as a2 M/cytokine complexes retain biological
activity.15'19 In the case of IL 6, a2 M was shown to
protect the cytokine from the action of proteases such as
trypsin and cathepsin G. a2 M may, therefore, act as a
carrier molecule and prevent the loss of cytokines from
the circulation. The molecular weight differences be¬
tween a2 M and the IL 1/3 binding protein described
here suggest that they are distinct. It is possible that the
smaller IL 1/3 binding protein represents a fragment of
a2 M. However, unlike the binding protein described
here, a2 M binding to IL 1/3 occurs in the absence of
covalent crosslinking agents and is retained on SDS-
PAGE in native conditions.
It is now known that some cytokine receptors can
exist in a soluble form. Initially it was demonstrated that
the IL 2 receptor (IL 2R) a chain21 could exist in a
soluble form (sIL 2R). The mechanism of release
appears to occur predominantly by proteolytic cleavage
of the receptor molecule at the cell surface20 and as sIL
2R retains ligand affinity,36 it may function as an IL 2
inhibitor.22,23 It is now known that IL 6, y IFN,24 TNF,25
EGF26 and the CSF l27 receptors can also exist in
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Figure 6. Specific binding of l25I IL 1 to soluble IL 1 binding proteins.
EL 4 NOB.l cell membranes solubilized with 8 mM CHAPS (A) or semi-purified IL 1/3 binding proteins from
synovial fluid (B) were incubated with varying concentrations of l25l IL 1 for 2 hr at 20°C and ligand-receptor
complexes precipitated with polyethylene glycol. Binding shown represents specific binding. Scatchard analysis
(insert) give Kd of approximately (a) 168 pm and (b) 370 pm. Results are representative of two experiments.
196 / Symons, Eastgate. Duff CYTOKINE, Vol. 2, No. 3 (May 1990: 190-198)
soluble form. The molecular weight, ligand affinity and
cellular source of the 1L 1/3 binding protein are
consistent with the protein being a shed form of the 80
kDa IL 1R. Cloning of the human6 and murine5 IL 1R
reveals that the extracellular domain consists of approx¬
imately 320 amino acids with seven potential N-linked
glycosylation sites. The cross-linked l25I IL 1 /binding
protein complex migrates at approximately 60 kDa on
SDS-PAGE suggesting that the binding protein may be
approximately 43 kDa. Digestion of the complex with
N-glycanase results in a band migrating at approxi¬
mately 47 kDa (unpublished data) suggesting that the
binding protein may have a molecular weight of 30 kDa
with 13 kDa of N-linked carbohydrate. However, Dower
et al.28 have shown that recombinant murine sIL 1R,
consisting of the extracellular region of the mature cell
surface IL 1 R, retains affinity for both IL 1/3 and IL la.
Recently, covalent labeling and ligand binding stud¬
ies have revealed important differences between the IL
1 R on T cell lines and B cell lines.29 Covalent labeling of
B cell lines with 125I IL 1 results in the formation of a 65
to 70 kDa complex. Additionally, some B cell lines
appear to bind IL la at a lower affinity than IL 1/3. It
has recently been shown that, in the mouse, these IL 1R
proteins are encoded by distinct genes.30 It is therefore
possible that the IL 1/3 binding protein reported here
represents a soluble form of a novel human IL 1R
protein.
The cell source of the IL 1/3 binding protein was
found to be PHA-activated PBMNC. Resting PBMNC
did not synthesize the binding protein, while PHA-
activated cells consistently produced binding protein
within 24 hr of stimulation. Concentrations of LPS,
optimal for monocyte activation, occasionally induced
binding protein production. However, production only
occurred after 72 hr stimulation, resulting in lower levels
of binding protein production possibly reflecting autolo¬
gous stimulation of lymphocytes by activated mono¬
cytes. Peripheral blood neutrophils were not found to
produce the binding protein even after zymosan-
stimulation and therefore, it is unlikely that the binding
protein is related to the neutrophil-derived IL 1 inhibi¬
tor, which is described by Tiku et al.31 We are currently
screening human lymphocyte cell lines for binding
protein activity.
Given that the IL 1/3 binding protein has a similar
affinity for IL 1/3 as the cell surface 80 kDa IL 1R, the
binding protein may function as a specific inhibitor for
IL 1/3. This may be important given the differential
distribution of IL la and IL 1/3 peptides. Several
studies have demonstrated that IL la remains predomi¬
nantly cell-associated, while more IL 1/3 is translocated
extracellularly.32'33 To unequivocally test whether the IL
1/3 binding protein is an effective inhibitor of IL 1
activity will require homogenous protein for use in IL 1
bioassays and receptor binding assays. To achieve this,
we have recently purified the IL 1/3 binding protein to
homogeneity from pooled synovial fluid by sequential
ion exchange chromatography, IL 1(3 ligand-affinity
chromatography and reverse-phase high performance
liquid chromatography (HPLC)16 with a view to N-
terminal sequencing and cloning.
MATERIALS AND METHODS
Reagents
Radioiodinated human recombinant (hr) IL la and hr IL
1/3 were obtained from Du Pont (NEN Products). IL la was
radioiodinated using the chloramine-T procedure to a specific
activity of 90.4 /iCi per ug (3.35 MBq//tg). IL 1/3 was labeled
with Bolton Hunter reagent to a specific activity of 158 [iCi/ng
(5.85 MBq/ug). Human recombinant IL 1 peptides were a gift
from Biogen SA, human recombinant TNF a was a gift from
Dr G. Adolf, Vienna, Austria. IL 1 and TNF a recombinant
peptides were regularly assessed for bioactivity using the EL 4
NOB.l/CTLL-2 conversion assay and L929 cytotoxicity as¬
say, respectively. The covalent cross-linking reagent disuccin-
imide suberate (DSS) was obtained from Pierce and Warriner
Ltd.
Synovial fluid effusions were taken into ethylene diami-
notetricetic (EDTA) tubes and blood into dry glass tubes for
serum collection. To remove cells from the synovial fluid and
sera, samples were centrifuged at 10,000 xg aliquoted and
stored at — 20°C until used. Synovial fluid aliquots were
treated with hyaluronidase (bovine testes, type VIII; 100
U/mL, 45 min, 37°C; Sigma), followed again by centrifuga-
tion at 10,000 xg.
Gel Filtration Analysis
Synovial fluid (1 mL) was incubated with l25I IL la (3
ng/mL), l25I IL 1/3 (1 ng/mL) or l25I IL 1/3 (1 ng/mL) plus
cold IL 1/3 (500 ng/mL) at 20°C for 90 min. The fluid was
then fractionated by gel filtration through a 1.5 x 90 cm
Sephacryl S-200 column (Pharmacia) equilibrated with PBS,
pH 7.2. One millilitre of sample was applied and eluted with a
buffer flow rate of 1 mL/min. Fractions of 1 mL were collected
and radioactivity assessed by 7-scintillation counting. The
column was calibrated with marker proteins of known molecu¬
lar weight. Data was expressed as a percentage of total counts
applied to the column.
Covalent Crosslinking and SDS-PAGE Analysis
Synovial fluid, serum or culture supernatant (50 /d) was
incubated overnight at 4°C with 125I IL la or l25I IL 1/3 at a
final concentration of 10 ng/mL with or without 100-fold
excess of cold IL la, IL 1/3, or TNF a. Subsequently, DSS
freshly prepared in DMSO, was added to a final concentration
of 1 mg/mL and the sample incubated at 4°C for 45 min.
Crosslinking reactions were terminated by the addition of 50
/d SDS-PAGE sample buffer (1% [wt/vol]) sodium dodecyl
sulphate [SDS], 10% [vol/vol] glycerol, 62.5 mM Tris-HCl,
pH 6.8). Samples, to be tested under reducing conditions, were
treated with dithiothreitol (100 mM; DTT) and boiled for 10
min. Cross-linked complexes were identified in 10% poly-
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acrylamide gels containing SDS34 by autoradiography (Hyper-
film MP; Amersham). After 16 to 24 hr exposure the 17 kDa
l25I IL 1 band was removed and the film re-exposed for 24 hr to
4 weeks. Iodinated cytokines were assessed for self-association
in all cross-linking experiments.
Isolation ofPBMNC and Cell Culture
PBMNC were obtained from heparinized peripheral
blood by density gradient centrifugation (pyrogen-tested lym-
phoprep; Nyegaard and Co). After washing, the cells were
resuspended at 2.5 x 106/mL in serum-free RPMI 1640,
containing penicillin (100 IU/mL), streptomycin (100 /ig/
mL) and L-glutamine (2 mM; Northumbria Biologicals
[NBL]). The cells were then distributed in 200 /d aliquots in
96-well microtiter plates (Costar, NBL). PBMNC were main¬
tained at 37°C in a humidified 5% C02/95% air atmosphere
for up to 7 days with or without a previously determined
optimal concentration of PHA (1 /rg/mL; Sigma), LPS (100
ng/mL; E Coli 0127:B8, TCA extracted, Sigma) or hr IL la
(10 ng/mL; Biogen). At the end of the culture, the medium
was aspirated, centrifuged at 10,000 xg and stored at — 20°C,
until used in cross-linking experiments.
Cell Surface Affinity Crosslinking
EL 4 NOB.l cells18 were maintained in RPMI 1640
containing 5% (vol/vol) fetal calf serum (FCS). For binding
assays, cells were harvested and washed 3 times in binding
buffer (RPMI 1640 containing 1% [wt/vol] bovine serum
albumin, 0.1% [wt/vol] sodium azide and 20 mM HEPES pH
7.2). Cells (1 x 107) were incubated with 125I IL la (1 ng) in
150 /d of binding buffer alone or binding buffer containing
100-fold excess unlabeled IL 1 or TNF a for 2 hr at 4°C, with
constant gentle agitation. The cells were subsequently washed
twice in ice cold protein-free buffer and resuspended in 100 /d
of the same buffer. DSS in DMSO was added to a final
concentration of 1 mg/mL and incubated at 4°C for 45 min.
The cells were washed twice in ice cold buffer and resuspended
in 100 /d PBS, containing 1% (wt/vol) SDS, with the protease
inhibitors phenyi-methylsuiphonyl fluoride, pepstatin, o-
phenanthroline and EDTA (all 2 mM; Sigma). After a 10 min
incubation at 4°C, the samples were centrifuged at 10,000 xg
and the supernatants stored at — 20°C until SDS-PAGE
analysis. An equal volume of SDS-PAGE sample buffer
containing 100 mM DTT was added to an aliquot of the cell
extract and the sample boiled for 10 min, and then subjected to
electrophoresis in 10% SDS-PAGE gels, as described previ¬
ously.
Soluble 1251 IL I Binding Assay
Soluble binding assays were performed on two sources of
IL 1 binding proteins. 3-([3-cholomidopropyl] dimethyl ammo-
nio)-l-propanesulfonate (CHAPS) solubilized EL 4 NOB.l
membranes were prepared, as described previously.35 Semipu-
rified IL 1/3 binding protein from synovial fluid was prepared
by sequential ion exchange chromatography on DEAE Sepha-
cel (Pharmacia LKB) and wheatgerm agglutinin affinity
chromatography (Pharmacia LKB).16 '7 For soluble binding
assays, IL 1 binding protein preparations were incubated with
various concentrations of 125I IL 1 in a final volume of 0.2 mL
in Hank's balanced salt solution, supplemented with 20 mM
HEPES, 1 mg/mL bovine serum albumin (Sigma; Cat. No.
A7906) and 0.02% (wt/vol) sodium azide, pH 7.4. For assays
with CHAPS solubilized EL-4 NOB.l membranes, the final
CHAPS concentration was adjusted to 0.8 mM. Nonspecific
binding was assessed by inclusion of 100-fold excess cold IL 1.
After incubation at 20°C for 2 hr, tubes were placed on ice and
bovine y globulin in PBS, added to a final concentration of
0.04% (vol/vol), and followed by 1.33 mL of 12% (wt/vol)
PEG-8000 in PBS (Sigma). After vortexing, tubes were placed
on ice for 10 min. Receptor/protein-bound 125I IL 1 was
separated from free 125I IL 1 by first diluting the PEG-
precipitated complexes with 3 mL cold 10% (wt/vol) PEG and
filtering the entire volume under vacuum onto GF/C glass
fibre filters (Whatman), mounted in a Millipore 1225 sam¬
pling manifold (Millipore). Filters were washed twice with 3
mL of 10% PEG solution, allowed to air dry and counted in a
gamma counter. All experiments were performed in duplicate
and results were expressed as specific binding activity after
subtraction of non-specific binding.
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Interleukin 1 (IL1) beta has been implicated as an inflammatory mediator in
rheumatoid arthritis (RA) but little is known about the related cytokine, IL1
alpha, in this disease. IL1 alpha has biological properties similar to IL1
beta but, unlike IL1 beta, remains mostly cell-associated. In this study
plasma IL1 alpha was measured by radioimmunoassay in patients with RA and in
healthy controls. Plasma levels were compared with conventional measures of
disease activity. The mean levels in the two groups were not significantly
different and, within the patient group (n=53), the only significant cross-
sectional correlation was between plasma IL1 alpha and ESR. In longitudinal
studies, some individual patients had plasma IL1 alpha levels that correlated
with different measures of disease activity. We conclude that while IL1 alpha
may be involved in the immunopathogenesis of RA, its measurement in plasma seems
to offer little of clinical value.






The two forms of IL1, alpha and beta, have similar receptor affinity (1)
and biological activities in inflammatory and immune reactions (2). They are
produced by different genes with inducible expression in macrophages and other
cell types. The initial translation product, a 31KDa propeptide, is processed
to produce biologically active 17KDa forms (3,4). The 31KDa IL1 alpha
propeptide is also biologically active.
The activities of IL1 suggest a pathogenic role in rheumatoid arthritis
(RA) (5). In synovial cells, IL1 augments the release of vasoactive agents and
mediators of tissue damage (6,2), it also stimulates bone (8) and cartilage
resorption (7), the acute phase response (9) and fever (10). IL1 may also
contribute to chronic inflammation by inducing lymphocyte growth factors and
their receptors (e.g. IL2, IL6, IL2 receptor) (11,12,13).
Evidence for IL1 involvement in RA includes: high levels in synovial
exudates (14); spontaneous production in vitro by synovial cells (15) and
detection of IL1 mRNA in synovial tissue sections (16); in animals, intra¬
articular injections of IL1 produced synovial fluid leucocytosis and cartilage
proteoglycan breakdown (17). Recently, a simple extraction procedure enabled
detection of IL1 beta in plasma (18), and showed raised levels in RA that
correlated with conventional laboratory and clinical measures of disease
activity (19). Interleukin 1 alpha has been less well studied and we have now
measured plasma IL1 alpha in patients with RA and in healthy volunteers. To our
knowledge this is the first report of immunoreactive IL1 alpha in the plasma of
RA patients.
METHODS
Patients with definite or classical RA (20) attending an out-patient clinic
or admitted to hospital with active disease were graded for disease activity by
Ritchie joint index (21), duration of early morning stiffness, and visual
analogue pain score. At the same time blood was taken for haemoglobin
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concentration, white cell count, platelet count, erythrocyte sedimentation rate
(ESR) and rheumatoid factor titer as part of normal management. Blood samples
for plasma preparation were collected into EDTA with aprotinin, separated and
stored as previously described (19). All patients received non-steroidal anti¬
inflammatory drugs (NSAID) and some received anti-rheumatic drugs including
intra-articular steroids.
IL1 alpha measurement
Samples were extracted according to the method of Cannon et al (18).
Treated plasma was tested in a specific radioimmunoassay (RIA) for IL1 alpha.
The assay is sensitive to 78pg/ml IL1 alpha, has parallel dilution
characteristics and less than 10% interassay variability. Recovery (detection)
of recombinant IL1 alpha added to RA plasma was 87% after extraction (n=8, mean
87.1% SEM = 6.7%). The difference in recovery of IL1 alpha added to RA plasma
compared with normal plasma was not significant. There is no cross reactivity
with IL1 beta. The RIA was developed by Amersham International, (Bucks, UK).
Samples or standards were incubated for 4 hours with rabbit anti-human IL1 alpha
1 25
antiserum. I-ILl-alpha tracer (human recombinant) was then added and
incubated overnight at 4° C. Donkey, anti-rabbit serum coated on magnetizable
polymer particles (Amerlex-M) was added for 10 minutes at room temperature.
After centrifugation, supernatant was removed and the pellet counted by gamma
scintillation. The standard curve was prepared with human recombinant IL1
alpha.
Statistical Methods
Mean values were compared by student's t-test and correlations assessed
with the Spearman rank correlation coefficient.
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RESULTS
IL1 alpha levels in plasma
In testing the extraction procedure, 17 normal plasma samples showed a
statistically non-significant increase in the level of IL1 alpha (unextracted
mean IL1- alpha = 222pg/ml, extracted mean IL1-alpha = 249pg/ml, p=0.08).
However, in the same experiment, 44 samples from RA patients showed a small but
significant increase in plasma ILl-alpha after extraction (unextracted mean IL1-
alpha = 192pg/ml, extracted mean ILl-alpha = 238.5pg/ml, R=0.535, p=0.0003).
Between the patient and control groups there was no significant difference
in the plasma IL1 alpha levels. (Table I) Mean ages of the two groups were 40
years (20-63) and 38 years (26-54) respectively.
Cross-sectional studies
Plasma IL-1 alpha levels in 53 RA patients were compared with conventional
measures of disease activity and also with IL1 beta levels. The only
significant, but weak, correlation found was between plasma IL-1 alpha and ESR
(R=+0.29, p<0.05). No obvious relation could be seen between IL1 alpha and drug
treatment.
Longitudinal studies
Serial measurements of IL1 alpha in plasma taken from 3 hospitalised
patients over a period of several weeks were compared with conventional measures
of disease activity (Fig. 1). Patient A showed a gradual reduction in disease
activity over the first 15 days but then had a secondary flare in disease
activity. Plasma ILl-alpha in this patient correlated positively with Ritchie
joint score (R= +0.678, p<0.005), analogue pain score (R= +0.59, p<0.02),
duration of morning stiffness (R= +0.538, p<0.05) and negatively with hemoglobin
concentration (R= -0.49, p<0.05). Other correlations were not significant.
Patient B showed significant correlations between plasma IL1 alpha and duration
of morning stiffness (R= +0.587, p<0.02) and with platelet count (R= +0.719,
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p<0.005). Patient C showed similar trends though none reached statistical
significance.
DISCUSSION
IL1 alpha was present at high levels relative to IL1 beta in both control
and patient populations (19). There was no significant difference in mean
plasma IL1 alpha levels between the two. There was no cross-sectional
correlation of plasma IL1 alpha levels with any of the measures of disease
activity except a weak relation to ESR. However, in two of the three patients
tested, serial measurement of immunoreactive IL1 alpha in plasma correlated with
some clinical and laboratory assessments of disease activity.
These results differ from those found for IL1 beta in plasma where
extracted IL1 beta levels were significantly higher in the patient group
compared with controls (lOOpg/ml vs 50pg/ml) and correlated with disease
activity in cross-sectional population analysis (19).
Monocytes stimulated in vitro produce both IL1 alpha and IL1 beta. The
latter is rapidly released (50% at 24 hours) with measurable extracellular
levels after 2 hours. In contrast, IL1 alpha remains predominantly cell-
associated (95% at 24 hours) and is not detected in supernatants until 12 hours
after initiation of culture (22). It has therefore been proposed that IL1 alpha
is a cell-associated form (23) and may be active on the cell surface. In
contrast, IL1 beta appears to be the predominant secreted form mediating
biological activity at a distance.
Other work suggests that different cell types vary in the ratio of IL1
forms that they produce and may also have different translocation patterns (24).
Keratinocytes, for example, are reported to produce mainly IL1 alpha and it is
secreted in culture (24).
Production of IL1 alpha by different cell types could explain the similar
blood levels in patients and control groups. A large cell population such as
the skin keratinocytes secreting predominantly IL1 alpha may be stimulated to a
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comparable level in both populations (e.g. by exposure to UV). This would lead
to detectable blood levels even in healthy individuals and increased production
from cells at a site of inflammation might appear in the plasma as a relatively
small increment on a high background.
IL1 alpha has been demonstrated in RA synovial fluid (12,25). Synovial
cells in RA and blood cells in Still's disease expressing IL1 alpha mRNA have
been detected by in situ hybridization (unpublished observations). Within
individuals, activated synovial cells producing IL1 alpha may account for
changing plasma levels with clinical disease activity. Our results give some
support for a role of IL1 alpha in RA but suggest that its measurement in plasma
is of limited clinical value.
7
ACKNOWLEDGEMENTS
We would like to thank Miss Anne S. Mitchell for preparation of the
manuscript. This work was supported by the Arthritis and Rheumatism Council
for Research, U.K.. J.A.E. holds a Glaxo studentship.
8
REFERENCES
1. Bird T.A., Saklatvala J.. Identification of a common class of high
affinity receptors for both types of porcine interleukin 1 on connective
tissue cells. Nature, 1986; 324: 263-6.
2. Di Giovine F.S., Duff G.W.. Interleukin 1: the first interleukin. Immunol.
Today, 1990; 11: 13-20
3. Lomedico P.T., Kilian P.L., Gubler U., Stern A.S., Chizzonite R..
Molecular biology of interleukin 1. Cold Spring Harbour Symp. Quant.
Biol., 1986; 41: 631-9.
4. March C.J., Mosley B., Larsen A., et al. Cloning, sequence and expression
of 2 distinct human IL1 cDNAs. Nature, 1985; 315: 641-7.
5. Duff G. Interleukin -1 in inflammatory joint disease. In: Bomford,
Henderson (Eds). Interleukin-1, inflammation and disease, Elsevier Science
Publications, Cambridge, 1990; 16: 243-255.
6. Duff G.W.. Peptide regulatory factors. Lancet June 24 1990; 1432-35.
7. Dingle J.T., Saklatvala J., Hembry R.M., Tyler J.A., Fell H.B., Jubb R.. A
cartilage catabolic factor from synovium. Biochem. J., 1979; 184: 177-80.
8. Gowen M., Wood D.D., Ihrie E.J., McGuire M.K.B., Russell R.G.G.. An
interleukin 1-like factor stimulates bone resorption in vitro. Nature,
1983; 306: 378-80.
9. Dinarello C.A.. Interleukin 1 and the pathogenesis of acute phase
response. New Engl. J. Med., 1984; 311: 1413-8.
10. Duff G.W., Durum S.K.. The pyrogenic and mitogenic actions of interleukin
1 are related. Nature, 1983; 304: 449-51.
11. Durum S.K., Schmidt J.A., Oppenheim J.J.. Interleukin 1: an immunological
perspective. Ann. Rev. Immunol., 1985; 3: 263-87.
12. Symons J.A., McDowell T.L., di Giovine F.S., Wood N.C., Capper S.J., Duff
G.W.. Interleukin-1 in rheumatoid arthritis: Potentiation of immune
responses within the joint. Lymphokine Res. 1989; 8: 365-372.
13. Van Damme J., Cayphan S., Opdenakker G., Billiau A., Van Snick J..
Interleukin 1 and poly (rl) poly (rC) induce production of a hybridoma
growth factor in human fibroblasts. Eur. J. Immunol., 1987; 17: 1.
14. Fontana A., Hengartner J., Weber E., Fehr K., Grob P.J. Cohen G..
Interleukin 1 activity in synovial fluid of patients with rheumatoid
arthritis. Arthritis Rheum., 1982; 2: 49-53.
15. Di Giovine F.S., Malawista S.E., Nuki G., Duff G.W.. Interleukin 1 as a
mediator of crystal arthritis: stimulation of T cell and synovial
fibroblast mitogenesis by urate-induced IL1. J. Immunol., 1987; 138: 3213-8.
16. Ogilvie A.D., Wood N.C., Dickens E., Wojtacha D., Duff G.W.. In situ
hybridization. Ann. Rheum. Dis., 1990; 49: 434-439.
9
17. Pettipher E.R., Higgs G.A., Henderson B.. Interleukin 1 induces leukocyte
infiltration and cartilage proteoglycan degradation in the synovial joint.
Proc. Nat. Acad. Sci. (USA), 1986; 82: 8749-53.
18. Cannon J.G., van der Meer J.W.M., Kwiatkowski D., et al. Interleukin-1
beta in human plasma: optimization of blood collection, plasma extraction
and radioimmunoassay methods. Lymphokine Res., 1988; 7: 457-467.
19. Eastgate J.A., Symons J.A., Wood N.C., Grinlinton F.M., di Giovine F.S.,
Duff G.W.. Correlation of plasma interleukin 1 levels with disease
activity in rheumatoid arthritis. Lancet, Sept 24 1988; 706-709.
20. Ropes M.W., Bennet G.A., Cobb S., Jacox R., Jesser R.A.. 1958 Revision of
the diagnostic criteria of rheumatoid arthritis. Bull. Rheum. Dis. 1958; 9:
175-176.
21. Ritchie D.M., Boyle J.A., Mclnnes J.M., et al. Clinical studies with an
articular index for the assessment of joint tenderness in patients with
rheumatoid arthritis. Quart. J. Med., 1968; 37: 393-406.
22. Di Giovine F.S., Symons J.A., Duff G.W.. Protein and mRNA analysis of
monokine production. Lymphokine Research, 1988; 7,3: 1.45 (Abstract).
23. Conlon P.J., Grabstein K.H., Alpert A., Prickett K.S., Hopp T.P., Gillis
S.. Localisation of human mononuclear cell interleukin 1. J. Immunol.,
1987; 1, 139: 98-102.
24. Kupper T.S., Ballard D.W., Chua A.O. et al. Human keratinocytes contain
mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA:
keratinocyte epidermal cell-derived thymocyte-activating factor is
identical to interleukin 1. J. Exp. Med., 1986; 164: 2094-2100.
25. Di Giovine F.S., Poole S., Situnayake R.D., Wadhwa M., Duff G.W.. Absence
of correlations between indices of systemic inflammation and synovial fluid
interleukin 1 (alpha and beta) in rheumatic diseases. Rheumatol. Int.,
1990; 9: 259-64.
10
Table I Plasma IL1 aloha levels in extracted plasma







Controls vs RA t=0.338 p=0.736
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Figure 1
Serial measurements of plasma IL1 alpha in three RA patients during
hospital admission with concurrent clinical and laboratory assessments of
disease activity.
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